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This thesis examines maternal and perinatal outcomes in pregnancy complicated by chronic 
hypertension. National guidance highlights the paucity of data from randomised controlled 
trials to guide choice of antihypertensive treatment for chronic hypertension in pregnancy. I 
performed a systematic review/meta-analysis of all randomised controlled trials comparing 
antihypertensive agents to non-active treatment/other antihypertensive agents for treatment 
of chronic hypertension in pregnancy. I demonstrated that antihypertensive agent use was 
associated with substantial reduction in the incidence of severe hypertension, but no 
significant differences in other maternal/perinatal outcomes were observed. The 
pathophysiology underpinning the increased risk of adverse maternal/perinatal outcome in 
women with chronic hypertension is poorly understood and likely to be multifactorial. I 
undertook a cohort study of 4481 pregnancies in women with chronic hypertension and 
assessed the impact of maternal characteristics on adverse perinatal outcome. Black ethnicity 
was strongly associated with adverse perinatal outcome. I conducted a randomised controlled 
feasibility study to compare labetalol and nifedipine for treatment of chronic hypertension in 
pregnancy. Feasibility of recruitment was confirmed and effectiveness of labetalol and 
nifedipine to control mean blood pressure to target examined. Outside pregnancy, Black 
women are recommended calcium-channel blockers as first-line antihypertensive treatment. I 
observed differences in treatment effect between ethnic groups and highlighted areas 
requiring further investigation. A nested mechanistic study within the trial demonstrated 
differences in placental/renal biomarker concentrations in women who developed 
superimposed pre-eclampsia, compared to those who did not, and between women of Black 
ethnicity compared to non-Black. Additional assessment of maternal vascular function across 
gestation showed no differences by ethnicity, but longitudinal variation in brachial blood 
pressure, central aortic pressure, pulse wave velocity, and augmentation index were 
demonstrated in women with chronic hypertension who developed adverse pregnancy 
outcome (superimposed pre-eclampsia and in those delivering small for gestational age 
infants) compared to those who did not. 
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CHAPTER 1 INTRODUCTION 
 
1.1 Chronic hypertension in pregnancy- importance and challenges 
Chronic hypertension is a common disorder affecting a quarter of the UK’s adult population.1 It 
may be primary, with no identifiable cause found, or secondary to another underlying medical 
condition (e.g. chronic kidney disease). Diagnosing chronic hypertension when it first occurs in 
an individual is a challenge, as it is not associated with a set of signs and symptoms and is 
instead most commonly detected following incidental blood pressure measurement. Chronic 
hypertension causes significant cardiovascular and cerebrovascular morbidity and mortality.2,3 
If left untreated, the risk of morbidity and mortality is accelerated.4   
 
The prevalence of chronic hypertension in pregnancy is rising due to increasing maternal age 
and the global obesity epidemic.5,6 The current incidence of chronic hypertension in pregnancy 
is estimated at 3%, making it the most common pre-existing medical disorder that directly 
impacts maternal and fetal wellbeing.7 The disorder is associated with adverse maternal and 
perinatal outcomes such as superimposed pre-eclampsia, perinatal mortality, fetal growth 
restriction and preterm birth.8 Pregnancy offers a screening opportunity for chronic 
hypertension, as routine blood pressure monitoring is incorporated into standard antenatal 
care and many women may not have had their blood pressure measured prior to pregnancy.    
 
There are many physiological mechanisms that play a role in blood pressure homeostasis. 
Although variation in these mechanisms have been implicated, no unifying pathophysiological 
pathway has been identified.9 The physiological changes associated with pregnancy cause a 
statistically significant reduction in blood pressure of 5 to 10 mmHg with the nadir in the 
second trimester.10 However, these data are derived from small numbers of women11,12 and 
not all studies agree, with a study reported by Nama and colleagues (2011) observing steady 
increase in blood pressure across gestation in low risk women.13 Data from the Pregnancy 
Physiology Pattern Prediction Study (4P Study; ISRCTN10838017), which aimed to recruit 1000 
low risk pregnant women should offer further insight into the clinical significance of reduction 
in blood pressure during pregnancy. The impact of chronic hypertension on the ability of the 
maternal vasculature to respond to these changes and the relationship between 
maladaptation and adverse outcome is not fully understood. Demographic and environmental 
risk factors associated with chronic hypertension have been identified such as age, smoking, 
obesity and ethnicity. Investigation of these risk factors and their association with adverse 
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maternal and perinatal outcomes would focus research prioritisation and guide choice of 
potential interventions. 
 
Internationally guidelines vary for the management of chronic hypertension in pregnancy.14 
Recent evidence from the CHIPS study (Control of Hypertension In Pregnancy Study, 2015) has 
highlighted the maternal benefit of ‘tight’ (to a diastolic target of 85 mmHg) control of blood 
pressure on the risk of severe hypertension without an increase in perinatal adverse 
outcomes.15 Current guidelines point to the lack of evidence from randomised controlled trials 
to guide antihypertensive prescription in pregnancy complicated by chronic hypertension.16 
With an ageing maternal population, rising obesity rates and advances in reproductive 
medicine, many more women with chronic hypertension are becoming pregnant and 
exploration of the most effective, safe and efficacious antihypertensive agents for treatment of 
this condition in pregnancy warrants investigation. 
 
1.1.1 Definition of chronic hypertension in the non-pregnant population 
Blood pressure is quantified as the systolic and diastolic arterial pressures in millimetres of 
mercury (mmHg). The systolic pressure represents the peak pressure during left ventricular 
systole and the diastolic pressure represents the pressure while the left ventricle is relaxed 
during diastole.17 It is most commonly measured at the brachial artery using manual or 
automated cuff devices.18 Chronic hypertension is defined as sustained raised arterial blood 
pressure. Blood pressure is normally distributed in the general population.1 The thresholds 
used for diagnosis are defined as the level of blood pressure above which treatment will 
reduce the development or progression of cardiovascular disease, but in the absence of end 
organ damage this is set at blood pressures >140/90 mmHg.1 Symptoms, if present, can 
include headache, tinnitus, vertigo or syncope. If severe hypertension is present at diagnosis 
then treatment should be initiated immediately, but otherwise it is recommended that the 
diagnosis should be confirmed following analysis of 24-hour ambulatory blood pressure 
monitoring.1,19,20  
 
1.1.2  Definition of chronic hypertension in pregnancy 
The International Society for the Study of Hypertension in Pregnancy defines chronic 
hypertension in the context of pregnancy, as a condition diagnosed prior to the last menstrual 
period or following two blood pressure readings with a systolic pressure ≥140 mmHg and/or 
diastolic pressure ≥90 mmHg prior to 20 weeks’ gestation.21 Pregnancy presents a screening 
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opportunity for hypertension, as longitudinal blood pressure monitoring is a routine aspect of 
antenatal care, with the first reading taken in the first trimester and repeat readings taken 
throughout pregnancy until the woman is discharged from midwifery care in the post-partum 
period.22    
 
The importance of defining the diagnosis in pregnancy lies in the clinical implications and 
subsequent management. Pregnancy can be complicated by gestational hypertension or de 
novo hypertension as a feature of pre-eclampsia, both conditions that are diagnosed after 20 
weeks’ gestation and should resolve after delivery. Pre-eclampsia can complicate chronic 
hypertensive pregnancy, but is described in this circumstance as superimposed and can be 
more difficult to confirm due to the pre-existing hypertension.16 It is important to monitor 
blood pressure closely in the post-partum period if de novo hypertension is revealed in 
pregnancy, as the physiological fall in blood pressure (described in more detail below) may 
have masked underlying pre-existing chronic hypertension in the first and second trimester 
that had not previously been recognised.23          
 
1.1.3  Prevalence of chronic hypertension in non-pregnant populations 
The World Health Organisation estimated in 2008 that 40% of adults aged 25 years and above 
had been diagnosed with chronic hypertension globally; the number of people with the 
condition increased from 600 million in 1980 to 1 billion in 2008.24 The increasing prevalence 
of chronic hypertension is thought to relate to an ageing population, the rise in obesity and 
other environmental risk factors.4 It is estimated that the prevalence is lower in high income 
countries affecting 25-35% of the adult population.1,4  
 
A population study conducted by Bateman and colleagues (2012) estimated prevalence of 
hypertension amongst women in their reproductive years (20 to 44 years) to be 7.7%.25 It is 
unclear why this is more than double the estimated prevalence observed in pregnancy, but 
may relate to fewer women becoming pregnant once they have a diagnosis of chronic 
hypertension, or hypertension being diagnosed after a woman’s family is complete. Risk 
factors for hypertension amongst this cohort included: older age, Black ethnicity, diabetes 
mellitus, chronic kidney disease and obesity.  Another study examining prevalence of medical 
disorders amongst women seeking contraception in the USA by Champaloux and colleagues 
(2015), found an 8.3% prevalence of chronic hypertension.26 Interestingly, when they 
examined the age associated prevalence, only 2.5% of those aged 15-34 years, but 15.6% of 
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those aged 35-44 years had chronic hypertension. This study is subject to selection bias, as 
women with medical conditions that impact pregnancy outcome may be more likely than 
normotensive women to seek contraception to prevent pregnancy and its associated 
complications.26  
 
Ethnic variation in the prevalence of hypertension is reported internationally across all ages 
and genders.4,27,28 The World Health Organization reports that, globally, the prevalence of 
hypertension is highest in Africa (46%).4 An American study published by Geronimus and 
colleagues (2007), found that men and women of Black ethnicity were at much greater risk of 
developing hypertension and at a younger age than men and women of White ethnicity.27 
Additionally, they observed that prevalence of hypertension amongst adults aged 15 to 65 
years, increased most rapidly in women and those of Black ethnicity.27    
 
1.1.4  Prevalence of chronic hypertension in pregnancy 
The prevalence of chronic hypertension in pregnancy is estimated to lie between 1 and 5%.29-31 
There is global and national variation in prevalence as found in the non-pregnant population. 
In addition, due to disparity in the definition used for diagnosis and errors in coding in medical 
databases, incidence reported in population studies are likely to underestimate the true 
prevalence.29,32 A recent study of UK primary care data by Cea Soriano and colleagues (2014), 
reported that 1.3% of their 148,554 cohort of completed pregnancies had a diagnosis of pre-
existing hypertension before their last menstrual period, but this does not include the women 
who had miscarriages (known to be increased in those with chronic hypertension), or women 
diagnosed with chronic hypertension in pregnancy.31  This study also reported that women 
with pre-existing hypertension were more likely to be obese, have diabetes mellitus, 
hyperlipidaemia, or hypothyroidism.31 Bateman and colleagues (2012) conducted a population 
study in USA using the Nationwide Inpatient Sample from 1995-2008 (56,494,634 deliveries), 
and found chronic hypertension increased from 1.0% in 1995/1996 to 1.8% in 2007/2008.29 
Compared to women without a diagnosis of chronic hypertension, the cohort with chronic 
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Figure 1.1 Nationwide Inpatient Sample trends in age-adjusted prevalence of chronic 
hypertension (primary and secondary hypertension) from 1995-1996 to 2007-2008, as 
published by Bateman and colleagues (2012)29 
 
 
The prevalence of chronic hypertension in pregnancy is rising for several reasons. The overall 
increase in maternal age is likely to make a large impact.33,34 A study by Matthews and 
colleagues (2009) reported that the maternal age at first birth had increased significantly 
between 1970 and 2006 in 14 countries studied with the range of mean increase in the order 
of 2.9 (Sweden) to 4.6 (Denmark) years.5 Data from the National Vital Statistics System in USA 
(2015), demonstrate a reduction in the birth rate of women aged under 30 years, but an 
increase in those aged 30 to 44 years.33,35 This is echoed by the findings of the report for 
previous years.35 Data from the Office of National Statistics in the UK suggest a similar rise in 
the mean age of women giving birth.36  
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Figure 1.2 Data from the Office of National Statistics regarding fertility rates in the United 
Kingdom 1981 to 2015 presented by age range36 
 
Another factor contributing to the rise in prevalence of chronic hypertension in pregnancy is 
the global obesity epidemic.6,37 In the USA in the 1970s, the proportion of women aged 20 to 
39 years with a body mass index greater than 30 kg/m2 was 10%; by 1990 this had risen to 15% 
and by the mid-2000s it was more than 25%.38 In the UK, the proportion of women classified as 
obese was estimated at 18-26%.6 A UK study by Knight and colleagues (2008) of women with 
morbid obesity found that the incidence of chronic hypertension was 6% in pregnant women 
with a body mass index greater than 50 kg/m2 compared to only 1% in those with a mean body 
mass index below 50 kg/m2.39    
 
 
1.1.5 Associated complications of chronic hypertension in the non-pregnant population 
Chronic hypertension is an important preventable cause of morbidity and mortality.1 It is 
strongly associated with an increased risk of cardiovascular disease and cerebrovascular 
disease in addition to renal disease and cognitive decline.1 A recent study by Rapsomaniki and 
colleagues (2014) found that amongst 83,098 cardiovascular disease presentations, the 
association of systolic hypertension was greatest for intracerebral haemorrhage, subarachnoid 
haemorrhage and stable angina, though the risk of all adverse cardiovascular outcomes was 
increased compared to normotensive individuals.40     
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Figure 1.3 Rapsomaniki and colleagues (2014): Lifetime risk (95% confidence interval) of 12 
different cardiovascular diseases at 30 years of age in people with hypertension or normal 
blood pressure 40 
 
Globally nearly one third of all deaths per year are due to cardiovascular disease; of these, 
over half are related to complications of hypertension.41,42 Chronic hypertension accounts for 
at least 45% of deaths from ischaemic heart disease and 51% of deaths from stroke (ischaemic 
and haemorrhagic).41 
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Figure 1.4 Heat map from the World Health Organisation demonstrating the global ischaemic 
heart disease and cerebrovascular disease mortality rates (age standardised, per 100,000)41     
 
1.1.6 Adverse maternal and perinatal outcomes associated with chronic hypertension 
Chronic hypertension is one of the most common pre-existing medical disorders in pregnancy. 
It is associated with a significant increase in adverse maternal and perinatal outcome. Mothers 
with chronic hypertension are at increased risk of pregnancy-specific morbidity such as 
superimposed pre-eclampsia,8,29,43-47 caesarean section,8,29,46 placental abruption,44,48, 
prolonged hospital stay29 and maternal mortality.29,49-51 They are also at an increased risk of 
other end-organ damage and complications: stroke,50,52 pulmonary oedema,29,50,51 and acute 
kidney injury29,50,51. Adverse perinatal outcomes include: prematurity,8,29,45 fetal growth 
restriction,30,45,53,54 neonatal unit admission,8,45 and perinatal death.8,29,55   
 
A recent systematic review of chronic hypertension and pregnancy outcomes by Bramham and 
colleagues (2014), reported a 26% incidence of superimposed pre-eclampsia from meta-
analysis of 38 studies.8 This study additionally compared data from US population studies to 
calculate the relative risk of superimposed pre-eclampsia in women with chronic hypertension 
(relative risk 7.7, 95% confidence interval 5.7 to 10.1) compared to pregnant controls.8 The 
other outcomes meta-analysed in this study included: caesarean section rate 41%, preterm 
birth (<37 weeks’ gestation) 28%, birthweight <2500g 17%, neonatal intensive care admission 
21% and perinatal death rate of 4%. The study was unable to assess other maternal and 
perinatal adverse outcomes due to inconsistencies in the reported outcomes of the studies 
identified. 
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Figure 1.5 Bramham and colleagues (2014), forest plot stratified by study design of studies 
assessing incidence of superimposed pre-eclampsia in women with chronic hypertension. 
(MELR = mixed effects logistic regression)8  
 
Bateman and colleagues (2012) compared maternal and perinatal outcomes in their previously 
described population study between women who did and did not have a diagnosis of chronic 
hypertension (1995 to 2008). Maternal outcomes reported included: superimposed pre-
eclampsia odds ratio (OR) 10.07 (95% confidence interval 9.68 to 10.48), 
stroke/cerebrovascular event OR 5.41 (95% confidence interval 4.27 to 6.86), acute kidney 
injury OR 14.62 (95% confidence interval 12.06 to 17.73), pulmonary oedema OR 9.26 (95% 
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confidence interval 6.67 to 12.85), length of stay greater than six days OR 6.73 (95% 
confidence interval 6.21 to 7.29), and in-hospital mortality OR 6.20 (95% confidence interval 
3.33 to 11.54). The perinatal outcomes reported included: stillbirth OR 2.31 (95% confidence 
interval 2.11 to 2.53), poor fetal growth OR 3.00 (95% confidence interval 2.83 to 3.19) and 
spontaneous preterm birth before 37 weeks’ gestation OR 3.01 (95% confidence interval 2.88 
to 3.14). This study also compared outcomes in a sub-group analysis of women with primary 
versus secondary hypertension and concluded that secondary hypertension was associated 
with a greater risk of all adverse outcomes than primary hypertension. The limitations of this 
study include identification of maternal and perinatal outcome from ICD-9 CM coding and 
difficulties in identifying women with mild chronic hypertension. The outcome of ‘poor fetal 
growth’ ICD-9 CM code 656.6x has high specificity for identifying the babies born with a 
birthweight below the 10th centile, but a low sensitivity as many babies will be misclassified.56 
Additionally the authors concede that certain potential confounders such as ethnicity and body 
mass index could not be adjusted for in the analysis. 
 
Hypertension in pregnancy remains one of the leading causes of maternal death globally.57 
However the recent MBRRACE-UK report showed that maternal deaths in the UK from pre-
eclampsia are at their lowest incidence to date, with the death rate at less than one per million 
maternities for the first time since maternal deaths have been systematically counted.58 An 
editorial by Shennan and colleagues (2017) reported that the proportion of maternal deaths 
from hypertensive disorders of pregnancy was 2·8% in the UK (2012 to 14),58 7·4% in the USA 
(2011 to 13),59 and 14% globally (2013)60.61 In 2011 the Centre for Maternal and Child Enquires 
(CMACE, now known as MBRRACE-UK) triennial report highlighted amongst its key 
recommendations the importance of treating systolic hypertension above 150 mmHg, as 
inadequate blood pressure control was a key factor in the maternal deaths from hypertensive 
disorders during that time period.49 This underlines the importance of epidemiological studies 
such as MBRRACE-UK and demonstrates that death from hypertensive disorders of pregnancy 
is preventable.61 Another study by Leffert and colleagues (2015) evaluated the trends and 
associations of hypertensive disorders in pregnancy with stroke risk in an American population 
study.62 They found that between 1994-1995 and 2010-2011 the rate of stroke with 
hypertensive disorders of pregnancy doubled from 0.8 to 1.6 per 10,000 pregnancy 
hospitalisations, compared with a more modest increase in the rate of stroke from 2.2 to 3.2 
per 10000 pregnancy hospitalisations not affected by hypertensive disorders.62 This increase is 
of particular interest given that a 10-year decline in overall stroke prevalence among older 
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adults in the USA has been reported.63 Unfortunately this study did not subdivide the women 
with hypertensive disorders of pregnancy to allow exploration of the impact of chronic 
hypertension and pre-eclampsia, rather than gestational hypertension alone. 
 
Assessing the impact of chronic hypertension on adverse perinatal outcomes is complex. The 
impact of increased incidence of superimposed pre-eclampsia on adverse perinatal outcome is 
significant, as assessed by Chappell and colleagues (2008).45 This UK-based study compared the 
proportion of infants with birthweight centiles below the 5th and 10th percentile in women with 
chronic hypertension who did and did not develop superimposed pre-eclampsia; they found 
that the risk ratio of birthweight centile <10th was 2.30 (95% confidence interval 1.85 to 2.84) 
in women who developed superimposed pre-eclampsia compared to the women who did not 
and even more strikingly the risk ratio of birthweight centile <5th was 2.94 (95% confidence 
interval 2.27 to 3.80) in the women who developed superimposed pre-eclampsia compared to 
those who did not.45 It is important to note that within this cohort 21% of babies born to 
mothers who did not develop superimposed pre-eclampsia were born with a birthweight <10th 
centile, which is double what would be expected in the general pregnant population.45 This 
underlines chronic hypertension as an independent risk factor for fetal growth restriction. 
Chappell and colleagues additionally report a stillbirth rate of 2.1% in this cohort, three and a 
half times that of the UK general pregnant population (0.6%).36,45 The difference in stillbirth 
rate in women who did and did not develop superimposed pre-eclampsia did not reach 
statistical significance.45 
 
Another population based study from Canada by Allen and colleagues (2004) examined the 
effect of hypertensive disorders in pregnancy on small for gestational age infants and 
stillbirth.54 They analysed data from 135,466 pregnancies and reported that the adjusted odds 
ratio of small for gestational age was significantly increased for all hypertensive disorders of 
pregnancy compared to the Canadian general pregnant population. However, the adjusted 
odds ratio of stillbirth was only significantly raised in women with chronic hypertension (aOR 
3.2, 95% CI 1.9 to 5.4) when rates were compared with the normotensive pregnant 
population.54 
 
There is an ongoing debate regarding the association between antihypertensive agent use and 
fetal growth restriction.64 There is additionally no consensus regarding blood pressure 
thresholds above which chronic hypertension should be treated in pregnancy.14 A meta-
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analysis of changes in mean arterial pressure and fetal growth restriction in pregnancy 
hypertension conducted by von Dadelszen and colleagues (2000), concluded that treatment-
induced falls in maternal blood pressure may adversely affect fetal growth. However, only 
three randomised controlled trials (including 350 women) comparing antihypertensive 
treatment to no treatment/placebo in women with chronic hypertension were included in the 
primary analysis. Differences in the pathophysiology of chronic hypertension and de novo 
hypertension as seen in gestational hypertension and pre-eclampsia may influence these 
findings. A systematic review of treatment of hypertensive disorders in pregnancy by Magee 
and colleagues (1999), did not demonstrate an association between antihypertensive use and 
small for gestational age infants (odds ratio 1.28, 95% confidence interval 0.69 to 2.36), but 
again this study was limited by the number of trials available for analysis.    
 
Studies assessing the impact of maternal characteristics on the risk of adverse perinatal 
outcome are limited. Further investigation of the factors that contribute to adverse perinatal 
outcome in women with chronic hypertension are needed. An understanding of these risk 
factors would guide research into the mechanisms, pathophysiology and potential treatment 
targets for women with chronic hypertension in pregnancy. Definitions of morbidity change 
over time and implications of diagnoses on long-term maternal and infant health need to be 
considered. An example of this is the definition of small for gestational age and fetal growth 
restriction; the former is widely accepted as neonatal birthweight below the 10th percentile 
and is associated with less morbidity and mortality than fetal growth restriction, which has 
recently been defined as birthweight below the 3rd percentile.65 Further studies using these 
definitions in pregnancy complicated by chronic hypertension are warranted. 
 
1.2 The physiology of blood pressure and pathophysiology of hypertension 
 
1.2.1  The physiology of blood pressure 
Blood pressure describes the maximum (systolic) and minimum (diastolic) pressure of the 
systemic arterial circulatory system. Blood is pumped from the left ventricle in cardiac systole 
into the aorta and then onto the arterial system before entering the peripheral capillaries and 
finally the venous system.17 The maximum pressure in the arteries occurs during cardiac 
systole and the minimum during diastole when the left ventricle is relaxed. The haemodynamic 
factors primarily affecting blood pressure include blood volume, cardiac output and systemic 
vascular resistance.17 There are many mechanical, hormonal and neurological influences on 
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these haemodynamic factors that achieve homeostasis in blood pressure in normotensive 
individuals. Consequently, an imbalance in haemodynamic factors can lead to hypertension (or 
hypotension) and an understanding of the pathophysiology unpinning these changes offers 
insight into potential treatment targets.    
  
 
Figure 1.6 Diagram of the human circulatory system highlighting in red the left ventricle and 
the arterial systemic circulation which establish blood pressure (Boston University School of 
Public Health)66 
 
Our understanding of the endogenous mechanisms controlling blood pressure is incomplete, 
but some key influences are well described. The systemic renin-angiotensin-aldosterone 
system (RAAS) is hormonally based and regulates plasma sodium concentration and 
consequently arterial blood pressure.67 Renin is secreted into the circulation primarily by the 
kidney (though it can be secreted by other organs) following conversion from prorenin (an 
intracellular protein) in the juxtaglomerular cells. It acts to cleave angiotensinogen (produced 
by the liver) into angiotensin I. Angiotensin I is then converted into the active vasoconstrictor 
angiotensin II by angiotensin-converting enzyme (ACE). ACE is found in endothelial cells of 
capillaries throughout the body, especially within the lungs and additionally in the epithelial 
cells of the kidneys. Angiotensin II causes the arterioles to constrict leading to increased blood 
pressure. Aldosterone secretion from the adrenal cortex is also stimulated by angiotensin II. 
Aldosterone acts to increase sodium reabsorption in the tubular epithelial cells of the kidneys 
back into the blood and increases renal potassium excretion.17 Aldosterone secretion can also 
be stimulated by high potassium, which plays a role in the pathophysiology of some secondary 
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causes of hypertension. Sodium retention increases intravascular fluid retention and 
consequently increases blood volume and indirectly increases blood pressure. 17 
 
 
Figure 1.7 Schematic representation of the systemic renin-angiotensin-aldosterone system68 
 
The autonomic nervous system also plays a role in blood pressure homeostasis.17 One of the 
principal actions is via the baroreceptors that are located in the aortic arch and the carotid 
sinuses in addition to other circulatory sites. These mechanoreceptors are sensitive to stretch 
and provide a rapid negative feedback loop via the central nervous system when blood 
pressure is increased, lowering heart rate and cardiac output, and consequently lowering 
blood pressure. If blood pressure is low, they act to increase heart rate and blood pressure. 
Baroreceptors also regulate secretion of renin and aldosterone, in addition to antidiuretic 
hormone (ADH). ADH (also known as vasopressin) is produced by the posterior pituitary gland. 
Its principal action is on the kidneys, causing water retention, but at very high levels it also 
causes vasoconstriction which in turn causes hypertension.17 Atrial natriuretic peptide (ANP) is 
secreted by the cardiac atrial myocytes in response to increased atrial filling pressure. It 
stimulates excretion of sodium and water in the renal tubules and has a weak vasodilator 
effect.17 Another group of hormones that interact with the autonomic nervous system are the 
catecholamines. Catecholamines such as adrenaline and noradrenaline are secreted by the 
adrenal medulla in response to stress and act on the sympathetic nervous system to cause the 
‘flight or fight’ response. This response in turn causes increased heart rate and hence 
increased blood pressure.17        
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1.2.2  The pathophysiology of hypertension  
The aetiology of primary hypertension is unclear. Primary hypertension describes chronically 
elevated arterial blood pressure without evidence of another causative disease process, but 
the disorder demonstrates strong associations with hereditable and environmental factors.9,69 
Animal models of genetic hypertension and human Mendelian forms of hypertension have 
provided insight into possible pathways that are disrupted in blood pressure homeostasis with 
most mechanisms relating to renal sodium reabsorption.69 Genetic studies in humans have 
revealed some population specific information about disease susceptibility from genome-wide 
association studies.70-72 However unpicking the effect of genetics from environmental risk 
factors, such as obesity, salt intake, smoking and alcohol intake, is complex.9  
 
Dysfunction of the hormonal pathways influencing blood pressure homeostasis have been 
characterised as specific disease processes causing secondary hypertension, such as Cushing’s 
and Conn’s syndromes causing hyperaldosteronism; however no consistent alterations in the 
systemic RAAS have been implicated in the pathophysiology of primary hypertension.73 On the 
contrary, marked heterogeneity in circulating renin and aldosterone levels exists in those with 
and without a diagnosis of hypertension.67 Further exploration of the variation in renin 
concentration amongst individuals with primary hypertension has shown that the majority 
have normal or high plasma renin activity, but around one third have low or supressed 
renin.67,73 Low plasma renin levels are associated with increased salt sensitivity and have been 
found more commonly in those of African or Caribbean ethnicity.74,75 These initial studies of 
serum plasma renin activity have been corroborated by genetic studies linking specific 
genotypes to low renin hypertension.76  
 
Variation in pathophysiology underpinning primary hypertension has been further elucidated 
through disparity in antihypertensive agent response. Antihypertensive agents targeting the 
RAAS, such as angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin 
receptor blockers (ARBs), are considered most effective at controlling blood pressure and 
reducing morbidity and mortality in those of non-Black ethnicity.1,77 However, evidence 
reported by Leenen and colleagues (2006) from the ALLHAT study (Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart Attack Trial) (total participants n=18,102), demonstrated 
an increased risk of combined cardiovascular disease (risk ratio 1.13; 95% confidence interval 
1.02 to 1.24) and stroke (risk ratio 1.51; 95% confidence interval 1.22 to 1.86) when lisinopril 
(ACE inhibitor) was prescribed as first-line antihypertensive treatment compared with 
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amlodipine (calcium-channel blocker) in Black participants (amlodipine n=3213 versus lisinopril 
n=3210).78 A further secondary analysis of the ALLHAT study by Piller and colleagues (2006) 
also reported an increase in the risk of angioedema in Black participants prescribed lisinopril 
compared to amlodipine or chlorthalidone (diuretic).79 More recently pharmacogenetic studies 
have aimed to provide insight into the ethnic variation in drug response, but quantifying the 
heritable contribution to drug response variability makes the clinical translation of such studies 
a challenge.80    
 
 
Figure 1.8 Brewster and colleagues (2013): Differences in clinical efficacy of antihypertensive 
drugs in ancestry groups81 
Data depicted are pooled estimates (95% confidence intervals) from systematic reviews.82,83 
ACE-i, angiotensin converting enzyme inhibitors. *Mean blood pressure reduction (mmHg). 
†The depicted difference is the weighted pooled difference in response between ancestry 
groups, with positive values indicating a greater response in patients of African ancestry and 
negative values indicating a greater response in patients of European ancestry. 
 
Hypertension has previously been demonstrated to impair baroreceptor modulation of heart 
rate.84-86 However, primary hypertension does not appear to alter the baroreflex sympathetic 
nervous system activity.87 More recently research has re-evaluated the association of 
sympathetic nervous system activity and hypertension.88 Novel device-based therapeutic 
interventions decreasing renal and systemic sympathetic nervous system activity have 
successfully reduced hypertension in drug-resistant individuals,88 however, the long-term 
success of renal denervation has not been repeated in larger more recent trials89 and this 
treatment is not yet recommended by national guidelines.1 Perhaps the most important 
association between sympathetic activation and elevated blood pressure is in obesity related 
hypertension. Animal models of obesity demonstrate a variety of associations between 
adiposity and activation of the sympathetic nervous system contributing to the subsequent 
development of hypertension.90-92 Given the international obesity epidemic, further 
investigation of the relationship between obesity and hypertension in humans is needed. 
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There are many causes of secondary hypertension. The relationship between secondary 
hypertension and the underpinning pathophysiology is usually clearer. The most common 
cause is chronic kidney disease.17 The key role of the kidney in plasma volume homeostasis 
conveys a significant effect of renal dysfunction on blood pressure equilibrium. Examples of 
endocrinological causes of secondary hypertension include hyperaldosteronism (Conn’s 
syndrome-an adrenal cortex tumour), excess glucocorticoid steroid production (Cushing’s 
syndrome), or excess catecholamine secretion (phaeochromocytoma-tumour of the adrenal 
medulla), which cause hypertension through hormonal excess within the pathways that 
maintain blood pressure homeostasis.17 There are many other less common causes of 
secondary hypertension which should be considered to ensure appropriate treatment in 
addition to blood pressure reduction with antihypertensive agents.      
 
1.2.3  The physiology of blood pressure in pregnancy  
The primary physiological change that occurs in pregnancy altering blood pressure 
homeostasis is marked vasodilatation of both the systemic and renal vasculature.93 This 
vasodilation occurs as early as five weeks’ gestation and is estimated to reach its nadir in the 
second trimester with either a plateau or slow increase towards the end of the third 
trimester.11 A recent study by Mahendru and colleagues (2014) in 54 women estimated 
changes in cardiac output and peripheral vascular resistance using a non-invasive inert gas re-
breathing technique, prior to conception and subsequently at 6, 23, and 33 weeks during their 
low-risk pregnancies and at 16 weeks postpartum. The relationship between time before, 
during and after pregnancy between cardiac output and peripheral vascular resistance is 
demonstrated in Figure 1.9. A reciprocal relationship between cardiac output and peripheral 
vascular resistance during pregnancy was observed. Cardiac output increased from 
preconception measures into the second trimester, remained increased during the third 
trimester, and then decreased back to baseline by 16 weeks’ postpartum. The peripheral 
vascular resistance decreased significantly from preconception levels by the second trimester, 
but increased in the third trimester and had returned to preconception values by 16 weeks 
postpartum.11  
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Figure 1.9 Mahendru and colleagues (2014): Longitudinal changes in cardiac output and 
peripheral vascular resistance from preconception to the postpartum period11 
 
The marked vasodilation appears to relate to the rise in circulating oestradiol and 
progesterone;94,95 however understanding of the mechanisms underpinning these changes is 
incomplete. Relaxin is a peptide hormone that has been shown to substantially rise in the 
maternal circulation during the first trimester before falling slightly across the second and third 
trimesters.96,97 A study by Kristiansson and colleagues on a Swedish cohort of 200 pregnant 
women found a significant relationship between higher first trimester relaxin and 
progesterone levels (but not oestradiol) and lower systolic blood pressure levels in the second 
and third trimester.98 They also noted lower relaxin levels in the first trimester were associated 
with subsequent diastolic blood pressure readings >90 mmHg.98 Nitric oxide is a potent 
vasodilator that appears to play an important role in reproductive physiology;99 however, 
studies conducted to date provide conflicting results regarding the role of nitric oxide in the 
vasodilation of pregnancy.100,101 This may relate to the instability of nitric oxide ex vivo and the 
complex models required to estimate activity.102  
 
Blood pressure, both systolic and diastolic, decrease in early pregnancy from pre-pregnancy 
values by 5 to 10 mmHg.11,12 The nadir of gestational arterial pressure is likely to occur in the 
second trimester. The study conducted by Mahendru and colleagues (2014) of 54 women, 
demonstrated a significant fall in blood pressure measures from pre-conception levels as early 
as six to eight weeks’ gestation. Interestingly they found the 16 week postpartum values of 
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blood pressure remained significantly lower than the pre-conception values and though the 
authors postulate that this may be because other studies compare gestational and postnatal 
blood pressure values, it seems probable that these findings require exploration in a larger 
cohort with evaluation of the impact of other hormonal influences such as breast feeding.11 
Grindheim and colleagues (2012) evaluated the impact of gestation on 57 women at 15, 23, 31 
and 36 weeks’ gestation and at six months postpartum, and demonstrated a nadir in blood 
pressure at 23 weeks’ gestation, with six month postpartum levels significantly higher than 
gestational values.12 Given the large number of demographic factors that influence blood 
pressure in normotensive women such as ethnicity, age and body mass index, the nadir of 
blood pressure readings is likely to vary depending on the sample of women studied and these 
findings serve primarily to highlight that raised blood pressure measures recorded before 20 
weeks’ gestation in women previously thought to be normotensive, are likely to represent 
underlying chronic hypertension.  
 
 
Figure 1.10 Mahendru and colleagues (2014): Serial blood pressures before, during and after 
pregnancy11 
 
The RAAS is upregulated in pregnancy as early as the first trimester.103 Renin is secreted by 
extra-renal sites such as the ovaries and maternal decidua, and increased oestrogen acts on 
the liver to increase circulating angiotensinogen.104 This causes an increase in angiotensin II 
and aldosterone concentrations.105 Angiotensin converting enzyme is the only RAAS 
component that has been demonstrated to fall during pregnancy.106 Activation of the RAAS in 
pregnancy is thought to maintain blood pressure by aiding salt and water retention, when 
Student Number: 1355203 
Student Name: Louise Mary Webster 
38 
 
maternal systemic and renal arterial dilation are creating a relatively underfilled circulatory 
system.10 Despite the increase in systemic RAAS concentrations, normotensive pregnant 
women appear to be refractory to the increase in angiotensin II and its vasopressor effects. A 
study reported by Assali and colleagues (1961) used animal models to demonstrate that 
pregnant dogs and sheep required double the intravenous infusion of angiotensin II compared 
with non-pregnant female dogs and sheep to achieve the same vasomotor response.107 A 
subsequent study in humans conducted by Gant and colleagues (1980), postulated that 
increased progesterone and prostacyclins found in pregnancy may decrease maternal 
sensitivity to angiotensin II.108 There remains much about the role of the systemic RAAS in the 
normal physiology of pregnancy that is poorly understood. 
 
1.2.4  Pathophysiology of chronic hypertension in pregnancy and superimposed pre-
eclampsia 
Women with uncomplicated chronic hypertension in pregnancy also demonstrate gestational 
fall in blood pressure. A longitudinal case-control study conducted by August and colleagues 
(1990) included 30 pregnancies in women with chronic hypertension and 14 normotensive 
pregnant controls. Mean blood pressure was compared prior to conception, and then at 10, 
20, 28, 32 and 38 weeks’ gestation between women with uncomplicated chronic hypertension 
in pregnancy (n=17), women with chronic hypertension who developed superimposed pre-
eclampsia (n=13), and normotensive pregnant controls (n=14). In all women a gestational fall 
in blood pressure was observed in the first and second trimesters, with subsequent rise in the 
third trimester (Figure 1.11), but in women with superimposed pre-eclampsia, this increase 
was greater.109 Another study by Tihtonen and colleagues (2007) demonstrated other 
gestational haemodynamic differences between women with chronic hypertension (n=20) and 
normotensive controls (n=30), including increased systemic vascular resistance index and pulse 
wave velocity.110 Stroke volume index was significantly lower in the early second trimester in 
women with chronic hypertension compared to normotensive women, which led the 
investigators to conclude that women with chronic hypertension may have a reduced 
intravascular volume increase during pregnancy.110     
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Figure 1.11 August and colleagues (1990): Serial changes in systolic and diastolic blood 
pressure in women with chronic hypertension and superimposed pre-eclampsia (open 
triangle), women with uncomplicated chronic hypertension (filled circle), and normotensive 
pregnant controls (open square)109 
 
The mechanisms underpinning the increased incidence of pre-eclampsia in women with 
chronic hypertension are yet to be elucidated fully. It has been suggested that women at 
increased risk of pre-eclampsia have genetic, biochemical, and metabolic abnormalities that 
are similarly associated with chronic hypertension.111 These abnormalities include a higher 
incidence of polymorphisms in the angiotensinogen gene, obesity, hypertriglyceridaemia, and 
insulin resistance. Variation in the RAAS has also been explored. The case control study 
conducted by August and colleagues (1990) quantified plasma renin activity and urinary 
aldosterone concentration in normotensive pregnant women and women with chronic 
hypertension who did and did not develop superimposed pre-eclampsia.109 Plasma renin 
activity decreased significantly between 20 to 32 weeks’ gestation in women who developed 
superimposed pre-eclampsia and increased significantly in normotensive pregnant controls. In 
women with uncomplicated chronic hypertension in pregnancy, plasma renin activity 
remained constant across gestation. Plasma renin activity was significantly lower in women 
with superimposed pre-eclampsia in the third trimester when compared to pregnant women 
with uncomplicated chronic hypertension and normotensive pregnant controls. Additionally 
this study found that urinary aldosterone concentrations were significantly lower in the third 
trimester in women with superimposed pre-eclampsia compared to both pregnant women 
without superimposed pre-eclampsia and normotensive pregnant controls.109  
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1.3 Current management strategies for chronic hypertension in pregnancy 
 
1.3.1 Pre-pregnancy advice 
Routine pre-pregnancy counselling for all women with pre-existing medical disorders is 
recommended by serial reports from MBRRACE-UK in order to optimise their medical 
condition prior to starting pregnancy.49 This is of particular importance in women with chronic 
hypertension, given the associated increased risk of maternal and perinatal morbidity and 
mortality.16 Discussion regarding potential change in antihypertensive treatment to agents that 
are safe in pregnancy and optimisation of blood pressure control are recommended.7 General 
health advice and discussion of potential lifestyle and dietary changes that may benefit 
pregnancy outcome are also advised.16 
 
Antihypertensive agents recommended in the non-pregnant population are outlined by the 
NICE guideline for the management of hypertension in adults;1 however not all of these drugs 
are considered safe in pregnancy.16 Outside of pregnancy, in those aged under 55 years of age 
(not of African or Caribbean family origin), ACE inhibitors or ARBs are recommended as first 
line treatment, and in those aged over 55 years or of African/Caribbean family origin, calcium 
channel blockers are recommended as first line treatment.1 If ACE inhibitors, ARBs or 
chlorothiazide are taken and pregnancy is confirmed, change of treatment to an agent 
recognised as safe for use in pregnancy (see below) is recommended.16  
 
1.3.2 Antenatal care pathways 
Pregnancy complicated by chronic hypertension is considered high risk and obstetric 
consultant-led care is recommended in the UK. The number of antenatal visits will be tailored 
to each woman and dictated by maternal history and events within the pregnancy. A detailed 
history and examination should be taken at the first medical antenatal appointment to 
establish whether the hypertension is primary or secondary and if further investigations or 
other specialist referral in pregnancy are required. Pregnancy represents an opportunity to 
further promote dietary and lifestyle changes that could impact the disease process associated 
with chronic hypertension; it may also be the first time the condition is diagnosed, and it is 
therefore important to ensure appropriate investigations and follow up are instigated. Women 
with secondary hypertension may need additional specialist care in pregnancy from an 
Obstetric Physician, Nephrologist, Cardiologist, or Endocrinologist, depending on the 
secondary cause and its severity. 
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1.3.3 Prevention of superimposed pre-eclampsia 
Chronic hypertension in pregnancy is associated with a four-fold increase in the risk of 
developing superimposed pre-eclampsia compared to the background pregnant population.8 
Changes in the platelet and clotting cascade that occur early in the pathogenesis of pre-
eclampsia have led researchers to explore antiplatelet agents for prevention of pre-eclampsia. 
A Cochrane review of the trials examining the efficacy of aspirin in prevention of pre-eclampsia 
in high risk pregnancies, found a 17% risk reduction with aspirin use compared to no active 
intervention (46 trials, 32,891 women; relative risk 0.83, 95% conﬁdence interval 0.77 to 
0.89).112 Reduction in the risk of preterm birth (29 trials, 31,151 women; relative risk 0.92, 95% 
confidence interval 0.88 to 0.97), fetal or neonatal deaths (40 trials, 33,098 women; relative 
risk 0.86, 95% confidence interval 0.76 to 0.98) and small-for-gestational age babies (36 trials, 
23,638 women; relative risk 0.90, 95% confidence interval 0.83 to 0.98) was also found to be 
associated with the use of antiplatelet agents compared to no active intervention.112 There 
remains ongoing debate regarding the potential utility of low-dose aspirin for prevention of 
pre-eclampsia in low-risk pregnant women.113 Although evidence for the optimal time to 
commence aspirin prophylaxis, and the optimal dose are not available, national UK guidance 
recommends 75mg/day is prescribed from 12 weeks’ gestation (as this was the gestation that 
treatment was commenced in most of the trials).16 
 
Other dietary supplements have been trialled for prevention of pre-eclampsia including 
calcium114 and vitamins such as C and E115, but the evidence for routine use of these 
supplements is lacking. There are ongoing trials assessing other supplements including folic 
acid. Initial data suggested that a significant risk reduction in the incidence of pre-eclampsia 
with high dose folic acid 4mg/day (adjusted odds ratio 0.37, 95% confidence interval 0.18 to 
0.75).116 However, these data were from an initial cohort study, and the results from the 
subsequent multicentred international Folic Acid randomised Controlled Trial (FACT) that has 
recently completed recruitment, are awaited.117  
 
 
1.3.4 Fetal monitoring 
The increased risk of fetal growth restriction, hypoxia and intrauterine death in pregnancy 
complicated by chronic hypertension has been established.8 Data regarding optimal fetal 
monitoring by ultrasound from cohorts of women with chronic hypertension are limited.16 
Uterine artery Doppler flow velocity waveforms are commonly measured around 20 weeks’ 
gestation, as raised mean pulsatility index (or resistance index) is associated with an increased 
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risk of subsequent fetal growth restriction and superimposed pre-eclampsia.118,119 Assigning 
level of risk can in turn guide frequency of subsequent longitudinal assessment of fetal 
biometry, liquor volume and fetal Doppler assessment, but the evidence for this management 
strategy is limited.16 National guidance currently recommends routine fetal biometry, liquor 
volume and fetal Doppler assessment around 28 weeks and 34 weeks’ gestation in pregnancy 
complicated by chronic hypertension. This should allow timely detection of fetal growth 




The routine use of cardiotocography for antenatal monitoring of fetal wellbeing in pregnant 
women with chronic hypertension is not recommended. However, routine cardiotocography 
during labour is recommended in UK intrapartum care guidance120 and healthcare 
professionals should be vigilant for abnormal fetal heart rate patterns and the increased risk of 
placental abruption in this group.43 
 
 
Figure 1.12 Doppler uterine artery assessment showing (A) normal flow velocity waveform 
with low resistance, and (B) abnormal flow velocity waveform with an early diastolic notch 
(arrow) and a high resistance index (James and colleague 2004)23 
 
1.3.5 The challenges of measuring blood pressure in pregnancy 
Accurate measurement of blood pressure in pregnancy is vital for diagnosis and safe 
management of chronic hypertension in pregnancy.121 National antenatal care guidelines 
highlight factors to be considered by all healthcare professionals when measuring blood 
pressure in pregnancy.22 These include: the use of a correctly sized inflation cuff, inflation of 
the cuff to 20-30 mmHg above the palpable systolic blood pressure, deflation of the cuff at a 
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rate of 2 mmHg per second, recording the blood pressure to the nearest 2 mmHg and use of 
Korotkoff V (disappearance of the sound) to indicate diastolic blood pressure.  
 
In practice many of these recommendations are not adhered to. Studies both in and outside 
pregnancy have identified the phenomenon of ‘terminal digit preference’ with healthcare 
professionals of all clinical backgrounds rounding blood pressure measures to the nearest 10 
mmHg.122,123 The incorrect selection of inflation cuff size is also commonly reported.121 If the 
arm circumference is greater than 33 cm a large cuff is mandated or the blood pressure 
recorded will be falsely elevated and therefore inaccurate.124 Pregnancy is associated with 
variable weight gain and consideration of arm circumference should be made at each 
antenatal assessment. 
 
Automated blood pressure devices may overcome much of the interobserver variation in 
blood pressure measurement described above, however, due to the physiological changes in 
maternal vasculature associated with pregnancy, individual machines require validation for use 
in pregnancy.125 Automated blood pressure devices that are not validated for use in pregnancy 
underestimate blood pressure in pre-eclampsia.126 This is thought to relate to decreased 
vascular compliance and increased interstitial oedema associated with pre-eclampsia.127 
 
In view of the importance of accurate blood pressure measurement in women with chronic 
hypertension in pregnancy, it is vital that clinicians caring for women with this condition are 
able to measure blood pressure correctly. Healthcare professionals should be aware of the 
advantages and disadvantages of the blood pressure devices available for use in pregnancy 
and feel able to raise concern regarding devices inaccurate for use in pregnancy or poor 
technique observed.    
 
1.3.6 Treatment initiation and therapeutic blood pressure targets 
Internationally, guidelines vary regarding the threshold above which hypertension should be 
treated in pregnancy.14 The UK guideline for the treatment of hypertension in pregnancy 
recommends that pregnant women with hypertension (gestational or primary chronic 
hypertension) should be prescribed antihypertensive treatment if blood pressure exceeds 
150/100 mmHg.16 The American College of Obstetricians and Gynaecologists recommends 
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utilising antihypertensive treatment to control chronic hypertension in pregnancy if blood 
pressure  exceeds 160/105 mmHg.128  
 
Once treatment is initiated, guidance for therapeutic blood pressure targets also varies.14 
There is evidence that control of blood pressure in pregnancy needs to be carefully balanced. 
Persistent severe hypertension causes end organ damage to the mother, but lowering the 
blood pressure too far is postulated to reduce placental blood flow and in turn increase the 
risk of fetal growth restriction.129,130 The Control of Hypertension In Pregnancy Study (CHIPS) 
randomised women with hypertension in pregnancy to ‘tight’ (target diastolic blood pressure 
85 mmHg) or ‘less tight’ control (target diastolic blood pressure 100 mmHg).15 Magee and 
colleagues (2015) reported that ‘tight’ control (versus ‘less tight’ control) did not impact the 
primary composite perinatal outcome of pregnancy loss and high-level neonatal care within 
the first 48 hours of infant life (31.4% versus 30.7%) or the overall risk of small for gestational 
age infants (birthweight <10th centile) ‘tight’ control 16.1% versus ‘less tight’ control 19.7% 
(odds ratio 0.78, 95% confidence interval 0.56 to 1.08). Subgroup analyses of those with 
chronic hypertension suggested a possible trend towards small for gestational age birthweight 
<10th centile (13.9% versus 19.7%; adjusted odds ratio 0.66, 95% confidence interval 0.44 to 
1.00), however it was notable that in this subgroup the primary perinatal outcome was no 
different (odds ratio 1.08, 95% confidence interval 0.78 to 1.51). The frequency of severe 
hypertension was significantly higher with less-tight control (40.6% versus 27.5%; odds ratio 
1.8, 95% confidence interval 1.3 to 2.4).15 There are likely to be additional benefits of reducing 
the incidence of severe hypertension through a decrease in short and long-term maternal 
morbidity and mortality from stroke and other end-organ damage,49,62,131-133 and potential cost 
savings with a reduction in healthcare resource use.134,135  
 
1.3.7 Timing of birth 
The timing of birth will depend on the maternal and fetal condition during pregnancy. If 
complications such as superimposed pre-eclampsia or fetal growth restriction develop, 
delivery may be expedited. However if the maternal condition is stable, and fetal biometry, 
liquor volume and Dopplers are normal, there are limited data in women with chronic 
hypertension to guide timing of birth once 37 weeks’ gestation is reached.16 The HYPITAT study 
(2009) reported findings from 756 women with gestational hypertension or mild pre-eclampsia 
and singleton pregnancies enrolled at 36 to 41 weeks’ gestation, who were randomly assigned 
to immediate delivery (within 24 hours) versus expectant management.136 There was a 
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significant reduction in the primary composite maternal adverse outcome (maternal mortality, 
eclampsia, HELLP syndrome, pulmonary oedema, thromboembolic disease, placental 
abruption, progression to severe hypertension or proteinuria, and major post-partum 
haemorrhage): 31% in the immediate delivery group versus 44% in the expectant management 
group (relative risk 0.71, 95% confidence interval 0.59 to 0.86). There were no differences in 
perinatal outcomes. Although Koopmans and colleagues did not enrol women with chronic 
hypertension, the findings of this study have been applied to national guidance and it is 
recommended that clinicians consider offering initiation of delivery from 37 weeks’ gestation 
following discussion of the potential risks and benefits with the individual woman and her 
partner.16 
 
The HYPITAT- II trial (2015) compared immediate birth versus expectant management in 897 
women with hypertensive disorders of pregnancy between 34 and 37 weeks’ gestation.137 
Broekhuijsen and colleagues found a small decrease in the composite adverse maternal 
outcome in those randomised to immediate birth versus those managed expectantly (1.1% 
versus 3.1%; relative risk 0.36, 95% confidence interval 0.12 to 1.11), but a significant increase 
in neonatal respiratory distress syndrome associated with immediate delivery versus expectant 
management (5.7% versus 1.7%; relative risk 3.3, 95% confidence interval 1.4 to 8.2).137 The 
authors concluded that ‘for women with non-severe hypertensive disorders at 34 to 37 weeks’ 
gestation, immediate delivery might reduce the already small risk of adverse maternal 
outcomes, but it signiﬁcantly increases the risk of neonatal respiratory distress syndrome, 
therefore, routine immediate delivery does not seem justiﬁed’. A limitation of this study was 
the inclusion of a heterogeneous group of women with hypertensive disorders of pregnancy. 
Pre-eclampsia is associated with a greater risk of adverse outcomes than gestational 
hypertension.138,139 The maternal and perinatal risks and benefits of immediate birth versus 
expectant management between 34 and 37 weeks’ gestation in women with pre-eclampsia is 
currently being examined in the PHOENIX trial (Pre-eclampsia in HOspital: Early iNductIon or 
eXpectant management: http://www.isrctn.com/ISRCTN01879376). The optimal timing of 
delivery in women with chronic hypertension warrants further investigation.         
 
1.3.8 Postnatal considerations 
National UK guidance for the management of women with hypertensive disorders 
recommends a minimum of daily maternal blood pressure monitoring for the first two days 
after birth, with a further blood pressure assessment between three to five days postpartum, 
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when blood pressure often increases.16 Additional monitoring during the postnatal period and 
prior to the six-week check with the woman’s primary care physicians will depend on blood 
pressure control and the complications that have arisen during the pregnancy, such as 
superimposed pre-eclampsia.16 Ideally the antihypertensive agent regime used during the 
pregnancy should be continued in the immediate postpartum period, but if methyldopa has 
been prescribed, cessation and initiation of a different agent is recommended within two days 
of birth due to the risk of postpartum depression.16 Antihypertensive agents that have no 
known adverse effects on breastfed infants include: labetalol, nifedipine, enalapril, captopril, 
atenolol, and metoprolol.16 Choice of agent will depend on pre-pregnancy treatment and the 
existence on other underlying pathology; for example, enalapril may be preferentially 
considered for women with chronic kidney disease.23 The target blood pressure is <140/90 
mmHg as per UK guidance for the management of hypertension outside pregnancy.1 The 
minimum standard of care required at the six-week postnatal review should include blood 
pressure measurement, urinanalysis to check for proteinuria and review of long term 
antihypertensive treatment.16  
 
The importance of postnatal follow-up is highlighted in a study conducted by Cirillo and 
colleagues (2015) which examined the relationship between pregnancy complications and 
cardiovascular disease or death in a 50-year follow-up of the Child Health and Development 
Studies pregnancy cohort.140 Their study included 14,062 women and found that pre-existing 
hypertension was associated with a hazard ratio of 3.5 (95% confidence interval 2.4 to 5.1) of 
death from cardiovascular disease compared to women without pre-existing hypertension and 
that if women with pre-existing hypertension developed superimposed pre-eclampsia, the risk 
of death increased further (hazard ratio 5.6; 95% confidence interval 2.09 to 15.18).140  
 
Pregnancy offers a unique opportunity to educate and empower women with chronic 
hypertension, in addition to optimising treatment and improving understanding of the impact 
of their disorder on their future health. 
 
1.4 Antihypertensive treatment  
Choice of antihypertensive agent in pregnancy is restricted by potential teratogenicity. Robust 
safety data for each class of drugs, as well as individual agents, are limited.  Antihypertensive 
agents commonly used in pregnancy include labetalol (combined alpha and beta-blocker), 
nifedipine (calcium channel blocker) and methyldopa (centrally acting agent).141 A population 
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study conducted by Cea and colleagues (2014) reported antihypertensive prescribing patterns 
captured by The Health Improvement Network (THIN) primary care database in 1995 women 
with chronic hypertension who were pregnant between 1996 and 2010.31 Only 36% of this 
cohort were prescribed antihypertensive treatment in the three months prior to pregnancy 
and the most common antihypertensive agents were diuretics (11%), beta-blockers (10%) and 
ACE inhibitors (10%). The most commonly prescribed antihypertensive agents in pregnancy 
were methyldopa and labetalol. This study was limited by the lack of secondary care data; high 
risk pregnancies, such as those complicated by chronic hypertension, are frequently cared for 
exclusively by obstetricians in secondary or tertiary care settings.  
 
Another population study conducted on the Medicaid beneficiaries in the USA by Bateman and 
colleagues (2012), examined the antihypertensive agent prescriptions in pregnancies between 
2000 to 2007.142 They found that in the three months prior to pregnancy, the most common 
medication classes were beta blockers, thiazides, ACE inhibitors, dihydropyridines (sub-group 
of calcium channel blockers), and central alpha antagonists. These agents were also the most 
common classes of exposure during the first trimester (though the proportion prescribed 
central alpha antagonists such as methyldopa, was much greater). In the second trimester, the 
proportion of women prescribed ACE inhibitors and thiazides had markedly reduced, and the 
proportion exposed to central alpha antagonists (methyldopa 42%), alpha beta blockers 
(labetalol 15%), and dihydropyridines (nifedipine 20%) increased. The most commonly 
prescribed agents in the third trimester were similar to those used in the second. The 
limitations of this study include the lack of detail regarding which agents were prescribed for 
which condition, and the assumption that all antihypertensive agents were being prescribed as 
blood pressure lowering treatment. Nifedipine can be prescribed in the third trimester off-
licence as a tocolytic and this is likely to have contributed to the substantial increase in the 
proportion of women prescribed dihydropyridines in the third trimester. 
 
The challenge of assessing the risk of teratogenicity of antihypertensive agents is increased 
due to the impact of the disease process itself on the risk of congenital malformations. 
Bateman and colleagues conducted a matched case-control study comparing data collected 
from a Medicaid cohort (878,126 women) and compared normotensive controls with women 
with treated and untreated chronic hypertension to compare the risk of congenital 
malformations.143 Pregnancies complicated by treated chronic hypertension compared to 
normotensive controls were at increased risk of congenital malformations (odds ratio 1.3, 95% 
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conﬁdence interval 1.2 to 1.5); however pregnancies with untreated chronic hypertension 
compared with normotensive controls were also at increased risk (odds ratio 1.2, 95% 
confidence interval 1.1 to 1.3). The analysis of organ-specific malformations revealed that 
treated and untreated chronic hypertension was associated with a signiﬁcant increase in the 
risk of cardiac malformations (odds ratio 1.6, 95% confidence interval 1.4 to 1.9 and odds ratio 




Labetalol is a racemate with alpha and non-selective beta adrenoceptor antagonist activity. 
Two of the four isomers contained within the clinical preparation are active, causing non-
selective competitive beta-1 and beta-2 receptor blockade, selective competitive blockade of 
post synaptic alpha-1 receptors, and partial agonist activity at the beta-2 receptors.144 
Labetalol is between three and seven times more potent for beta blockade than alpha 
blockade, an effect that is most apparent at low oral doses and when given intravenously.145,146 
Blood pressure is lowered partially through alpha blockade causing decreased peripheral 
vascular resistance and therefore vasodilation, activation of the beta-2 adrenoreceptors on the 
vascular smooth muscle, and beta-1 adrenoceptor blockade preventing reflex sympathetic 
stimulation of heart rate and cardiac output, and reducing renal renin secretion.146,147  
 
Figure 1.13 Chemical structure of labetalol (5-(1-hydroxy-2-[(1-methyl-3-phenylpropyl) 
amino] ethyl) salicylamide)(Magee and colleagues, 2015)144 
 
Pharmacokinetics 
Labetalol has extensive first-pass hepatic metabolism and demonstrates increased 
bioavailability when taken with food.148 Peak plasma concentrations usually occur two hours 
after oral ingestion and maximal blood pressure lowering effect is noted one to four hours 
post ingestion.144 Approximately 60% of the drug is renally excreted.148 It has a short half-life (4 
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to 6 hours), requiring dosing to be split to two to three times per day, which can contribute to 
difficulties with adherence. A recent study examining the impact of gestation on the 
pharmacokinetics of labetalol by Fisher and colleagues (2014) found a significant increase in 
the oral clearance rate across gestation and when compared to the oral clearance rate outside 
pregnancy.149 Possible side-effects include drowsiness, weakness, and somnolence, and it is 
relatively contraindicated in women with asthma as it can cause bronchospasm.  
 
Safety 
The fetal risks of labetalol appear to be low.144,150,151 Labetalol is the only antihypertensive 
agent that holds a Medicines and Healthcare Regulatory Agency (MHRA) licence for use in 
pregnancy, but this is primarily a reflection of the difficulties surrounding licensing drugs for 
use in pregnancy.152 In spite of this the manufacturers of labetalol still advise avoidance in the 
first trimester, which is often not feasible for women with chronic hypertension. A meta-
analysis performed by Yakoob and colleagues (2013) assessed the risk of congenital 
malformations with the use of beta-blockers in early pregnancy and found no increased odds 
of all or major congenital anomalies (odds ratio 1.00, 95% confidence interval 0.91 to 1.10; 5 
studies).153 However, in the analyses examining organ-specific malformations, there was a 2.01 
odds ratio of cardiovascular defects (95% confidence interval 1.18 to 3.42; 4 studies), 3.11 
odds ratio of cleft lip and palate (95% confidence interval 1.79 to 5.43; 2 studies), and a 3.56 
odds ratio of neural tube defects (95% confidence interval 1.19 to 10.67; 2 studies) reported, 
however, the independent impact of chronic hypertension on these risks was not adjusted for 
in this study. They concluded that ‘causality was difficult to interpret given the small number of 
heterogeneous studies and possibility of biases’.153 A Cochrane review of oral beta blockers for 
mild to moderate hypertension in pregnancy found a small increased risk of small for 
gestational age infants (risk ratio 1.36, 95% confidence interval 1.02 to 1.82; 12 trials, 1346 
women), but raised concerns that this finding related to one outlying trial by Butters and 
colleagues154.151 They concluded that ‘beta blockers are equally as safe as methyldopa’ and 
that further evidence from large randomised controlled trials was needed to determine the 
optimal agent(s) and safety profile.151 There are no convincing data from adequately powered 
randomised controlled trials to suggest that labetalol use is associated with fetal growth 




Student Number: 1355203 





Nifedipine is a dihydropyridine sub-type of calcium channel blocker (calcium antagonist). It 
primarily acts to prevent calcium ions entering at the L-type calcium channels in cardiac muscle 
and blood vessels, but is likely to possess some non-specific activity towards other voltage-
gated calcium channels.147 A decrease in cellular calcium results in less contraction of the 
vascular smooth muscle and therefore vasodilation. Nifedipine additionally causes uterine 
relaxation (hence its use as tocolytic agent) and bladder smooth muscle relaxation. The 
vasodilatation achieved with nifedipine in hypertensive women does not appear to occur in 
normotensive pregnant women, which explains the absence of severe hypotension induced by 
high doses of calcium antagonists for tocolysis in normotensive patients.155 The ability of 
nifedipine to improve urine output by increasing renal blood flow and inhibiting the release of 
anti-diuretic hormone, in addition to reducing systemic vascular resistance, makes it a highly 
appropriate drug for use in hypertension in pregnancy.147 Side-effects commonly experienced 
include headache, oedema, flushing, and fatigue.  
 
Figure 1.14 Chemical structure of nifedipine (Ayacop, 2007)156  
 
Pharmacokinetics 
Nifedipine is rapidly and completely absorbed by the gastrointestinal tract after oral 
administration. A large proportion of the drug is metabolised via the first-pass effect in the 
gastrointestinal wall and the liver, leaving around 60% active product with approximately 50% 
bioavailability.147 The inactive metabolites are predominantly excreted by the kidneys. The 
elimination half-life of nifedipine depends on the formulation, but has been demonstrated 
outside pregnancy at 2.5 to 3.4 hours with oral capsules and 6 to 11 hours with oral tablets.157 
Peak serum concentrations after administration of 10mg of oral nifedipine have been 
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demonstrated at 73 ng/ml (standard deviation 17) in non-pregnant individuals.158 Large 
variation in peak plasma concentrations after oral administration have been shown and are 
thought to be due to inter-individual variation in the first-pass effect.159 
 
Prevost and colleagues (1992) studied the pharmacokinetics of oral nifedipine in 15 pregnant 
women with gestational hypertension.160 They found peak serum concentrations of 39 ng/ml 
(standard deviation 18) occurred at approximately 40 minutes after ingestion of  nifedipine 10 
mg, lower and faster than in non-pregnant controls. The elimination half-life was also shorter 
than that demonstrated in the non-pregnant group. The authors hypothesise that these 
differences are partly due to the physiological changes that occur in pregnancy, but also due to 
increased first-pass effect.160   
 
Safety 
Nifedipine does not hold a licence for use before 20 weeks’ gestation. This is predominantly 
due to animal data suggesting teratogenic risk although this increased risk has not been 
observed in human pregnancy. It has been suggested that since nifedipine is off patent, it is 
not in the financial interest of pharmaceutical companies to pursue a change in licensing. 
There is an inherent reluctance to give medication in pregnancy if there is any risk, but NICE 
state in their hypertension guideline that all antihypertensive medications have some level of 
risk. The need to treat the mother must be weighed against the potential risks to the fetus. 
This drug is used widely both nationally and internationally for treatment of chronic 
hypertension throughout pregnancy and, in what follows, the argument for its use as a first-
line treatment option from 12 weeks’ gestation are reviewed.  
 
There are theoretical concerns about use of calcium-channel blockers in early pregnancy. 
Many of the processes of embryogenesis appear to be calcium-dependent in animals and are 
thought to be blocked by calcium antagonists. Such processes include development of the 
somites, optic cup formation, and possibly organization of the morula. Teratology studies in 
rabbits have shown an increase in digital defects in the offspring of female rabbits treated with 
nifedipine.161,162 These defects consisted of reduction, absence, or malformation of the distal 
phalanges, associated with abnormal cartilage differentiation and ossification. It is believed 
that the abnormalities were secondary to decreased uteroplacental blood flow rather than a 
direct effect of the drug on the phalanges; however, experiments in rats suggest that 
hyperphalangism produced in the offspring by maternal nifedipine may be due to effects on 
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calcium channels of the limb bud mesenchymal cells.163,164 At high doses, nifedipine and other 
calcium channel blockers increased the incidence of cardiac defects in rats.165 Use of nifedipine 
during pregnancy in sheep has also been associated with cardiovascular changes in the ewe 
including hypotension166 and decreased uterine blood flow167. Additionally a study in late 
pregnant rats found high dose nifedipine (30 mg/kg/day) to be associated with vasodilatation 
in the uterus and in the placenta and some decrease in pup weight, but no adverse effects on 
pup survival.168 Human studies have not reproduced these findings. 
 
These animal studies are flawed in two ways. Firstly, none of these animals were hypertensive, 
so the large doses of nifedipine they were given caused relative hypotension, which is known 
to have an adverse effect on the developing fetus by decreasing uteroplacental blood flow and 
secondly, the animal species have significant pharmacokinetic or pharmacodynamic 
differences to humans. For example, it was not understood why cleft palate followed 
gestational exposure to corticosteroids in animals but not in humans until it was shown that 
these drugs mediate their effect through a receptor that does not exist in the human 
embryonic palate.169 This highlights the importance of understanding the mechanism by which 
drugs cause defects before extrapolating data from animal studies to human pregnancy. Scott 
and colleagues (1997) concluded in one of their animal studies ‘we interpret these results to 
indicate that high dosage of calcium channel blockers during rat embryogenesis leads to a low 
incidence of cardiovascular malformation and an increase of anatomic variants. It is impossible 
at this time to decide whether these adverse outcomes are indirect, resulting from the toxicity 
to maternal cardiovascular function or a direct effect on calcium homeostasis in the embryo. 
Nevertheless, at therapeutic doses where maternal toxicity is minimal these agents should 
pose little hazard for the mammalian embryo’.165  
 
An analysis of all reports submitted to the US FDA of congenital defects in pregnancies 
involving nifedipine between 1981 and 2000 identified 15 that included congenital defects,170 
but these case reports cannot be used to establish causation. A randomised clinical trial 
conducted by Bortolus (2000), found no significant increase in the frequency of congenital 
anomalies, small size, or developmental delay in 94 eighteen-month old children whose 
mothers were treated with nifedipine for hypertension between 12 and 34 weeks gestation.171 
The successful use of nifedipine to control hypertension in severe pre-eclampsia has also been 
reported with no harmful fetal effects.172-176 Parazzini and colleagues (1998) randomised 145 
pregnant women with chronic hypertension between 12 to 34 weeks’ gestation to nifedipine 
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or no treatment for control of their blood pressure. They reported congenital anomalies in 
both treatment and the control group and found no significant increase with nifedipine.177 
Magee and colleagues also published a multicentre cohort study in 1996 examining the safety 
of calcium-channel blockers in the first trimester of pregnancy and found no increase in major 
malformations within the 78 cases studied.178 They concluded calcium-channel blockers do not 
represent a major teratogenic risk, although it is recognised that teratogenicity studies may 
need to be considerably larger to reach this conclusion safely. Weber-Schoendorfer and 
colleagues (2008) conducted a multicentre prospective observational study of the European 
Network of Teratology Information Services (ENTIS), comparing the major birth defect rates 
between a cohort of pregnant women exposed to calcium channel blockers during the first 
trimester (n = 299) and a control group not exposed to potential teratogens (n = 806). The 
results demonstrated that major birth defects were no more common in the study group than 
in the control group.179  
 
1.4.3  Methyldopa and other antihypertensive agents 
Methyldopa is a methyl-substituted amino acid that acts as a precursor for methylated 
catecholamine analogues which compete with catecholamines in the nervous system.180,181 The 
antihypertensive effect is mediated by an accumulation of methylated catecholamine 
analogues in vasoactive centres of the central nervous system, which interferes with the effect 
and synthesis of noradrenaline and other active catecholamines.182 Methyldopa is 
incompletely absorbed from the gastrointestinal tract. Bioavailability is estimated at 25% 
(interquartile range 8 to 62%) and maximum plasma concentrations after a single 500mg oral 




The safety of methyldopa has been assessed in a randomised controlled trial of 242 
participants for the treatment of hypertension in pregnancy in the 1970s.183 The infants born 
to the mothers that took part in this study were followed-up until they were seven years old 
with no adverse effects demonstrated.184 However, in the postnatal period, national UK 
guidance recommends cessation of this treatment immediately following delivery due to risk 
of depression.16 Depression and somnolence are also evident during pregnancy and some 
clinicians question if methyldopa should be a first line agent antenatally. This agent has not 
been studied in the work presented in this thesis. 
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ACE inhibitors are contraindicated in the second and third trimester as in-utero exposure is 
associated with oligohydramnios, intrauterine growth restriction, hypocalvaria, renal dysplasia 
and stillbirth.185,186 There are differing opinions on the use of these agents in the first trimester 
due to concerns regarding an associated increased risk of congenital malformations;187 
however, some studies suggest the increased risk seen is likely to relate to the condition itself 
rather than this agent.143,188 Similarly, avoidance of ARBs is also recommended based on 
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Table 1.1 Safety data for antihypertensive drugs in pregnancy (derived from data presented 
in the NICE ‘Hypertension in pregnancy’ guideline)16 
Agent Safety summary 
Centrally acting  
Methyldopa Mild hypotension in babies in first 2 days of life, but no obvious 
association with congenital abnormalities. 
Beta-blockers  
Labetalol Rare mild hypotension in first 24 hours of life and very rare 
hypoglycaemia have been reported. No obvious association with 
congenital abnormalities has been demonstrated. 
Atenolol Low birthweight and placental weight have been demonstrated. 
Decreased fetal heart rate has also been described, but no 
obvious association with congenital abnormalities has been 
reported.  
Metoprolol No association with congenital abnormalities has been reported. 
Oxprenolol No association with congenital abnormalities has been reported. 
Pindolol No association with congenital abnormalities has been reported. 
Calcium channel blockers   
Nifedipine No association with congenital abnormalities has been reported 
in humans. 
Amlodipine No reports available. 
Verapamil No association with congenital abnormalities has been 
demonstrated. 
Alpha-blockers  
Doxazocin No known association with congenital abnormalities. 
Prazosin No known association with congenital abnormalities. 
Diuretics  
Chlorothiazide Possible association with congenital abnormalities and 
additionally, possible neonatal thrombocytopaenia, 
hypoglycaemia and hypovolaemia, and electrolyte imbalances 
Bendroflumethiazide No adverse fetal effects reported, but maternal hypovolaemia 
evident. 
Furosemide No obvious fetal or neonatal effects. 
 
1.5 Placental, endothelial and renal biomarkers in hypertensive disorders of pregnancy   
Despite decades of research, the prediction and diagnosis of superimposed pre-eclampsia and 
fetal growth restriction remain a challenge. Identifying the women at greatest risk would aid 
stratification of antenatal care pathways and target utilisation of additional resources such as 
fetal ultrasound surveillance. The discovery of biomarkers associated with adverse outcomes 
in women with chronic hypertension would also facilitate recruitment to trials of potential 
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Figure 1.15 Biomarkers of pre-eclampsia grouped into four major categories (Carty and 
colleagues, 2008)190 
 
Within this chapter, the potential utility of biomarkers within the categories of placental 
dysfunction (Placental growth factor), endothelial dysfunction (Syndecan-1), and renal 
dysfunction (renin, aldosterone, angiotensinogen: creatinine ratio, protein: creatinine ratio 
and albumin: creatinine ratio) are considered. 
  
1.5.1 Placental growth factor 
Placental growth factor (PlGF) is a dimeric glycoprotein and member of the vascular 
endothelial growth factor (VEGF) family of proangiogenic growth factors.191 The human plgf 
gene has been mapped to chromosome 14q24.192 PIGF is expressed predominantly in the 
placenta across gestation and is suggested to regulate trophoblast growth and 
differentiation.192,193 PlGF is also thought to be involved in the invasion of the trophoblasts into 
the maternal decidua.194 It is capable of inducing proliferation, migration, and activation of 
endothelial cells. PlGF is additionally expressed at low concentrations in other organs including 
the heart, lung, thyroid, skeletal muscle, and adipose tissue under normal physiological 
conditions.195-197  
Student Number: 1355203 









The role of PlGF in the pathogenesis of pre-eclampsia has been the focus of more recent 
research in this field. Reduced concentrations of circulating PlGF have been observed in 
women with pre-eclampsia in association with increased concentrations of sFlt-1 (an anti-
angiogenic protein). It is hypothesised that s-Flt-1 binds to the PlGF receptor binding domain, 
which in turn prevents PlGF interacting with the endothelial receptors on cell surfaces and 
induces endothelial dysfunction.199,200  Chappell and colleagues (2002) conducted a cohort 
study examining the relationship between longitudinal concentrations of biomarkers of 
placental and endothelial dysfunction and subsequent diagnosis of pre-eclampsia.200 They 
demonstrated that lower concentrations of PlGF at 20 and 24 weeks’ gestation in the women 
who subsequently developed pre-eclampsia, compared to those who did not, were predictive 
of subsequent diagnosis of pre-eclampsia (ROC area 0.85; 95% CI 0.71- 0.99 versus low risk 
controls, at 24 weeks’ gestation).200 Subsequently, Levine and colleagues (2004) confirmed 
these findings in a nested case-control study in 120 pregnant women, 60 with subsequent pre-
eclampsia and 60 who remained normotensive throughout pregnancy.199 They demonstrated a 
gestational rise in PlGF concentrations with a peak at 26 to 30 weeks and then a decline 
towards term. The PlGF concentrations across gestation were significantly lower in the women 
who developed pre-eclampsia compared to those who did not.199 
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Figure 1.17 Levine and colleagues (2014): Mean concentration of placental growth factor 
across gestation in pregnant women who did and did not develop pre-eclampsia199 
 
 
Data from this work, and another follow-up study from this group, demonstrated that prior to 
the onset of clinical signs or symptoms of pre-eclampsia, lower concentrations of circulating 
PlGF were detected.199,201 A case-control multicentre study reported by Verlohren and 
colleagues (2010), demonstrated that mean serum sFlt-1/PlGF ratios in patients with pre-
eclampsia were significantly higher than that of women in the control group (354.5 ± 44.84 
versus 19.43 ± 1.62, respectively; P < 0.0001) and that the sFlt-1/PlGF ratios related to disease 
severity, thus offering a potential aid in the management of pre-eclampsia.202 This study was 
unable to determine which of these biomarkers provided the optimal tool in the diagnosis and 
management of pre-eclampsia.  
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Figure 1.18 Verlohren and colleagues (2010): Maternal serum levels of sFlt-1, PIGF, and sFlt-
1/PIGF ratio in pre-eclampsia versus controls202 
Scatterplots of maternal serum concentrations of A, soluble fms-like tyrosine kinase (sFlt)-1; B, 
placental growth factor (PIGF); and C, calculated sFlt-1/PIGF ratio of preeclamptic (PE) versus 
gestational age-matched control patients. Red triangles represent serum values of sFlt, PIGF, 
and calculated sFlt-1/PIGF ratio of PE pregnancies. Grey dots represent control patients. 
 
The PELICAN study, reported by Chappell and colleagues (2013), examined the diagnostic 
accuracy of low plasma PlGF concentrations (<5th centile for gestation) in women presenting 
with suspected pre-eclampsia between 20 and 35 weeks’ gestation.203 In women enrolled 
before 35 weeks’ gestation (n=287). PlGF <5th centile had high sensitivity (0.96; 95% 
confidence interval, 0.89 to 0.99) and negative predictive value (0.98; 95% confidence interval 
0.93 to 0.995) for confirmed pre-eclampsia requiring delivery within 14 days.203 In addition the 
area under the receiver operating characteristic curve for low PlGF (0.87, standard error 0.03) 
for predicting pre-eclampsia requiring delivery within 14 days was greater than all other tests 
commonly used in the diagnosis and management of pre-eclampsia in women presenting with 
suspected preeclampsia.203  
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Figure 1.19 Chappell and colleagues (2013): Receiver operator characteristics areas (standard 
error) for PlGF compared with five other tests (systolic and diastolic blood pressure, uric 
acid, and alanine transaminase) in determining pre-eclampsia requiring delivery within 14 
days203 
Analysis includes 176 women presenting before 35+0 weeks’ gestation with all tests measured 
using routine parameters. ALT indicates alanine transaminase; DBP, diastolic blood pressure; 
PlGF, placental growth factor; and SBP, systolic blood pressure. 
 
The utility of PlGF in the diagnosis of superimposed pre-eclampsia has also been explored by 
Bramham and colleagues (2016), who measured longitudinal and time-of-disease PlGF 
concentrations in a cohort of women with chronic hypertension and/or chronic kidney 
disease.204 Lower values of plasma PlGF (less than the fifth centile) were associated with a 
diagnosis of superimposed pre-eclampsia requiring delivery within 14 days when assessed 
between 20+0 and 36+6 weeks’ gestation (receiver operating characteristic 0.85; standard error 
0.06). This is particularly important given the challenges of diagnosing superimposed pre-
eclampsia in women with underlying hypertension and proteinuria. 
 
1.5.2 Syndecan-1 
The syndecans are a group of cell surface heparan sulphate proteoglycans.205 Syndecans are 
expressed on the surface of all adherent cells and on many non-adherent cells. They are 
transmembrane proteins with an extracellular domain where heparan sulphate chains attach 
to the plasma membrane with a signature transmembrane and cytoplasmic domain, which are 
highly homologous among the different syndecans.205 Syndecan-1 was one of the first 
syndecans to be described in 1989 by Saunders and colleagues.206 It is predominantly 
expressed on epithelial, endothelial and plasma cells.207 Syndecan-1 regulates diverse cell 
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behaviours including adhesion, proliferation, motility, intracellular signalling, growth factor cell 
surface binding and angiogenesis. Syndecan-1 is strongly expressed on villus 
syncytiotrophoblast microvillous membranes and this expression is reduced in pre-eclampsia 
and fetal growth restriction compared with uncomplicated pregnancy.208-211 
 
The extracellular domains of syndecan-1 are constitutively shed. The soluble form of syndecan-
1 has important paracrine and autocrine functions and is a competitor for extracellular 
syndecan-1 growth factors and other extracellular ligands.207,212 Syndecan-1 shedding has been 
described in response to wound healing with effects on inflammation, proliferation and 
remodelling.213,214 Increased circulating syndecan-1 concentrations have been found in 
response to reactive oxygen species inflammatory stimuli such as sepsis.213,215,216 Given the role 
of oxidative stress and endothelial dysfunction in the pathophysiology of pre-eclampsia, 
further investigation of circulating syndecan-1 in pre-eclampsia is needed. 
 
Gandley and colleagues (2016) conducted a nested case-control study (n=44) to examine the 
relationship between circulating syndecan-1, gestation and subsequent diagnosis of pre-
eclampsia.207 They demonstrated that soluble circulating syndecan-1 concentrations increased 
significantly across gestation. They also found that syndecan-1 concentrations were 
significantly lower in the women who went on to develop pre-eclampsia compared to 
normotensive pregnant controls (174 versus 272 ng/ml; p <0.05).207 Given the small numbers 
in this study further investigation is required. 
 
Figure 1.20 Gandley and colleagues (2016): Plasma soluble syndecan-1 is reduced at 20 
weeks’ gestation in women who later develop pre-eclampsia.207 
Box-plot of syndecan-1 concentrations in mid-pregnancy by pregnancy outcome group. The 
solid line through the interior of each box and the accompanying numerical value correspond to 
the group median.  
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1.5.3 Renin, aldosterone and urinary angiotensinogen: creatinine ratio 
The importance of the renin-angiotensin-aldosterone system (RAAS) in blood pressure 
homeostasis has been described in Chapter 1.2. Understanding of the changes in the RAAS that 
occur in pregnancy is incomplete. Variation in RAAS components in women with chronic 
hypertension who develop superimposed pre-eclampsia, compared to those who do not has 
been described previously,109 but this study was limited by the number of participants and 
further investigation of the role of the systemic RAAS in the pathophysiology of superimposed 
pre-eclampsia is needed. The impact of ethnicity on the systemic RAAS in pregnancy 
complicated by chronic hypertension is yet to be investigated and may offer insight into the 
mechanisms underpinning disparity in maternal and perinatal outcomes associated with 
ethnicity.   
 
The intrarenal renin-angiotensin system (RAS) is locally and independently active and activated 
in salt-sensitive rat models.217 This has led to the hypothesis that individuals who are salt-
sensitive, including those of African and Caribbean ethnicity, may have locally active intrarenal 
RAS, despite suppressed systemic RAAS.218 This is of particular interest given that systemic 
RAAS is suppressed in salt-sensitive individuals. There are no studies examining ethnic 
differences in intrarenal RAS activity in chronic hypertension in pregnancy. Urinary 
angiotensinogen: creatinine ratio is a novel biomarker of intra-renal RAS activity.219 Further 
investigation of longitudinal variation in the systemic RAAS and intrarenal RAS in women with 
chronic hypertension in pregnancy may provide further insight into pathophysiology.  
  
1.5.4 Urinary protein: creatinine ratio and albumin: creatinine ratio  
Proteinuria is a hallmark of pre-eclampsia, having been first described by John Lever in 1843 in 
association with eclampsia.220 However, interpreting abnormal proteinuria in pregnancy 
remains a clinical challenge.221 The normal physiological changes that occur in pregnancy 
include a 50% increase in the glomerular filtration rate, with dilatation of the renal calyces, 
pelvises and ureters.93,221 Consequently, the accepted normal levels of proteinuria in 
pregnancy are increased to 300 mg/day, which is around double the value considered normal 
outside pregnancy.221-223 An additional challenge to the evaluation of proteinuria in pregnancy 
complicated by chronic hypertension lies in the potential for underlying nephropathy (or other 
co-morbidities with associated proteinuria) in this cohort.224  
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More recently clinical practice has moved towards utilisation of the spot urinary protein: 
creatinine ratio and assessment of microalbuminuria via the albumin: creatinine ratio, rather 
than the ‘gold standard’ of 24-hour urine collection.225,226 A systematic review conducted by 
Cote and colleagues (2008), identified nine studies including 1003 women and found spot 
urinary protein: creatinine ratio had a pooled sensitivity of 84% (95% confidence interval 78% 
to 90%), with a specificity of 76% (95% confidence interval 73% to 80%), positive likelihood 
ratio of 3.53 (95% confidence interval 2.83 to 4.49), and negative likelihood ratio of 0.21 (95% 
confidence interval 0.13 to 0.31).225 De Silva and colleagues (2013) assessed the utility of 
albumin: creatinine ratio in pregnancy given that it can be assessed as a point-of-care test, and 
found that 48 of 160 (30%) of third trimester samples were too dilute to allow detection of 
urinary albumin.226 They concluded that this made the calculation of a normal range for 
albumin: creatinine ratio a challenge and therefore it was less clinically useful.226 
 
Poon and colleagues (2008) examined the potential of urinary albumin quantification in the 
prediction of pre-eclampsia between 11 and 13 weeks’ gestation.227 Their cohort study 
included 2679 pregnant women, 51 (1.9%) of whom developed pre-eclampsia. The median 
albumin: creatinine ratio in the pre-eclampsia group was higher than that in the unaffected 
group (0.87 mg/mmol, interquartile range 0 to 1.71 versus 0.53 mg/mmol, interquartile range 
0 to 0.88; p < 0.001).227 However, the authors concluded after further analysis, that albumin: 
creatinine ratio did not offer additional value to the prediction of pre-eclampsia when 
compared to other maternal variables.227 
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Figure 1.21 Receiver operating characteristic curve of maternal history (A), urine albumin 
concentration (B), urine albumin: creatinine ratio (C), the combination of history and urine 
albumin concentration (D) and the combination of history and albumin: creatinine ratio (E) 
in the prediction of pre-eclampsia (Poon and colleagues, 2008)227 
 
Bramham and colleagues (2013) further investigated the relationship between proteinuria and 
adverse outcome performing a nested case-control study of the women who participated in 
the Vitamins in Pregnancy Trial.228 They compared outcomes in pregnant women with pre-
eclampsia and a 24 hour proteinuria between 300 to 499 mg/day (PE300) (n=60), with women 
with pre-eclampsia and a 24 hour proteinuria ≥500 mg/day (PE500) (n=161), and 725 pregnant 
women with either chronic or gestational hypertension but no proteinuria. They demonstrated 
an increase in adverse maternal and fetal outcome in the PE500 group compared with both 
the PE300 and non-proteinuric women, with the risk ratio of birthweight <5th centile 1.56 (95% 
confidence interval 1.04 to 2.33) in the PE500 group compared to the PE300 group and 
preterm birth before 37 weeks’ gestation risk ratio 2.41 (95% confidence interval 1.56 to 3.89) 
in the PE500 group compared to the PE300 group.228 They also highlighted that PE300 was 
associated with an increased risk of adverse maternal and fetal outcome compared with non-
proteinuric pregnancy, justifying inpatient management of women with a confirmed diagnosis 
of pre-eclampsia. This study highlighted a relationship between proteinuria and adverse 
pregnancy outcome, which has been debated by other researchers.221,228 Interestingly, and 
perhaps unsurprisingly, the PE500 group had higher peak serum creatinine concentrations 
than the PE300 group (median 75 versus 69 µmol/L; risk ratio 1.11, 95% confidence interval 
1.04 to 1.19). This finding highlights the possible relationship between pre-eclampsia severity 
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and proteinuria. Further exploration of the utility of proteinuria assessment in pregnancy is 
warranted.     
 
1.6 Non-invasive assessment of vascular function in chronic hypertension 
Measures of arterial stiffness in addition to brachial blood pressure are increasingly used in the 
assessment of vascular function in the non-pregnant population.229 More recently the 
potential utility of vascular function assessment in pregnancy has been explored.230-232 
Additional assessment of maternal vascular function may provide insight into pathophysiology 
and mechanism of adverse maternal and perinatal outcomes in hypertensive disorders in 
pregnancy and these measures may provide insight into the relationship between maternal 
systemic arterial stiffness and placental function.    
 
1.6.1 The importance of vascular function assessment 
Hypertension is a well-recognised cardiovascular risk factor. Arterial stiffness is affected by 
many factors including age,233 hypertension,234 diabetes mellitus,235 atherosclerosis,236 and 
end-stage renal disease.237 In the non-pregnant general population, high systolic blood 
pressure, and left ventricular hypertrophy have been identified as independent risk factors for 
cardiovascular morbidity and mortality;238,239 however, interest in other markers of arterial 
stiffness and hence assessment of individual cardiovascular risk has grown. Vascular function 
markers include pulse wave velocity (speed of travel of the pulse along an arterial segment), 
augmentation index (increase in aortic pressure after the peak of blood flow in the vessel) and 
central aortic pressure (the estimated peak systolic pressure in the aorta).229 
 
 
Figure 1.22 The central aortic pulse waveform represented schematically. (Khalil and 
colleagues, 2009)230  
Typical ascending aortic pulse waveform, showing two systolic peaks (P1 and P2). 
Augmentation index is calculated as the difference between P2 and P1, expressed as 
percentage of pulse pressure. P1 = the first inflection point; P2 = the second inflection point 
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Several studies have demonstrated the independent relationship between pulse wave velocity 
and subsequent cardiovascular disease. Blacher and colleagues (1999) conducted a cohort 
study of 710 patients with chronic hypertension.240 They measured pulse wave velocity using 
the Complicor Colson device which has transducers over the carotid and femoral arteries. This 
study demonstrated that pulse wave velocity was strongly associated with the presence of 
atherosclerosis and was an independent predictor of cardiovascular risk in hypertensive 
patients.240 Increased pulse wave velocity in the general population has also been 
demonstrated as a risk factor for subsequent cardiovascular disease, independent of brachial 
blood pressure. Hansen and colleagues (2006) conducted age and sex-stratified sample cohort 
study with 1678 participants (aged 40 to 70 years) and demonstrated that pulse wave velocity 
predicted a composite of cardiovascular outcomes with greater performance than other 
cardiovascular risk factors, including 24-hour mean brachial arterial pressure.241 
 
Augmentation index is regarded as an indirect marker of arterial stiffness, but a direct measure 
of wave reflection.242 London and colleagues (2001) demonstrated an association between 
increased augmentation index and mortality in 180 cohort study participants with end stage 
renal disease.243 After adjustment for confounding factors, the risk ratio for each 10% increase 
in augmentation index was 1.51 (95% confidence interval 1.23 to 1.86) for all-cause mortality 
and 1.48 (95% confidence interval 1.16 to 1.90) for cardiovascular mortality.243  
 
The potential clinical utility of vascular function assessment was highlighted in the CAFÉ study 
reported by Williams and colleagues (2006).244 This was a nested cohort study within the 
ASCOT trial, a randomised controlled trial comparing amlodipine and atenolol as treatment for 
chronic hypertension.245 The CAFÉ study enrolled 2199 participants at five centres and 
compared vascular function parameters between antihypertensive treatment groups. They 
demonstrated that amlodipine use resulted in an average decrease in central aortic pressure 
of 4.3 mmHg (95% confidence interval 3.3 to 5.4 mmHg) compared to atenolol. Those 
randomised to amlodipine also demonstrated a mean 6.5% decrease (95% confidence interval 
5.8 to 7.3%) in augmentation index compared to those randomised to atenolol.244 These 
findings were in the absence of a significant difference in treatment effect observed in brachial 
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1.6.2 Non-invasive techniques used to assess vascular function 
There are a variety of devices available to measure vascular function parameters. Pulse wave 
analysis is a technique that allows peripheral pressure waveforms to be recorded with 
subsequent generation of the corresponding central waveform, from which the pulse wave 
velocity, augmentation index and central aortic pressure can be derived. Pulse wave analysis is 
a highly reproducible technique and easy to apply.246 It is most commonly performed on the 
carotid, brachial, radial or femoral arteries and can be measured using applanation tonometry, 
piezo-electronic method or oscillometric techniques.242 Each device has its own merits and 
weaknesses, requiring internal and external validation and establishment of a normal range for 
each measured parameter.229 Validation of these devices in pregnancy provides an additional 
challenge.   
 
Within this thesis, pulse wave analyses were measured with the Arteriograph® (Tensiomed, 
Budapest, Hungary), which is an oscillometric single-cuff device. Readings were obtained from 
the brachial artery once an estimated aortic length and upper arm circumference had been 
entered into an automated computer package that programmes the device. This device has 
been validated against both tonometric and piezo-electronic methods for estimation of arterial 
stiffness parameters.242 Unpublished work by our collaborators Cockerill and colleagues (2016), 
demonstrated that pulse wave velocity and augmentation index measured using the 
Arteriograph® in women with chronic hypertension in pregnancy had acceptable 
reproducibility for use in clinical practice.247 
 
 
Figure 1.23 The Arteriograph® (Tensiomed, Budapest, Hungary)248  
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1.6.3 Assessment of vascular function in pregnancy 
Vascular function measurement in pregnancy is a developing field, with potential prognostic 
value in hypertensive disorders.249 A cohort study conducted by Mahendru and colleagues 
(2014) examined changes in pulse wave velocity, augmentation index and central aortic 
pressure from pre-conception, in each trimester and at four months postpartum in 54 
normotensive women.11 They demonstrated that central aortic pressure and augmentation 
index decrease from preconception levels during pregnancy reaching a nadir in the second 
trimester, and then increasing in the third trimester and returning to preconception levels by 
four months postpartum.11 Pulse wave velocity does not alter from preconception levels 
during uncomplicated normotensive pregnancy.11 Although this study only included a small 
number of women, these findings are similar to other studies examining the relationship 
between vascular function and normotensive pregnancy.230,232  
 
 
Figure 1.24 Mahendru and colleagues (2014): Changes in the augmentation index adjusted 
for heart rate from pre-pregnancy to the postpartum period.11 
T2= second trimester, T3= third trimester and AIx= augmentation index  
 
The relationship between pre-eclampsia and vascular function parameters has also been 
explored. Kaihura and colleagues (2009) conducted a case-control study including 69 
normotensive pregnant women and 54 women with a diagnosis of pre-eclampsia, measuring 
vascular function at ‘time-of-disease’.250 In women with a diagnosis of pre-eclampsia, 
compared to the normotensive pregnant controls, all parameters were increased: pulse wave 
velocity (9.5 m/s (standard deviation 1.1) versus 7.5 m/s (standard deviation 1.2); p <0.0001), 
Student Number: 1355203 
Student Name: Louise Mary Webster 
69 
 
augmentation index (24% (standard deviation 10) versus 4% (standard deviation 14); p 
<0.0001) and central aortic pressure (125 mmHg (interquartile range 120 to 134 mmHg) versus 
97 mmHg (interquartile range 89 to 102 mmHg); p <0.0001) .250 It is important to highlight that 
brachial blood pressure was also significantly raised in the women who developed pre-
eclampsia compared to the normotensive pregnant controls. Khalil and colleagues (2009) also 
demonstrated that central aortic pressure and augmentation index were significantly 
increased in women with pre-eclampsia (n=51) compared to normotensive controls (n=80).251 
Again brachial blood pressure was also significantly increased in the women who were 
diagnosed with pre-eclampsia compared to normotensive pregnant controls, so the clinical 
utility of these tests at the time of disease is yet to be established. A more promising clinical 
utility of vascular function measures in predicting subsequent pre-eclampsia has been 
investigated. Khalil and colleagues (2014) enrolled 245 women between 11+0 and 13+6 weeks’ 
gestation who were at high risk of developing pre-eclampsia.252 Vascular function parameters 
were measured every four weeks from recruitment to delivery. Pulse wave velocity and 
augmentation index were significantly higher at 16 to 17 weeks’ gestation in the women who 
were diagnosed with pre-eclampsia prior to 37 weeks’ gestation compared to the 
normotensive group.252 However, this study found no significant differences in the vascular 
function of women who developed pre-eclampsia after 37 weeks’ gestation compared to 
normotensive pregnant controls. Further research is needed to establish if these markers offer 
additional sensitivity and specificity in identifying women at risk of pre-eclampsia. 
 
There are very limited data regarding vascular function exclusively in pregnant women with 
chronic hypertension. A study reported by Tomimatsu and colleagues (2014) measured 
vascular function in 41 pregnant women with chronic hypertension between 26 and 32 weeks’ 
gestation.253 They found that women who developed superimposed pre-eclampsia and small 
for gestational age infants had higher central aortic pressure (151 mmHg (standard deviation 
12) versus 125 mmHg (standard deviation 15); p <0.05), augmentation index (78% (standard 
deviation 8.4) versus 65% (standard deviation 13); p <0.05) and brachial systolic blood pressure 
(147 mmHg (standard deviation 12) versus 126 mmHg (standard deviation 13); p <0.05) at 26 
to 32 weeks’ gestation compared with controls. Women who subsequently developed 
superimposed pre-eclampsia without small for gestational age infants had significantly higher 
central aortic pressure (142 mmHg (standard deviation 21) versus 125 mmHg (standard 
deviation 15); p <0.05) at 26 to 32 weeks’ gestation compared to controls, and women who 
delivered a small for gestational age infant had significantly higher adjusted augmentation 
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index (81% (standard deviation 8.9) versus 68% (standard deviation 12); p <0.05) compared to 
controls.253 This study is limited by the small number of participants and the division of 
participants into multiple outcome groups for comparison. They also assessed vascular 
function at a relatively late and wide gestational time point, which impacts the clinical utility of 
these data. The association of vascular function parameters and adverse maternal and 
perinatal outcome in women with chronic hypertension warrants further exploration.  
 
1.7  Summary 
The prevalence of chronic hypertension in pregnancy is increasing. Chronic hypertension is 
associated with an increased risk of adverse maternal and perinatal outcomes, as well as long 
term cardiovascular morbidity and mortality risk for the mother. The 2010 NICE ‘Hypertension 
in Pregnancy’ guideline states that ‘the evidence from trials on treatment of blood pressure 
does not make it possible to determine the preferred antihypertensive agent for pregnant 
women with chronic hypertension'.16 Given the wealth of data from randomised controlled 
trials comparing antihypertensive treatment outside pregnancy, further investigation of the 
optimal treatment within pregnancy is warranted. 
 
Previous studies have suggested that Black ethnicity is associated with an increased risk of 
adverse maternal and perinatal outcome in normotensive women. The impact of maternal 
characteristics such as ethnicity warrant further investigation in women with chronic 
hypertension in pregnancy, particularly when choosing the optimal antihypertensive agent. 
Additionally, exploration of variation in biomarkers and vascular function measures in an 
ethnically diverse group of women with chronic hypertension in pregnancy may increase our 
understanding of pathophysiological mechanisms and highlight potential clinical utility of these 
markers.  
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CHAPTER 2 HYPOTHESES, RESEARCH QUESTIONS AND PROJECT OBJECTIVES 
 
The subject underpinning the studies conducted within this thesis is chronic hypertension in 
pregnancy. The hypotheses, research questions and study specific objectives for each stream 
of work conducted within the PhD programme are outlined below. 
 
2.1  Hypotheses 
• The use of antihypertensive agents for the treatment of chronic hypertension in 
pregnancy improves maternal outcome without adverse effect on perinatal outcome. 
 
• Maternal characteristics such as ethnicity impact the risk of adverse maternal and 
perinatal outcome in women with chronic hypertension. 
 
• Labetalol and nifedipine demonstrate comparable effectiveness at controlling chronic 
hypertension in pregnancy, but nifedipine (a calcium-channel blocker) offers greater 
efficacy in women of Black ethnicity.  
 
• Variation in clinical outcomes in women with chronic hypertension in pregnancy can 
be explained by longitudinal differences in biomarkers and vascular function measures. 
 
• Ethnic variation in pregnancy outcome in women with chronic hypertension is 
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2.2 Research questions and project objectives 
 
2.2.1 Systematic review and meta-analysis assessing the impact of antihypertensive 
treatment on maternal and perinatal outcomes in pregnancy complicated by chronic 
hypertension (Chapter 3) 
Objectives:  
To perform a systematic review and meta-analysis of all randomised controlled trials to date 
enrolling women with chronic hypertension in pregnancy to answer the following questions:  
• Which antihypertensive treatment is associated with fewest episodes of severe 
hypertension in pregnancy?  
• Does frequency of adverse maternal outcomes (e.g. superimposed pre-eclampsia, 
stroke, death) vary by antihypertensive agent? 
• Does frequency of perinatal adverse outcomes (e.g. fetal growth restriction, 
preterm delivery, neonatal unit admission) vary by antihypertensive agent? 
 
2.2.2 Cohort study investigating the prevalence of adverse perinatal outcomes and 
associated risk factors in women with chronic hypertension (Chapter 4) 
Objectives:  
To perform a cohort study of women with chronic hypertension in pregnancy at three UK 
centres to answer the following research questions: 
• What is the risk of adverse maternal and perinatal outcome in women with chronic 
hypertension in pregnancy in the UK compared with the general pregnant population? 
• Which maternal characteristics (e.g. ethnicity, maternal age, level of deprivation, 
smoking history) are associated with an increased risk of adverse fetal and neonatal 
outcomes (e.g. stillbirth, fetal growth restriction, preterm delivery)? 
 
2.2.3 Randomised controlled feasibility study comparing labetalol and nifedipine for 
treatment of chronic hypertension in pregnancy (Chapter 5) 
Objectives: 
To undertake a randomised controlled feasibility trial in an ethnically diverse group comparing 
labetalol and nifedipine in pregnant women with chronic hypertension with the following 
research questions:  
• Is enrolment of an ethnically diverse group of pregnant women with chronic 
hypertension to a randomised controlled trial comparing labetalol and nifedipine as 
first line antihypertensive treatment feasible? 
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• Is nifedipine as effective as labetalol at controlling blood pressure in women with 
chronic hypertension in pregnancy?  
• Can potential mechanistic treatment effects be explained by differences in biomarkers 
(e.g. PlGF, syndecan-1, renin, aldosterone, PCR, ACR) and vascular function parameters 
(e.g. central aortic pressure, pulse wave velocity, augmentation index)? 
 
2.2.4 Nested cohort studies examining the longitudinal variation in biomarker and 
vascular function parameters in an ethnically diverse group of pregnant women with chronic 
hypertension (Chapters 6 and 7)   
Objectives: 
To assess longitudinal variation in placental, endothelial and renal biomarkers in women with 
chronic hypertension in pregnancy, and additionally to assess longitudinal variation in vascular 
function parameters measured using pulse wave analysis in women with chronic hypertension 
to answer the following questions: 
• Do longitudinal changes in biomarker and vascular function parameters pre-date the 
development of placental pathology (superimposed pre-eclampsia and fetal growth 
restriction)? 
• Does ethnic variation in longitudinal biomarkers and vascular function parameters in 
women with chronic hypertension in pregnancy exist? 
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CHAPTER 3 THE IMPACT OF ANTIHYPERTENSIVE TREATMENT ON MATERNAL AND 
PERINATAL OUTCOMES IN PREGNANCY COMPLICATED BY CHRONIC HYPERTENSION: 
A SYSTEMATIC REVIEW AND META-ANALYSIS 
 
3.1 Abstract 
Chronic hypertension complicates around 3% of all pregnancies. There is evidence that 
treating severe hypertension reduces maternal morbidity. This study aimed to systematically 
review randomised controlled trials of antihypertensive agents treating chronic hypertension 
in pregnancy, to determine the effect of this intervention. Medline (via OVID), Embase (via 
OVID) and the Cochrane Trials Register were searched from their earliest entries until 
30.11.16. All randomised controlled trials evaluating antihypertensive treatments for chronic 
hypertension in pregnancy were included. Data were extracted and analysed in Stata (version 
14.1). Fifteen randomised controlled trials (1166 women) were identified for meta-analysis. A 
clinically important reduction in the incidence of severe hypertension was seen with 
antihypertensive treatment versus no antihypertensive treatment/placebo (five studies, 446 
women; risk ratio (RR) 0.33, 95% confidence interval (CI) 0.19 to 0.56; I2 0.0%). There was no 
difference in the incidence of superimposed pre-eclampsia (seven studies, 727 women; RR 
0.74, 95%CI 0.49 to 1.11; I2 28.1%), stillbirth/neonatal death (four studies, 667 women; RR 
0.37, 95%CI 0.11 to 1.26; I2 0.0%), birthweight (seven studies, 802 women; weighted mean 
difference -60g, 95%CI -200g to 80g; I2 0.0%), or small for gestational age (four studies, 369 
women; RR 1.01, 95%CI 0.53 to 1.94; I2 0.0%) with antihypertensive treatment versus no 
treatment/placebo. Antihypertensive treatment reduces the risk of severe hypertension in 
pregnant women with chronic hypertension. A considerable paucity of data exists to guide 
choice of antihypertensive agent. Adequately powered head-to-head randomised controlled 
trials of commonly used antihypertensive agents are required to inform prescribing.  
 
3.2 Introduction 
Chronic hypertension complicates around 3% of all pregnancies.29,32 There is growing evidence 
that the incidence is rising with increasing maternal age and obesity.5,29,39,254 The increased 
risks of adverse perinatal outcomes for pregnant women with chronic hypertension are well 
established.8,45 In addition, controlling severe systolic hypertension has been recommended 
repeatedly by national and international guidance to reduce the risks of maternal morbidity 
and mortality.16,49,57  
 
There remains some debate regarding the efficacy of treating chronic hypertension in 
pregnancy before it reaches severe levels due to concerns for fetal growth.64,129,151,255-257 
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Internationally guidelines vary for the management of chronic hypertension in pregnancy.14 
However, the Control of Hypertension in Pregnancy Study (CHIPS), published in 2015, reported 
that there was no effect of tight blood pressure control (target diastolic 85 mmHg) compared 
to less tight control (target diastolic 105 mmHg) on a composite outcome of pregnancy loss 
and high-level neonatal care within the first 48 hours of infant life (31.4% versus 30.7%) and 
the overall risk of small for gestational age infants (birthweight <10th centile) was not different 
between groups (16.1% versus 19.7%; odds ratio 0.78, 95% confidence interval 0.56 to 1.08). 
The frequency of severe hypertension was significantly higher with less-tight control compared 
to tight control (40.6% versus 27.5%; odds ratio 1.8, 95% confidence interval 1.3 to 2.4).15 
There are likely to be additional benefits of reducing the incidence of severe hypertension 
through a decrease in short and long-term maternal morbidity and mortality from stroke and 
other end-organ damage,49,62,131-133 and potential cost savings with a reduction in healthcare 
resource use.134,135  
 
Given the physiological demands of pregnancy, duration of treatment and potential impacts on 
maternal and perinatal outcomes, there is a need for evidence on efficacy and safety of 
antihypertensive treatment specifically in pregnancy complicated by chronic hypertension. 
Current international guidance points to the lack of evidence for antihypertensive agent 
prescribing in chronic hypertension in pregnancy.14,16 As the benefits of tight control blood 
pressure targets have now been demonstrated in women with hypertension in pregnancy, this 
study aimed to systematically review and meta-analyse available data from randomised 
controlled trials specifically in chronic hypertension to establish the efficacy and safety of 
antihypertensive agents or class of agents. 
 
3.3 Methods 
The study protocol for this systematic review was developed in line with the PRISMA-P 
statement258 and registered on the PROSPERO database 
(http://www.crd.york.ac.uk/PROSPERO/prospero.asp reference number CRD42015020733).  
 
Literature search 
A comprehensive literature review using Medline (via Ovid), Embase (via Ovid) and the 
Cochrane Trials Register from their earliest entries until the 30th November 2016 was 
performed. Search strategies were adapted to each database. Searches of exploded MeSH 
terms ‘pregnancy’, ‘hypertension’ and ‘antihypertensive’ (Embase) or ‘cardiovascular agent’ 
(Medline) individually were performed, and then combined in each database. For Medline and 
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Embase searches, a search filter for randomised controlled trials was then applied as 
recommended in the Cochrane Handbook for Systematic Reviews of Interventions.259 Relevant 
unpublished data were sought by searching for trials registered on clinicaltrials.gov and ISRCTN 
(www.isrctn.com), and reviewing thesis titles from the World Cat dissertations and theses 
database. References of retrieved studies and relevant review articles were also searched 
using the snowballing approach. No language restrictions were applied.  
 
Study selection criteria 
All randomised controlled trials of pregnant women with chronic hypertension comparing an 
antihypertensive agent with another treatment arm as long-term antepartum management 
were included. No blood pressure cut-offs were utilised in the eligibility criteria for inclusion, 
but studies examining acute treatment of severe hypertension via intravenous/fast-acting 
routes were excluded. Comparisons with other antihypertensive drug(s), placebo, no 
treatment, or an alternative such as bed rest, were eligible for inclusion. Studies that included 
participants with gestational hypertension and chronic hypertension were only eligible for 
inclusion if the data for the women with chronic hypertension population were reported 
separately to allow fair comparison. Studies that compared management strategies only but 
did not include a randomised comparison of drug treatments were not eligible for inclusion. 
Trials that did not report any of the pre-defined outcomes were excluded. Trials that did not 
include sufficient information on the outcomes (e.g. standard deviations) could not be 
included in the meta-analysis. No other restrictions were applied to the study search.  
 
Data extraction 
The titles, abstracts and selected full texts generated from the literature search were 
independently screened by authors LMW and FCR. Data from the trials that met all inclusion 
criteria were manually extracted and entered into a standard extraction table independently 
from full texts by LMW and FCR. The authors were not masked to the results of the study or 
authors. Where two articles published results from the same study, individual pertinent 
outcomes were extracted from both articles without repetition of data extraction. The primary 
outcomes were maternal severe hypertension (definitions used in each study documented) 
and neonatal birthweight. In addition, the following secondary outcome measures were 
recorded for each study; maternal: superimposed pre-eclampsia (definitions used in each 
study documented), caesarean section delivery, abruption; perinatal: stillbirth/neonatal death, 
small for gestational age infants (within trial definition), preterm birth (defined as less than 37 
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completed weeks’ gestation), and Apgar score less than seven at five minutes. Details of 
potential confounders (maternal age, body mass index, ethnicity) were recorded wherever 
provided in the manuscripts. The PRISMA statement was considered and observed for all 
procedures and reporting.260 
 
Study quality assessment 
Each trial was independently quality assessed using the Cochrane Collaboration Risk of Bias 
tool by LMW and FCR.259 The risk of bias in each of the following domains was assessed: 
sequence generation, allocation concealment, blinding, incomplete outcome data, selective 
outcome reporting, and other sources of bias.  
 
Statistical methods 
Data were analysed in the statistical package Stata (version 14.1, Stator, College Station, 
Texas), using the metan suite of commands.261 All outcomes were analysed on an intention to 
treat basis. Per-protocol data for an endpoint were excluded from the analysis. Meta-analysis 
was performed using a fixed effects model where there was more than one study with 
analysable data. If there was evidence of significant heterogeneity, the meta-analysis was 
repeated using the random effects model for comparison, however the results presented are 
from the fixed effects analysis. Initial analysis of treatment effects was performed by class of 
antihypertensive agent and subsequently by active versus non-active treatment. Treatment 
effects are presented as estimated differences in mean or risk ratios with 95% confidence 
intervals. Heterogeneity was quantified via the Tau-squared and I-squared statistics.262  
 
3.4 Results 
Description of studies 
The study selection process is illustrated in the flow chart, Figure 3.1. After removal of 
duplicates the initial search generated 501 titles and abstracts for review. Following screening, 
39 articles underwent full text assessment. 16 articles met inclusion criteria, reporting on 15 
trials that recruited a total of 1166 women, with a median of 20 participants per trial 
(interquartile range 12 to 60 participants per trial).  
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Figure 3.1 Flow chart of articles identified reporting randomised controlled trials of 
antihypertensive agents for the treatment of chronic hypertension in pregnancy 
The characteristics of the studies meeting entry criteria are presented in Table 3.1. 
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Methods Participants with chronic 
hypertension 









treatment or no 
treatment 
• No allocation 
concealment.  
• 58 women 
• History of hypertension before 
pregnancy (BP >140/90 mmHg)  
• OR hypertension in 2 
consecutive measurements 
more than 24 hours apart at <20 
weeks’ gestation  
• AND diastolic BP <100 mmHg 
and no end organ damage 
Excluded:  
• Nulliparous women  
• Major obstetric or medical 
problem e.g. diabetes 
• >20 weeks’ gestation 
Active:  










Versus Non-active:  















• Double blind 
randomised 
controlled trial 
• 29 women 
• Systolic BP 140-170 mmHg or 
diastolic BP 90-110 mmHg on 2 
occasions separated by at least 
24 hours between 12 and 24 
weeks’ gestation in women with 
known essential hypertension 
Excluded:  
• Contra-indication to β-blocker  
Active:  
• Atenolol 50-200 
mg/day 
Versus Non-active:  
• Placebo tablets 
Perinatal:  
• Stillbirth 
• Birthweight  












• Open label 
• 46 women 
• Diastolic BP >95 mmHg on 2 
occasions at least 24 hours apart 
<32 weeks’ gestation 
• OR diastolic BP > 105 mmHg on 
1 occasion at <32 weeks’ 
gestation 
Excluded:  
• Diabetes  
• Multiple pregnancy 
• Already taking antihypertensive 
treatment 
• Significant medical condition 
Active:  
• Methyldopa 750-
3000 mg/day  
Versus Active:  





• Mode of delivery 
Perinatal: 
• Birthweight 








• No information on 
allocation 
concealment  
• 40 women 
• Known chronic hypertension 
• Diastolic BP >95 mmHg.  
Excluded:  
• Proteinuria at study entry 




















• Randomised using 
serial numbers in 
blocks of 6  
• No information on 
allocation 
concealment 
• 27 women 
• Elevated BP prior to pregnancy 
or diastolic BP 85-99 mmHg at 
<20 weeks’ gestation.  
Excluded:  
• Known medical or obstetric 
complication that could affect 
pregnancy outcome 
Active:  
• Pindolol 10-20 
mg/day 
Versus Non-active:  







• Small for 
gestational age 
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• 16 women 
• Known essential hypertension  
• OR failure of hypertension to 
resolve 12 weeks postpartum 
from previous pregnancy 





Versus Non-active:  








• Women divided 
into two groups – 
treatment and 
control 
• No information 
regarding 
concealment 
• 100 women 
• BP >140/90 mmHg before 20 
weeks’ gestation  
Excluded:  
• Proteinuria at study entry 
• Contraindication to β-blockers 
Active:  
• Pindolol 10-30 
mg/day 
Versus Non-active:  
















• Open label 
• 202 women  
• BP >140/90 mmHg on 2 
occasions at least 24 hours apart 
before 28 weeks’ gestation 
Excluded:  
• BP at study entry >170 mmHg 
systolic or >110 mmHg diastolic 
• Multiple pregnancy 
• Rhesus incompatibility 
• Severe maternal disease 
Active:  
• Methyldopa – 
dosing regimen not 
specified 
Versus Non-active:  



















• Open label 
• 126 women 
• Known chronic hypertension 
prior to pregnancy with 2 
consecutive diastolic BP >90 
mmHg 
• OR diastolic BP >90 mmHg 
before 20 weeks’ gestation 
Excluded:  
• Chronic disease e.g. diabetes, 
renal disease 
• Fetal malformations 
• Already on antihypertensive 
treatment 
• Contraindications to nifedipine 
Active:  
• Nifedipine slow 
release 20-80 
mg/day 
Versus Non-active:  













treatment group  
• Open label 
• 208 women 
• BP >140/90 mmHg on 2 
occasions at least 24 hours apart 
before 28 weeks’ gestation. 
Excluded:  
• Severe hypertension at study 
entry (systolic BP >170 mmHg or 
diastolic BP >110 mmHg) 
• Already on antihypertensive 
treatment 
• Multiple pregnancy 
• Diabetes 
• Rhesus immunisation  
Active:  
• Methyldopa – 
dosing regimen not 
specified 
Versus Non-active:  











• 20 women  Active: Maternal:  
• Superimposed 
pre-eclampsia 
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• Open label  
• Long-term history of 
hypertension, diastolic BP >90 
mmHg and <110 mmHg 
• Receiving diuretics prior to 
pregnancy 
• Diuretics – specific 
agent(s) and doses 
not specified 
Versus Non-active:  
• No treatment 
(diuretics 
discontinued) 
• Mode of delivery  
Perinatal:  
• Birthweight 
• Preterm birth 








list of numbers 
• Open label 
• 263 women 
• History of chronic hypertension 
prior to pregnancy 
Excluded:  
• Medical complications other 




Versus Active:  
• Labetalol 300-2400 
mg/day 
Versus Non-active:  




• Mode of delivery 




















• 138 women 
• Diastolic BP persistently >80 
mmHg between 12 and 20 
weeks’ gestation without 
proteinuria 
Excluded:  
• Multiple pregnancy 
• Bradycardia on ECG 
Active:  
• Ketanserin 40-80 
mg/day 
Versus Non-active: 





















• Open label 
• 49 women 
• Known chronic hypertension 
with BP >159/99 mmHg twice 24 
hours apart 
Excluded:  
• Women requiring more than 1 
drug to control BP 
Active:  
• Atenolol 50-200 
mg/day 
Versus Active:  
• Methyldopa 500-
2000 mg/day 
Versus Active:  









• Double blind 
randomised study 
• 25 women  
• Chronic hypertension, BP 
140/90 mmHg on 2 occasions >6 
hours apart 
• No proteinuria 
• Singleton pregnancies 




Versus Non-active:  





















• 21 women  
• With documented pre-
pregnancy history of elevated 
BP >140/90 mmHg on 2 
occasions >6 hours apart  
• OR in first 2 trimesters of 
pregnancy  
• OR undocumented history of 
hypertension for which the 
patient was taking 
antihypertensive treatment 
before or during pregnancy 
Excluded:  
• Diabetes requiring insulin 
• Multiple pregnancy 
Active:  
• Methyldopa 750 
mg/day- maximum 
dose not given  
Versus Active:  
• Hydralazine 75 
mg/day- maximum 
dose not given  
Versus Non-active:  







• Small for 
gestational age 
 
BP = blood pressure *Participants randomised to antihypertensive treatment (not to an agent) 
versus no antihypertensive treatment. †Papers reporting on the same study population.  
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All studies included in the meta-analysis were completed prior to 1998. Ten of the trials were 
conducted in a pre-defined chronic hypertension cohort alone,154,263,265,266,268,270-272,274,275 and 
the remaining five reported outcomes for a subgroup of women with chronic 
hypertension.177,183,264,267,269,273 Six studies were head-to-head comparisons of two or more 
antihypertensive agents (435 women),264,265,267,271,273,275 four were placebo-controlled studies of 
a single antihypertensive agent (219 women),154,266,272,274 and five were studies of single 
antihypertensive agent compared to no treatment (714 women).177,183,263,268-270  
 




Reason for exclusion and study details 
Antony,  
South Africa, 1990276 
Study participants had gestational and not chronic hypertension. 
Methods: Prospective, randomised block design, no further details given.  
Participants: 60 women at 28-36 weeks’ gestation with mean 24-hour diastolic BP 100-120 mmHg 
+/- proteinuria. 




Study participants had gestational or chronic hypertension. Outcomes for those with chronic 
hypertension not reported separately. 
Methods: Randomised, open-label multicentre trial.  
Participants: 31 women, 26 to 32 weeks’ gestation with diastolic BP >110 mmHg and previously 
normotensive or in women with chronic hypertension diastolic BP >20 mmHg compared to BP at 
<20 weeks’. 
Intervention: IV ketanserin 5 mg bolus then 4 mg/hour versus IV dihydralazine 1 mg/hour. 
Bott-Kanner,  
Israel, 1992278 
Study participants had gestational or chronic hypertension. Outcomes for those with chronic 
hypertension not reported separately. 
Methods: Randomised, double-blind trial. Women randomised in blocks of 6 using serial numbers. 
Participants: 60 women before 35 weeks’ gestation with diastolic BP 85-99 mmHg. 




Study participants had gestational and not chronic hypertension. 
Methods: Randomised open-label trial, using numbered sealed envelopes. 
Participants: 114 women with singleton pregnancies between 24 and 39 weeks’ gestation, 
diastolic BP >90 mmHg for >24 hours in absence of proteinuria.  
Intervention: Labetalol 100 mg twice daily versus no treatment. 
Faneite,  
Venezuela, 1988280 
Study participants had gestational or chronic hypertension. Outcomes for those with chronic 
hypertension not reported separately. 
Methods: Randomised trial.  
Participants: 31 women >14 weeks’ gestation, with BP >140/90 mmHg and <170/110 mmHg on 2 
occasions.  
Intervention: Mepindolol 5 mg once daily versu0s methyldopa 250 mg twice daily.  
Gallery,  
Australia, 1979281 
Study participants had gestational or chronic hypertension. Outcomes for those with chronic 
hypertension not reported separately. 
Methods: Randomised comparison study.  
Participants: 56 women at any gestation with sitting diastolic BP >95 mmHg on 2 occasions at least 
24 hours apart or 100 mmHg on two occasions at least 8 hours apart.  
Intervention: Oxprenolol versus methyldopa. Doses not specified. 
Gallery,  
Australia, 1985282 
Study participants had gestational or chronic hypertension. Outcomes for those with chronic 
hypertension not reported separately. 
Methods: Randomised open study, allocation by random number series. 
Participants: 183 women with singleton pregnancies and sitting diastolic BP of >90 mmHg on two 
occasions at least 24 hours apart or >95 mmHg on 2 occasions 12 hours apart or >100 mmHg on 2 
occasions 8 hours apart.  
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Intervention: Oxprenolol 40 mg twice daily versus methyldopa 250 mg twice daily.  
Hall,  
South Africa, 2000283 
Study participants had pre-eclampsia, gestational or chronic hypertension. Outcomes for those 
with chronic hypertension not reported separately. 
Methods: Randomised single blind controlled trial. Computer generated balanced blocks of 50 
numbers. Women allocated using consecutive, numbered, opaque envelopes containing 
medication. 
Participants: 150 women with severe early onset pre-eclampsia or hypertension and BP not 
controlled with methyldopa 2 mg/daily. 
Intervention: Nifedipine 10 mg three times daily versus prazosin 1 mg three times daily.  
Henderson-Smart, 
Australia, 1984284 
Details of participants with chronic hypertension not stated. 
Methods: Reporting neonatal outcomes of infants born to women with hypertension in pregnancy 
who were entered in a prospective randomised double blind trial.   
Participants: 95 infants born to mothers treated with clonidine hydrochloride and methyldopa.  
Intervention: Clonidine hydrochloride 150-1200 µg/day versus methyldopa 250-2000 mg/day. 
Hogstedt,  
Sweden, 1985285 
Study participants had gestational or chronic hypertension. Outcomes for those with chronic 
hypertension not reported separately. 
Methods: Randomised open controlled trial.  
Participants: 161 women in antenatal care with diastolic BP > 90 mmHg on two occasions at least 
6 hours apart, confirmed the following day with diastolic BP >90 mmHg for at least 2 out of 4 BP 
readings.  
Intervention: 50 mg metoprolol and 25 mg hydralazine twice daily versus no treatment. 
Jannet,  
France, 1994286 
Study participants had gestational or chronic hypertension or pre-eclampsia. Outcomes for those 
with chronic hypertension not reported separately. 
Methods: Randomised comparative trial. Computer generated random numbers, allocated using 
sealed envelopes. 
Participants: 100 women with singleton pregnancies at >20 weeks’ gestation with systolic BP > 140 
mmHg and/or diastolic BP > 90 mmHg on 2 successive measurements. 




Study participants had gestational or chronic hypertension. Outcomes for those with chronic 
hypertension not reported separately. 
Methods: Randomised open comparative trial.  
Participants: 63 women between 7 and 36 weeks’ gestation with diastolic BP > 90 mmHg on two 
occasions at least 8 days apart.  




Outcome data not presented with adequate statistical information to allow inclusion in the meta-
analysis. 
Methods: Randomised controlled trial. 
Participants: 100 women with diastolic BP > 90 mmHg on two occasions at least 48 hours apart.  




Study participants had gestational and not chronic hypertension. 
Methods: Randomised prospective study, no further details given. 
Participants: 28 women with BP > 140/90 mmHg on 2 consecutive readings at least 24 hours apart.  
Intervention: Propanolol versus methyldopa. Doses not specified. 
Moore,  
UK, 1982290 
Study participants had gestational or chronic hypertension. Outcomes for women with chronic 
hypertension not reported separately. 
Methods: Randomised trial, no further details given. 
Participants: 74 women at < 36 weeks’ gestation with systolic BP > 170 mmHg and/or diastolic BP 
> 110 mmHg.  
Intervention: Labetalol 100 mg four times daily versus 250 mg methyldopa four times daily.  
Plouin,  
France, 1988291 
Study participants had gestational or chronic hypertension. Outcomes for women with chronic 
hypertension not reported separately. 
Methods: Randomised open controlled trial. Stratified randomisation using blinded envelopes. 
Participants: 176 women with a singleton pregnancy, gestational age between 12 and 34 weeks 
and diastolic BP >89 mmHg on 2 separate occasions. 
Intervention: Labetalol 400 mg in two doses versus methyldopa 500 mg in two doses.  
Rosenfeld,  
Israel, 1986292 
Study participants had gestational or chronic hypertension. Outcomes for those with chronic 
hypertension not reported separately. 
Methods: Randomised study, no further details given. 
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Participants: 44 women at <36 weeks’ gestation with systolic BP >150 mmHg or diastolic BP >90 
mmHg on 2 separate occasions at least 24 hours apart. 
Intervention: Hydralazine 25 mg twice daily versus hydralazine 25 mg twice daily and pindolol 5 
mg twice daily. 
Steyn,  
South Africa, 2001293 
Reporting data from same trial as Steyn 1997272, reported no additional outcomes. 
Methods: Randomised double blind controlled trial. Computer generated balanced block 
structure. 
Participants: 102 women between 12 and 20 weeks’ gestation with diastolic BP >80 mmHg 
without proteinuria.  
Intervention: Ketanserin 20 mg twice daily and aspirin 75 mg once daily versus placebo 1 tablet 
twice daily and aspirin 75 mg once daily.  
Tuimala,  
Finland, 1988294 
Study participants had gestational and not chronic hypertension. 
Methods: Randomised trial, no further details given. 
Participants: 51 women with BP >149/94 mmHg x 2 in sitting position after 2 days bed rest in 
hospital. 
Intervention: Atenolol 50-100 mg/day versus pindolol 10-20 mg/day. If needed, hydralazine 150 
mg/day added. 
Vigil-De Gracia,  
Panama, 2014295 
Three arm pilot study including a third active treatment arm of aspirin. 
Methods: Randomised open label pilot trial. Computer generated code with block size of six, 
allocation through sealed envelopes. 
Participants: 63 women at <20 weeks’ gestation with systolic BP 90-109 mmHg 




Study participants had gestational or chronic hypertension or pre-eclampsia. Outcomes for those 
with chronic hypertension not reported separately. 
Methods: Randomised open study, no further details given.  
Participants: 20 women with systolic BP >159 mmHg and/or diastolic BP >99 mmHg recorded 
twice 24 hours apart.  
Intervention: Ketanserin 20-80 mg daily versus methyldopa 500-2000 mg daily. 
Wichman,  
Sweden, 1984297 
Study participants had gestational and not chronic hypertension. 
Methods: Randomised placebo controlled trial. Selective allocation. 
Participants: 52 women at <37 weeks’ gestation with systolic BP >140 mmHg or diastolic BP >90 
mmHg or if there was an elevation of >30 mmHg systolic or >15 mmHg diastolic from previous 
readings. 
Intervention: Metoprolol 50 mg twice daily versus placebo 1 tablet twice daily.  
Wide-Swensson,  
Sweden, 1995298 
Study participants had gestational and not chronic hypertension. 
Methods: Randomised parallel double blind multicentre trial. Block randomisation by numbers, 
allocation by sealed envelope. 
Participants: 118 women with singleton pregnancy, gestational age between 25 and 37 weeks’ and 
diastolic BP between >95 mmHg and <110 mmHg. 
Intervention: Isradipine slow release 5 mg twice daily versus placebo 1 tablet twice daily. 
IV= intravenous, BP=blood pressure 
Of the 23 articles that were excluded, 14 studies included a mixed population of gestational 
and chronic hypertension and did not report outcomes separately, six studies included only 
gestational hypertension, one paper reported no additional outcomes for a trial already 
included in the meta-analysis (Table 3.2). In addition, Leather and colleagues reported a 
randomised controlled trial in 1968 that recruited 47 chronic hypertensive participants 
randomised to bendroflumethiazide and methyldopa versus no treatment. This paper could 
not be included due to inadequate reporting of the statistical information relating to the 
outcomes, prohibiting inclusion of the data in the  meta-analysis.288 Leather and colleagues 
concluded that the treatment of ‘early hypertension’ (present before 20 weeks gestation) 
resulted in a longer pregnancy, increased birthweight and reduced perinatal mortality. A pilot 
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study by Vigil-De Gracia and colleagues in 2014, compared furosemide, amlodipine and aspirin 
in a three arm randomised controlled trial, and found no significant difference in outcomes 
between all treatment arms.295 These data could not be included in the active versus non-
active treatment meta-analysis, as the third arm of aspirin was considered active treatment 
given that the other arms did not receive this agent. In addition, the data from the amlodipine 
and furosemide arms could not be included in the antihypertensive treatment versus 
antihypertensive treatment meta-analysis as there are no other head-to-head trials evaluating 
calcium-channel blockers or diuretics for comparison.   





Definition of severe hypertension Definition of superimposed pre-eclampsia 
Arias,  
USA, 1979263 
‘Pregnancy aggravated hypertension’: >28 weeks’ 
gestation diastolic BP >100 mmHg in 2 consecutive 
readings 6 or more hours apart 
>1+ proteinuria or more than 300 mg/L protein 
in 24-hour collection with ‘pregnancy 




Not reported Not reported 
Fiddler,  
UK, 1983264 





Diastolic BP persistently >110 mmHg 
Systolic BP increased by 30 mmHg or diastolic BP 
increased by 20 mmHg for 2 consecutive 




Uncontrolled elevation of diastolic BP >100 mmHg Not reported 
Horvath,  
Australia, 1985267 








Systolic BP >170 mmHg or diastolic BP >110 mmHg 
on 2 occasions >4 hours apart 
Oedema, proteinuria from mid-stream urine in 
absence of infection and raised plasma urate 
Parazzini,  
Italy,1998177 
Not reported Not reported 
*Redman,  
UK, 1976183 
Systolic BP >170 mmHg or diastolic BP >110 mmHg 
on 2 occasions >4 hours apart 
Oedema, proteinuria from mid-stream urine in 








Systolic BP >160 mmHg or diastolic BP >100 mmHg 
Proteinuria (>1 g/24hrs) or elevated uric acid 




Single diastolic BP >120 mmHg OR 2 consecutive 
readings of 110 mmHg at least 4 hours apart 
Single diastolic BP >110 mmHg or 2 consecutive 
measurements of 90 mmHg or more at least 4 
hours apart with proteinuria 300 mg/L on 24-
hour collection OR 2+ proteinuria on dipstick 
Voto,  
Argentina, 1990273 




Sudden rise in systolic BP >30 mmHg or diastolic 
BP >15 mmHg and sudden weight gain >2 lbs per 
week OR proteinuria 2+ or more on dipstick 
Welt,  
USA, 1981275 
Diastolic BP >100 torr on 2 occasions 6 or more 
hours apart 
Proteinuria >trace on dipstick or >300 mg/L in 24 
hours, oedema, or both 
BP=blood pressure. *Papers reporting the same study population. 
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Definitions of severe hypertension and superimposed pre-eclampsia for each included study 
are listed in Table 3.3. Minimum diastolic and systolic blood pressure eligibility cut-offs ranged 
from 80 to 99 mmHg and 140 to 160 mmHg respectively. Two studies excluded women with 
proteinuria,265,274 three studies included women with proteinuria at study entry,264,267,273 and 
the remainder of studies did not specify presence or absence of proteinuria in their methods. 
Six studies excluded multi-fetal pregnancies263,264,270,271,274,275; the remainder either included 
women with multi-fetal pregnancies or did not specify inclusion or exclusion in their methods. 
Maternal age was the only potential confounding baseline characteristic consistently reported. 
This ranged from 28 to 33 years and no adjustment was deemed pertinent to this analysis. 
Body mass index was not reported in any of the trials, but six studies reported maternal weight 
at trial entry. Ethnicity of the participants was not considered or recorded in any of the trials.     
 
 
Risk of bias in included studies  
All studies were assessed to be at high risk of bias apart from Steyn et al,272 which was assigned 
unclear risk of bias. Full details of the allocated risk of bias scoring displayed in Figure 3.2. No 
formal assessment of socioeconomic settings of the studies was made given the small number 
of studies, but all were from middle or high income countries (see Table 3.1). 
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Figure 3.2 Risk of bias assessment of each study included in the meta-analysis 
A. By individual assessment of criteria for each study. Randomised controlled trials are 
listed alphabetically by author name. 
B. Risk of bias items presented as percentages across all included studies 
*Redman183 (1976) and Mutch269 (1977) both publish data from the same study, only the 
Redman paper has been assessed for risk of bias. Risk of bias summary showing review 
authors’ judgments about each risk of bias domain in randomised controlled trials on efficacy 
of antihypertensive treatment for chronic hypertension in pregnancy. 
 
Effects of intervention (active versus non-active treatment) 
Antihypertensive treatment reduces the incidence of severe hypertension in pregnancy 
complicated by chronic hypertension compared with no antihypertensive or placebo, with a 
risk ratio of 0.33 (95% confidence interval 0.19 to 0.56), based on 446 women from five 
studies. The risk of superimposed pre-eclampsia was not significantly different between those 
randomised to active versus non-active treatment; risk ratio 0.74 (95% confidence interval 0.49 
to 1.11: 727 women, seven studies) (Figure 3.3). 
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Figure 3.3 Maternal outcomes: active versus non-active treatment 
A. Severe hypertension 
B. Superimposed pre-eclampsia 
*Where studies had more than one active treatment arm, the data from the active treatment 
arms were pooled and compared with the non-active treatment data. Studies are listed in order 
of the year they were published. Antihypertensive agents used in each study are listed in Table 
3.1.  The number of participants experiencing severe hypertension or superimposed pre-
eclampsia in each treatment group are denoted as ‘n’, with the total number of participants 
with chronic hypertension in each study arm denoted as ‘N’. 
 
Perinatal outcomes were assessed to determine the potential fetal and neonatal risks 
associated with antihypertensive use when compared to non-active treatment. The analysis of 
stillbirth and neonatal death demonstrated a non-significant reduction with the use of 
antihypertensive treatment: risk ratio 0.37 (95% confidence interval 0.11 to 1.26: 667 women, 
four studies). Birthweight was not significantly different when active versus non-active 
treatments were compared (-60g weighted mean difference, 95% confidence interval -200g to 
80g; 802 women, seven studies). There was no difference in small for gestational age infants 
with the use of antihypertensive agents (risk ratio 1.01, 95% confidence interval 0.53 to 1.94; 
369 women, four studies) (Figure 3.4).  
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Figure 3.4 Perinatal outcomes: active versus non-active treatment 
A. Stillbirth or neonatal death 
B. Birthweight 
C. Small for gestational age infants 
*Where studies had more than one active treatment arm, the data from the active treatment 
arms were pooled and compared with the non-active treatment data. Studies are listed in order 
of the year they were published. Antihypertensive agents used in each study are listed in Table 
3.1.  The number of participants experiencing a stillbirth/neonatal death or small for 
gestational age infant in each treatment group are denoted as ‘n’, with the total number of 
participants with chronic hypertension in each study arm denoted as ‘N’. 
 
A single study by Butters and colleagues (1991) comparing atenolol to placebo found a 
significant reduction in birthweight and increase in small for gestational age in the active 
treatment arm.154 Given the degree of heterogeneity, these results were explored further with 
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Egger’s test. This demonstrated the Butters study154 as an outlier (Figure 3.5).When this study 
was included in the meta-analysis, weighted mean difference in birthweight did not reach 
significance, -100g (95% confidence interval -240g to 40g; I2 49.6%)  and similarly though the 
risk of small for gestational age increased, it did not reach significance (risk ratio 1.58, 95% 
confidence interval 0.88 to 2.85; I2 38.6%). 
 
Figure 3.5 Funnel plot comparing birthweight difference between studies 
Funnel plot demonstrating Butters and colleagues154 (1990) (atenolol versus placebo) is an 
outlier within the meta-analysis of birthweight when comparing active and non-active 
treatment. Antihypertensive agents used in each study are listed in Table 3.1.   
 
The additional maternal and perinatal outcomes meta-analysed between active and non-active 
arms are listed in Table 3.4. There were no additional significant differences. 
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Table 3.4 Summary of meta-analysis findings comparing active with non-active treatment 
and the effect on maternal and perinatal outcomes in pregnancy complicated by chronic 
hypertension 
















Maternal      
Severe 
hypertension 
5 446 0.33 0.19 to 0.56 0.0% 
Superimposed 
pre-eclampsia 
7 727 0.74 0.49 to 1.11 28.1% 
Caesarean section 
delivery 
4 543 1.23 0.92 to 1.63 0.0% 
Abruption 2 401 0.35 0.10 to 1.27 20.9% 
Perinatal      
Stillbirth/Neonatal 
death 
4 667 0.37 0.11 to 1.26 0.0% 
Birthweight (g) 7 802 -60 -200 to 80g 0.0% 
Small for 
gestational age 
4 369 1.01 0.53 to 1.94 0.0% 
Gestation at 
delivery (weeks) 
7 785 0.10 -0.05 to 0.24 83.7% 
Preterm birth 3 341 1.23 0.58 to 2.54 0.0% 
Apgar score <7 at 
5 minutes 
4 410 1.13 0.40 to 3.20 0.0% 
Risk ratios provided where binary data was analysed and weighted mean difference given for 
continuous outcomes.  
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Table 3.5 Summary of meta-analysis findings comparing methyldopa with other 
antihypertensive agents and the effect on maternal and perinatal outcomes in pregnancy 
complicated by chronic hypertension 
















Maternal      
Severe 
Hypertension 
3 101 1.13 0.71 to 1.81 36.4% 
Superimposed 
pre-eclampsia 
4 277 0.99 0.62 to 1.58 0.0% 
Perinatal      
Stillbirth/Neonatal 
death 
2 186 2.24 0.35 to 14.28 0.0% 
Birthweight (g) 3 259 50 -200 to 290 0.0% 
Risk ratios provided where binary data was analysed and weighted mean difference given for 
continuous outcomes.  
 
Effects of intervention (antihypertensive agent versus antihypertensive agent) 
Due to the small number of studies, comparison of antihypertensive agents was restricted to 
methyldopa versus other classes of antihypertensive, and where possible methyldopa versus 
beta-blockers (Table 3.5). There was no difference in incidence of severe hypertension 
between agents when methyldopa was compared with other antihypertensive treatments. 
Two head-to-head studies (86 women) reported incidence of severe hypertension comparing 
methyldopa and beta-blocker antihypertensive treatment: risk ratio 0.85 (95% confidence 
interval 0.57 to 1.37). There was no difference in the incidence of superimposed pre-eclampsia 
when methyldopa was compared with other antihypertensive agents. There were additionally 
no significant differences in perinatal outcomes between antihypertensive agents. Forest plots 
of these meta-analyses are presented in Figures 3.6 and 3.7.   
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Figure 3.6 Maternal outcomes: comparison of methyldopa versus other antihypertensive 
agents 
A. Severe hypertension  
B. Superimposed pre-eclampsia 
Studies listed in order of the year they were published. Antihypertensive agents used in each 
study are listed in Table 3.1.  The number of participants experiencing severe hypertension or 
superimposed pre-eclampsia in each treatment group are denoted as ‘n’, with the total number 
of participants with chronic hypertension in each study arm denoted as ‘N’. 
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Figure 3.7 Perinatal outcomes: comparison of methyldopa versus other antihypertensive 
agents 
A. Stillbirth and neonatal death 
B. Birthweight 
*Comparison made between methyldopa and beta-blockers as these were the only agents used 
in head-to-head trials reporting birthweight. Studies are listed in order of the year they were 
published. Antihypertensive agents used in each study are listed in Table 3.1.  The number of 
participants experiencing a stillbirth/neonatal death in each treatment group are denoted as 




This is the largest systematic review of the evidence from randomised controlled trials to guide 
antihypertensive treatment specifically for chronic hypertension in pregnancy. Other 
systematic reviews have pooled results for chronic and gestational hypertension, but given the 
different aetiology and duration of treatment there are concerns with this approach. The 
reduction in the incidence of severe hypertension in pregnant women with chronic 
hypertension with the use of antihypertensive treatment is clinically important given the short 
and long-term associated maternal morbidity and mortality.16,49,57,62,131,132 It is not possible at 
this time to recommend one agent over another for optimal blood pressure control, as there 
have only been three head-to-head randomised controlled trials enrolling 101 women that 
have examined this outcome.264,265,275 No overall reduction in the risk of pre-eclampsia was 
seen with the use of antihypertensive treatment.  
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The paucity of data to guide selection of antihypertensive treatment for chronic hypertension 
in pregnancy is also highlighted. Only 15 randomised controlled trials totalling 1166 
pregnancies meeting study eligibility criteria were identified and many of these were too small 
to address whether antihypertensive treatments reduce the risk of superimposed pre-
eclampsia or influence other measures of perinatal morbidity. The only study published in the 
last 18 years by Vigil and colleagues compared three active treatment arms and 
antihypertensive treatments not recommended by most international guidelines as first line 
agents (amlodipine, furosemide and aspirin).14 It could not be included in the meta-analysis 
given this design. This compares with many more trials and participants outside pregnancy; a 
recent systematic review of antihypertensive treatment (excluding pregnant participants) for 
the prevention of cardiovascular disease identified 123 randomised controlled trials including 
613,815 participants.299 Of the 15 studies reported here, only ten focused on chronic 
hypertension in pregnancy and the other five enrolled a mixed population of chronic and 
gestational hypertension, from which data for the participants with chronic hypertension were 
extracted. Given the changes in management of hypertension both inside and outside 
pregnancy, and that all of these trials were published between 1976 and 1998, optimal 
antihypertensive therapy for treating chronic hypertension in pregnancy warrants further 
investigation through large randomised controlled trials.  
 
Antihypertensive use in pregnancy complicated by chronic hypertension does not increase the 
risk of stillbirth or neonatal death, no reduction in birthweight or increase in small for 
gestational age infants was seen, though heterogeneity was evident. This strengthens the 
finding that antihypertensive agents do not significantly affect perinatal morbidity; agent 
selection and higher than recommended dose are likely to account for the evidence from 
Butters and colleagues154 who published data from a study of 29 participants randomised in 
the second trimester to atenolol or placebo.154 Whilst it is evident the results of this study have 
influenced clinical practice,14,16 this appears to be specific to this agent, or the very high doses 
that were used (up to 200 mg daily). Doses above 50 mg atenolol daily are not recommended 
and infrequently used nowadays for hypertension, as above this the dose-response curve is 
typically quite flat for blood-pressure lowering, with the maximum licensed dose for other 
indications being 100 mg daily. The primary results for this analysis have been presented 
without the inclusion of this study for these reasons. Von Dadelszen and colleagues (2000) also 
analysed with and without the data from the Butters study when examining the impact of 
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antihypertensive treatment on the risk of small for gestational age due to concerns over trial 
reporting.129,300   
 
Ten of the 15 studies included in the meta-analysis evaluated agents that are no longer used 
for the routine management of hypertension in pregnancy in many countries (atenolol, 
acebutalol, oxprenolol, pindolol, bendroflumethiazide, hydrochlorothiazide, furosemide) or in 
the general non-pregnant population (ketanserin), accounting for about 45% of the 
participants studied. Whilst the labetalol is commonly used in pregnancy, not all beta-blockers 
can be considered equivalent. Labetalol is a racemate with alpha and non-selective beta 
antagonist activity (in a ratio of around one to three) for oral labetalol.146,301 Oxprenolol, 
acebutalol and pindolol are more selective for beta-1 receptors than beta-2 receptors but are 
additionally partial agonists, possessing intrinsic sympathomimetic activity (resulting in less 
effect on reducing heart rate). Whilst licensed for hypertension, beta-blockers are no longer 
recommended as first line antihypertensive treatment, but are now regarded as fourth line 
agents for resistant hypertension in the general (non-pregnant) population.1 The dose of 
bendroflumethiazide used (5-10 mg daily) is higher than that currently used for hypertension 
(2.5 mg daily). Therefore, a substantial proportion of the evidence for treatment of 
hypertension in pregnancy is based on outdated drugs and outdated doses. It is difficult to 
draw conclusions over the effect of antihypertensive agents on other maternal and perinatal 
outcomes. Meta-analysis of many maternal and fetal secondary outcomes was not possible 
due to a lack of reporting in the trials conducted to date. In addition, the planned adjustment 
for potential confounders such as body mass index was not possible due to inconsistent or 
absent reporting in the trial manuscripts. Further studies are needed to answer these 
questions and assess the potential impact of maternal characteristics such as obesity and other 
medical co-morbidities.  
 
The Cochrane risk of bias assessment was high or unclear for all the studies included. This is 
primarily due to assignment of unclear risk of bias to many areas of study conduct and 
restrictions in the Cochrane tool. Many studies were open-label assigning them high risk of 
bias, which reflects the difficulties in blinding medication within pregnancy when blood 
pressure is dynamic and multiple dosing changes are required over a short time period.  
Additionally, the studies are not uniform in their reported outcome measures, which reflects 
the large time frame and variation in geographical setting of the studies. All studies included 
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are at least 18 years old and given the improvements in standards of clinical care in addition to 
standards of study conduct, there is the potential for substantial bias to be introduced.  
 
Previous meta-analyses of the antihypertensive treatment of chronic hypertension in 
pregnancy are smaller than this study and have focussed on other interventions and 
outcomes.257,302 The most recent of these was published in 2000. This study aimed to assess 
long-term treatment of chronic hypertension in pregnancy and the majority of trials did not 
provide sufficient detail to allow categorisation into mild or severe hypertension. In addition, a 
considerable portion of women will cross over from one group to the other making analysis 
problematic. A Cochrane review has been conducted on the use of antihypertensive treatment 
for ‘mild to moderate’ hypertension in pregnancy.256 The authors conclude ‘whether the 
reduction in the risk of severe hypertension is considered sufﬁcient to warrant treatment is a 
decision that should be made by women in consultation with their obstetrician’ and classed 
‘mild to moderate’ hypertension as a systolic blood pressure up to and including 169 mmHg. In 
contrast, the Control of Hypertension in Pregnancy Study concludes that ‘tight control’ of 
blood pressure should be recommended to reduce the risk of short and long-term maternal 
morbidity given that this does not affect fetal or neonatal outcome adversely.15,133  Subgroup 
analyses of those with chronic hypertension suggest a possible trend towards small for 
gestational age birthweight <10th centile (13.9% versus 19.7%; adjusted odds ratio 0.66, 95% 
confidence interval 0.44 to 1.00), however it is notable that in this subgroup the primary 
perinatal outcome was no different (odds ratio 1.08, 95% confidence interval 0.78 to 1.51). A 
post-hoc analysis of CHIPS found severe hypertension occurring in either intervention group 
(tight versus less-tight control) was associated with higher rates of pregnancy loss/neonatal 
unit admission and birthweight <10th centile,133 suggesting a perinatal benefit to reducing the 
risk of severe hypertension. Additionally, those with severe hypertension in the less-tight 
control group were found to have an increased risk of serious maternal morbidity/mortality 
(odds ratio 3.74, 95% confidence interval 1.25 to 11.22).133 Whilst some still question the need 
to treat hypertension before it reaches severe levels, the American Heart Association and the 
American Stroke Association recommend systolic blood pressure should be treated above the 
level of 150 mmHg to reduce the risk of stroke.303 This recommendation is echoed in the 
findings of the UK triennial enquiry into maternal death, which found severe hypertension to 
be a factor in a significant proportion of hypertension related deaths.49 Of note since this 
recommendation deaths from pre-eclampsia have fallen to less than 1 per million in the UK.304 
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The potential effects of ‘less-tight control’ on long-term maternal morbidity and mortality has 
recently been highlighted.131,132 The Systolic blood Pressure INtervention Trial (SPRINT) 
stopped recruitment early due to the significant 25% reduction seen in a composite 
cardiovascular outcome (stroke, myocardial infarction and cardiac failure) with tighter control 
of systolic hypertension to a target of 120 mmHg rather than the standard treatment target of 
140 mmHg; however this was coupled with a significant increase in serious adverse events 
such as hypotension, syncope and acute kidney injury.305 Women of reproductive age with 
chronic hypertension are at substantially increased risk of cardiovascular morbidity and 
mortality.306 Reducing the incidence of severe hypertension and maintaining tighter blood 
pressure control in pregnancy might contribute to lowering their long-term cardiovascular risk 
and warrants further investigation. 
 
Earlier systematic reviews have focused on magnitude of initial hypertension rather than the 
underlying condition causing the hypertension. However, separating chronic and gestational 
hypertension, given the differing pathophysiological pathways and implications of treatment, 
allows focus on optimising treatment for each condition and is much more relevant to clinical 
practice.151,256 Advances in the understanding of the mechanisms behind the exacerbation of 
hypertension in pregnancy and the associated increased risk of superimposed pre-eclampsia 
should be complemented with randomised controlled trials that examine how 
antihypertensive treatment may need to be tailored to the underlying pathophysiology. The 
International Society for the Study of Hypertension in Pregnancy guidelines classifying sub-
types of hypertension in pregnancy have been refined over time and head-to-head randomised 
controlled trials comparing antihypertensive agents specifically for the treatment of chronic 
hypertension in pregnancy using these definitions are urgently needed.21  
 
There is emerging evidence that tighter control of hypertension outside pregnancy reduces 
risks of long-term cardiovascular morbidity and mortality.305 In light of the Control of 
Hypertension In Pregnancy Study data suggesting fetal safety with tighter control of 
hypertension, future research should focus on head-to-head randomised controlled trials of 
the most commonly used antihypertensive agents in current practice; this should include 
smaller trials to evaluate efficacy and larger trials to assess effectiveness of agent(s) for control 
of chronic hypertension in pregnancy. In addition, further consideration of the impact of 
maternal demographic factors should be considered such as body mass index and ethnicity. 
Outside pregnancy, calcium-channel blockers are recommended as first line antihypertensive 
Student Number: 1355203 
Student Name: Louise Mary Webster 
99 
 
therapy for those of African or Caribbean family origin.1 This is due to differing 
pathophysiological pathways causing hypertension that vary with ethnic origin.78 It is possible 
that the efficacy of antihypertensive treatment is similarly affected by maternal ethnic 
background. This systematic review provides evidence to recommend women with chronic 
hypertension in pregnancy should receive antihypertensive treatment to reduce the incidence 
of severe hypertension and its associated maternal morbidity, without adversely affecting 
perinatal outcome.  
 
In conclusion, antihypertensive treatment reduces the risk of severe hypertension in pregnant 
women with chronic hypertension. A considerable paucity of data exists from randomised 
controlled trials to guide choice of antihypertensive agent for chronic hypertension in 
pregnancy. Adequately powered head-to-head randomised controlled trials of the commonly 
used antihypertensive agents are required to inform prescribing. 
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CHAPTER 4 PREVALENCE OF ADVERSE PERINATAL OUTCOMES AND ASSOCIATED RISK 
FACTORS IN WOMEN WITH CHRONIC HYPERTENSION 
 
4.1 Abstract 
The objective of this study was to quantify the risk of adverse perinatal outcome in women 
with chronic hypertension compared to the general pregnant population, and to assess the 
impact of maternal characteristics on the risk of adverse perinatal outcome in women with 
chronic hypertension. Demographic and delivery data of women with chronic hypertension 
and singleton pregnancies from three obstetric units (2000-2014) were collated and compared 
with national maternity data. Then multivariable logistic regression models were used to 
calculate risk ratios (RR) for adverse perinatal outcome in women with chronic hypertension 
adjusted for maternal characteristics. The cohort included 4045 women (4481 pregnancies) 
with chronic hypertension. The incidence of adverse outcome was increased in the cohort 
compared with national maternity data: stillbirth 1.6% versus 0.6% (RR 2.83; 95% CI 2.25, 
3.55), preterm birth <37 weeks 16% versus 8.9% (RR 2.16; 95% CI 2.00, 2.34), and birthweight 
<2500g 16% versus 6.6% (RR 2.63; 95% CI 2.43, 2.85). Maternal characteristics associated with 
an increased risk of adverse outcome included non-White ethnicity, advanced maternal age, 
primiparity, smoking, and deprivation. Black women, compared to White women, had the 
highest risk for all adverse outcomes: stillbirth: 3.1% versus 0.6% (adjusted RR 5.56; 95% CI 
2.79, 11.1), preterm birth <37 weeks 21% versus 11% (aRR 1.70; 95% CI 1.43, 2.02), 
birthweight <3rd centile 16% versus 7.4% (aRR 2.07; 95% CI 1.71, 2.51). Non-White (particularly 
Black) ethnicity, deprivation, advanced maternal age, primiparity, and smoking all increase the 
risk of adverse perinatal outcome in women with chronic hypertension.  
 
4.2 Introduction 
The prevalence of chronic hypertension in pregnancy is rising due to increasing maternal age 
and the global obesity epidemic.7,29,33,34,307 The current incidence of chronic hypertension in 
pregnancy is estimated at 3%, making it the most common pre-existing medical disorder that 
directly impacts maternal and fetal wellbeing.29,32,45 The increased vascular resistance and 
decreased vascular compliance associated with chronic hypertension may cause 
maladaptation of the maternal circulation to the physiological demands of pregnancy.110,308 
Superimposed pre-eclampsia, stillbirth, fetal growth restriction, and preterm birth all occur 
more frequently in pregnancies complicated by chronic hypertension, compared with 
normotensive women.8,29,50,53,54 This causes substantial maternal and perinatal morbidity and 
mortality and is therefore associated with increased healthcare cost.309 The understanding of 
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mechanisms contributing to the increased risk of adverse outcomes among women with 
chronic hypertension is incomplete and the aetiology is likely to be multifactorial.  
 
Previous cohort studies of women with chronic hypertension in pregnancy have focused on the 
maternal characteristics (age, body mass index, ethnicity) associated with an increased risk of 
superimposed pre-eclampsia. 43,45,47,54 However, increased adverse perinatal outcomes, 
independent of a diagnosis of superimposed pre-eclampsia, have been reported in women 
with chronic hypertension compared to the general pregnant population.43,45,47,54 Maternal 
characteristics associated with adverse perinatal outcome in normotensive pregnancy have 
been established and include age,310 obesity6,311, smoking312 and ethnicity313-315. Data 
examining the maternal characteristics associated with these increased risks in women with 
chronic hypertension in pregnancy are limited.43,316-318   
 
Given the global changes in maternal demographics and its consequent effect on the 
prevalence of chronic hypertension in pregnancy, contemporaneous cohorts investigating 
incidence of adverse perinatal outcome and impact of maternal characteristics are needed to 
enable prioritisation of areas for further research. The objectives of this large multicentre 
cohort study were two-fold: firstly, to quantify the risk of adverse perinatal outcome in women 
with chronic hypertension and compare with the general pregnant population, and secondly, 
to assess the impact of maternal characteristics on the risk of adverse perinatal outcome in 
pregnancy complicated by chronic hypertension.   
 
4.3 Methods 
The cohort was collated from three obstetric units in the United Kingdom (UK): Guy’s and St 
Thomas’ National Health Service (NHS) Foundation Trust (London), St George’s University 
Hospitals NHS Foundation Trust (London), and Central Manchester University Hospitals NHS 
Foundation Trust (Manchester). All deliveries after 20 weeks’ gestation recorded on maternity 
databases between 2000 and 2014 with maternal history of chronic hypertension or a 
documented blood pressure greater than 140 mmHg systolic and/or 90 mmHg diastolic 
recorded before 20 weeks’ gestation (as per the International Society for the Study of 
Hypertension in Pregnancy classification)21 were extracted for analysis. Multifetal pregnancies 
were then excluded from the cohort due to a risk of confounding perinatal outcomes.319 
Demographic and delivery data were recorded for all the remaining singleton pregnancies 
complicated by chronic hypertension. Only pregnancies with a complete baseline demographic 
dataset (comprising maternal age, body mass index, parity, smoking, ethnicity, and deprivation 
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index) were included in the analysis. The size of the study was dictated by the earliest year 
maternal demographic and delivery data were recorded electronically at each centre. 
 
Ethnicity (as recorded at antenatal booking) was assigned using four ethnic groups, White, 
Black, Asian, and Other, based on the grouping used by the UK Office for National Statistics.320 
Women of mixed ethnic origin were included in the group that they shared heritage with in the 
following order of priority: Black, Asian, White and Other. Socioeconomic status was classified 
using maternal postcode data, linked to lower super output area for calculation of indices of 
deprivation; participants were then categorised into the five groups with one being the least 
deprived and five being the most deprived.321 Where the participant had no fixed abode they 
were included in deprivation index (Index of Multiple Deprivation) group five. 
 
Birthweight centiles were calculated using birthweight centile charts (Gestation Related 
Optimal Weight (version 6.7.5.1 2014) and Intergrowth-21st 
(http://intergrowth21.ndog.ox.ac.uk/)).322,323 The GROW customised birthweight centiles 
adjust for maternal height, maternal weight, maternal ethnicity, parity, gestation at delivery, 
infant sex and infant birthweight in its calculation.322 The Intergrowth-21st birthweight centiles 
adjust for gestation at delivery, infant sex and infant birthweight.323 Infants were then 
categorised into those with a birthweight less than the 10th centile and less than the 3rd centile 
(characterised as fetal growth restriction (FGR) by a recent Delphi consensus65). GROW 
birthweight centiles322 were used in the primary analysis and Intergrowth-21st323 for 
subsequent comparison. Preterm births (spontaneous and iatrogenic) were categorised as 
those born before 37 weeks’ gestation and 34 weeks’ gestation. Stillbirths were defined as 
infants born without signs of life after 20 weeks’ gestation. Neonatal unit admission included 
infants requiring neonatal intensive care unit and/or special care baby unit admission. 
 
Statistical Analysis 
Means with standard deviation (SD) or medians with interquartile range (IQR) were calculated 
for continuous variables and numbers with percentages within the categories used for the 
regression models were calculated for maternal demographic characteristics and outcomes of 
the cohort with chronic hypertension and the NHS maternity statistics for England 2013-
2014.324 The mean and SD for maternal age from the NHS maternity dataset were estimated by 
replacing the age groups with their midranges. Comparison of maternal and perinatal 
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outcomes between the cohort and NHS maternity statistics was made by calculating risk ratios 
(RR) and associated 95% confidence intervals (95% CI).  
 
Within the cohort of pregnancies complicated by chronic hypertension, unadjusted risk ratios 
and associated 95% CIs were calculated by generalised linear models using the statistical 
package Stata (version 14.1) for baseline demographic factors and subsequent perinatal 
outcomes (including stillbirth, preterm birth, neonatal unit admission, birthweight <10th 
centile, and birthweight <3rd centile). Adjusted risk ratios were then calculated using a 
multivariable regression model including demographic factors that could be explanatory or 
confounding in association with adverse perinatal outcome: ethnicity, deprivation index, 
maternal age, parity, body mass index, smoking history, and year of delivery. Allowance was 
made for women having more than one pregnancy within the cohort duration by adjusting the 
standard errors for clustering by hospital identification number. The validity of the model was 
confirmed by repeating the multivariable regression only including the significant risk factors 
for each perinatal outcome. In addition, a sensitivity analysis assessing the impact of centre on 
the results was conducted. 
 
Further associations of adverse outcome and maternal characteristics were explored via chi-
squared test or linear regression models. This included comparison of GROW and Intergrowth-
21st birthweight centiles and their impact on the study findings. Investigation of possible 
confounding included assessing the impact of centre of delivery on each perinatal outcome.  
 
The study was reported in line with STROBE guidance for observational studies.325 
 
4.4 Results 
Data from 4481 singleton pregnancies in 4045 women with chronic hypertension between 
2000 and 2014 were included in the analysis. The flow diagram of participants is shown in 
Figure 4.1. Only pregnancies with all demographic characteristics required for the multivariate 
regression model were included in the final analysis (86% of singleton pregnancies identified). 
The most common missing data point was body mass index accounting for 13% of pregnancies 
excluded from the analysis with the majority of these in the earliest years of the dataset. 
Sixteen postcodes could not be linked to lower super output areas; these participants were 
also excluded from the analysis. Thirteen women had no fixed abode and were included in 
deprivation index group five. 
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Figure 4.1 Flow diagram of identification of the study cohort 
 
 
Comparison of the cohort of pregnancies with chronic hypertension to national maternity 
statistics 
The summary demographic characteristics of the cohort and the NHS maternity statistics for 
2013 to 2014 are provided in Table 4.1. There was a higher proportion of Black women in the 
cohort with chronic hypertension compared with the general pregnant population (36% versus 
4.8%; p <0.001) and the proportion of women aged 40 years or older was also higher (13% 
versus 3.9%; p <0.001).324 There were a greater number of pregnancies included in the cohort 
from 2010 onwards as maternity records from Central Manchester University Hospitals NHS 
Foundation Trust were not available before this date. 
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Table 4.1 Demographic characteristics of the cohort (2000-2014) 
Maternal Characteristic Pregnancies with 
chronic hypertension 
n=4481 
NHS maternity statistics 
England 2013 to 2014 
n= 646,904 
Significance 
Age at delivery, years 
mean (SD) 
33 (5.8) 30 (5.5) 
P <0.001 
<25 384 (8.5%) 136,420 (21%)  
25-29.9 762 (17%) 181,017 (30%)  
30-34.9 1454 (32%) 194,398 (30%)  
35-39.9 1299 (29%) 100,339 (16%)  
≥40 582 (13%) 24,953 (3.9%)  






<25 1463 (33%)   
25-29.9 1332 (30%)   
30-34.9 945 (21%)   
≥35 741 (17%)   
Parity*    
Nulliparous 2112 (47%) 164,774 (37%) P <0.001 
Multiparous 2369 (53%) 283,952 (63%)  
Non-smoker 4169 (93%)   
Smoker 312 (7%)   
Ethnicity*    
White 2122 (47%) 463,049 (72%) P <0.001 
Black 1601 (36%) 31,176 (4.8%)  
Asian 379 (8.5%) 69,734 (11%)  
Other 379 (8.5%) 33,606 (5.2%)  
Deprivation Index    
1 (least deprived) 350 (7.8%) 94,245 (15%) P <0.001 
2 462 (10%) 100,495 (16%)  
3 953 (21%) 117,629 (18%)  
4 1403 (31%) 143,982 (22%)  
5 (most deprived) 1313 (29%) 177,252 (27%)  
Year of pregnancy    
2000-2004 836 (19%)   
2005-2009 1598 (36%)   
2010-2014 2047 (46%)   
Centre    
Guy’s and St Thomas’ NHS 
Foundation Trust 
2016 (45%)  
 
St George’s University Hospitals 
NHS Foundation Trust 
2029 (45%)  
 
Central Manchester University 
Hospitals NHS Foundation Trust 
436 (9.7%)  
 
*30% of the parity data and 7% of the ethnicity data for the NHS maternity statistics was 
unknown. For all continuous variables, the categories used in the regression model are 
additionally shown.  
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All major adverse perinatal outcomes, with the exception of macrosomia, were significantly 
higher in women with chronic hypertension compared to the general pregnant population: 
stillbirth, birthweight <2500g, preterm birth <37 weeks’ gestation, iatrogenic delivery, and 
Caesarean delivery (Table 4.2). The stillbirth rate was nearly three times that seen in the 
general pregnant population (RR 2.83; 95% CI 2.25 to 3.55). The risk of preterm birth before 37 
completed weeks’ gestation was more than double in the cohort of women with chronic 
hypertension (RR 2.16; 95% CI 2.00 to 2.34). The proportion of babies born weighing <2500g 
was more than twice as high in the cohort of women with chronic hypertension (RR 2.63; 95% 
CI 2.43 to 2.85), but the proportion of babies born >4500g was comparable between the 
cohort and national data. In addition, higher rates of induction of labour and caesarean section 
birth were found in the cohort with chronic hypertension (Table 4.2). 
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NHS maternity statistics 




Maternal Outcomes    
Gestation at delivery, weeks 
median (IQR) 
39.3  
(38.0 to 40.4) 
  
Onset of labour    
Spontaneous 1832 (40.8%) 319,146 (60.1%)  
Induction 
1471 (32.8%) 100,913 (19.0%) 
2.53 
(2.38 to 2.69)* 
Pre-labour caesarean section 1007 (22.5%) 68,103 (12.8%)  
Mode of delivery†    
Spontaneous vaginal delivery 2152 (48.0%) 319,238 (60.1%)  
Instrumental delivery 
580 (12.9%) 67,312 (12.7%) 
1.28 
(1.17 to 1.40) 
Caesarean section delivery 
1749 (39%) 135,516 (25.5%) 
1.82 
(1.71 to 1.93) 
Elective caesarean section 611 (13.6%) 56,675 (10.7%)  
Emergency caesarean 
section 
1138 (25.4%) 78,841 (14.8%)  
Estimated blood loss, ml,  
mean (SD)  
500 (420)   
High dependency unit 
admission‡ 
417 (10.5%)   
Fetal outcomes    
Stillbirth 
72 (1.6%) 3125 (0.6%)§ 
2.83 
(2.25 to 3.55) 
Preterm birth    
<37 weeks 
701 (15.6%) 41,631 (7.8%) 
2.16 
(2.00 to 2.34) 
<34 weeks 305 (6.8%)   
Birthweight, g,  
median (IQR) 
3230  
(2780 to 3630) 
  
<2500g 
708 (15.8%) 36,598 (6.6%)ǁ 
2.63 
(2.43 to 2.85) 
>4500g 
68 (1.5%) 9087 (1.6%)ǁ 
0.93 
(0.73 to 1.18) 
Birthweight centile    
<10th centile 1047 (23.4%)   
<3rd centile 499 (11.1%)   
Neonatal unit admission  413 (9.2%)   
*Risk ratio calculated for iatrogenic onset of labour compared with spontaneous, †data 
reported for n=521,346, ‡data regarding maternal high dependency unit admission was only 
available for 79% of the cohort, §data reported for n=552,036, ǁ data reported for n=555,445, 
IQR= interquartile range, SD= standard deviation 
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Multivariable regression model analysis of risk factors contributing to adverse perinatal 
outcome in the cohort of pregnancies complicated by chronic hypertension 
Using stillbirth as an important perinatal endpoint, the impact of maternal characteristics was 
assessed in a multivariable regression model. The only maternal characteristics remaining 
significant in the adjusted model were Black and Asian ethnicity. Black women had a risk ratio 
of 5.56 (95% CI 2.79 to 11.09) of having a stillbirth compared to White women, and Asian 
women had risk ratio of 3.03 (95% CI 1.11 to 8.28) compared to White women (Table 4.3). 
  
Table 4.3 Effect of baseline characteristics on risk of stillbirth 
* Results reaching statistical significance p<0.05 
 
Risk category Unadjusted Risk Ratio  
(95% CI) 
Adjusted Risk Ratio  
(95% CI) 
Age, years                       
  
<25 0.76 (0.29 to 1.97) 0.60 (0.22 to 1.62) 
25 to 29.9 0.53 (0.23 to 1.23) 0.46 (0.20 to 1.07) 
30 to 34.9 1.00 (Reference)  
35 to 39.9 0.99 (0.56 to 1.74) 0.91 (0.51 to 1.61) 
≥40 1.30 (0.67 to 2.52) 1.07 (0.54 to 2.13) 
BMI, kg/m2                     
  
<25 1.00 (Reference)  
25 to 29.9 1.21 (0.66 to 2.25) 0.92 (0.49 to 1.72) 
30 to 34.9 1.47 (0.77 to 2.78) 1.00 (0.52 to 1.92) 
≥35 1.45 (0.73 to 2.88) 1.03 (0.51 to 2.08) 
Nulliparity 1.00 (0.63 to 1.59) 1.56 (0.94 to 2.60) 
Multiparity 1.00 (Reference)  
Non-Smoker 1.00 (Reference) 
 
Smoker 0.38 (0.09 to 1.55) 0.53 (0.12 to 2.20) 
Ethnicity        
  
White 1.00 (Reference)  
Black 5.41* (2.89 to 10.1) 5.56* (2.79 to 11.09) 
Asian 2.80* (1.06 to 7.40) 3.03* (1.11 to 8.28) 
Other 2.33 (0.83 to 6.56) 2.28 (0.81 to 6.42) 
Year of delivery     
  
2000 to 2004 1.01 (0.54 to 1.87) 1.06 (0.57 to 1.98) 
2005 to 2009 0.90 (0.54 to 1.51) 0.95 (0.57 to 1.98) 
2010 to 2014 1.00 (Reference)  
Deprivation Index     
  
1 to 3 1.00 (Reference)  
4 1.72 (0.96 to 3.09) 1.23 (0.69 to 2.18) 
5 (most deprived) 1.91* (1.07 to 3.42) 1.31 (0.60 to 2.12) 
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When the risks were calculated for birthweight <3rd centile, women aged 40 years or older (RR 
1.53; 95% CI 1.09 to 2.16), women who smoked (RR 1.53; 95% CI 1.15 to 2.04) and women of 
Black (RR 2.07; 95% CI 1.71 to 2.51), Asian (RR 1.69; 95% CI 1.24 to 2.30) or Other ethnicity (RR 
1.70, 95% CI 1.26 to 2.31) were at significantly increased risk (Table 4.4). Baseline 
characteristics significantly increasing the risk of birthweight <10th centile in the adjusted 
model included being aged 40 years or older (RR 1.34; 95% CI 1.06 to 1.69), nulliparity (RR 
1.16; 95% CI 1.03 to1.30), smoking (RR 1.52; 95% CI 1.28 to 1.81), living in an area of greatest 
deprivation (RR 1.20; 95% CI 1.04 to 1.38), and Black ethnicity (RR 1.64; 95% CI 1.45 to 1.87) 
(Table 4.5).  
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Table 4.4 Effect of baseline characteristics on risk of birthweight <3rd centile 
CI= confidence interval * Results reaching statistical significance p<0.05. 
 
  
Risk category Unadjusted Risk Ratio  
(95% CI) 
Adjusted Risk Ratio  
(95% CI) 




Age, years                          
<25 1.03 (0.74 to 1.43) 0.89 (0.64 o 1.25)  
25 to 29.9 0.97 (0.74 to 1.26) 0.92 (0.70 to 1.19)  
30 to 34.9 1.00 (Reference)   
35 to 39.9 1.07 (0.86 to 1.33) 1.05 (0.84 to 1.31)  
≥40 1.64* (1.29 to 2.09) 1.51* (1.18 to 1.93) 1.53* (1.09 to 2.16) 
BMI, kg/m2                        
<25 1.00 (Reference) 
 
 
25 to 29.9 1.29* (1.04 to 1.60) 1.11 (0.89 to 1.38)  
30 to 34.9 1.35* (1.07 to 1.70) 1.07 (0.84 to 1.37)  
≥35 1.14 (0.87 to 1.49) 0.90 (0.68 to 1.20)  
Nulliparity 0.96 (0.81 to 1.13) 1.19 (0.99 to 1.42)  
Multiparity 1.00 (Reference) 
 
 
Non-Smoker 1.00 (Reference) -  
Smoker 1.32 (0.99 to 1.75) 1.57* (1.18 to 2.09) 1.53* (1.15 to 2.04) 
Ethnicity           
White 1.00 (Reference) -  
Black 2.10* (1.73 to 2.53) 2.04* (1.66 to 2.52) 2.07* (1.71 to 2.51) 
Asian 1.63* (1.20 to 2.23) 1.67* (1.22 to 2.29) 1.69* (1.24 to 2.30) 
Other 1.70* (1.26 to 2.31) 1.65* (1.22 to 2.24) 1.70* (1.26 to 2.31) 
Year of delivery        
2000 to 2004 0.92 (0.73 to 1.16) 0.95 (0.76 to 1.19)  
2005 to 2009 0.84 (0.69 to 1.01) 0.87 (0.72 to 1.05)  
2010 to 2014 1.00 (Reference)   
Deprivation Index        
1 to 3 1.00 (Reference) -  
4 1.35* (1.10 to 1.66) 1.15 (0.94 to 1.42)  
5 (most deprived) 1.46* (1.19 to 1.79) 1.14 (0.92 to 1.42)  
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Table 4.5 Effect of baseline characteristics on risk of birthweight <10th centile 
CI= confidence interval * Results reaching statistical significance p<0.05. 
 
Factors increasing the risk of preterm birth before 37 weeks’ gestation included: being aged 40 
years or older (RR 1.52; 95% CI 1.13 to 2.05), nulliparity (RR 1.17; 95% CI 1.01 to 1.35), living in 
area of greatest deprivation (RR 1.42; 95% CI 1.18 to 1.70), and Black or Asian ethnicity (RR 
1.70; 95% CI 1.43 to 2.01 and RR 1.82; 95% CI 1.41 to 2.35 respectively) (Table 4.6). When the 
analysis was repeated assessing the risk of preterm birth before 34 weeks’ gestation, only 
women of Black (RR 2.69; 95% CI 2.03 to 3.55), Asian (RR 2.48; 95% CI 1.69 to 3.66) and Other 
ethnic groups (RR 1.69; 95% CI 1.07 to 2.68), and women living in the most deprived areas (RR 
Risk category Unadjusted Risk Ratio  
(95% CI) 
Adjusted Risk Ratio  
(95% CI) 




Age, years                       
  
 
<25 1.08 (0.88 to 1.33) 0.95 (0.77 to 1.17) - 
25 to 29.9 1.02 (0.87 to 1.20) 0.96 (0.82 to 1.13) - 
30 to 34.9 1.00 (Reference)  - 
35 to 39.9 1.05 (0.91 to 1.21) 1.03 (0.90 to 1.19) - 
≥40 1.36* (1.15 to 1.59) 1.26* (1.07 to 1.49) 1.34* (1.06 to 1.69) 
BMI, kg/m2                     
  
 
<25 1.00 (Reference)  - 
25 to 29.9 1.13 (0.98 to 1.30) 1.01 (0.88 to 1.16) - 
30 to 34.9 1.16 (0.99 to 1.35) 0.99 (0.85 to 1.15) - 
≥35 1.15 (0.97 to 1.35) 0.96 (0.81 to 1.14) - 
Nulliparity 0.99 (0.89 to 1.10) 1.15* (1.03 to 1.29) 1.16* (1.03 to 1.30) 
Multiparity 1.00 (Reference)   
Non-Smoker 1.00 (Reference) - - 
Smoker 1.39* (1.16 to 1.66) 1.53* (1.28 to 1.81) 1.52* (1.28 to 1.81) 
Ethnicity        
  
 
White 1.00 (Reference) - - 
Black 1.68* (1.49 to 1.89) 1.65* (1.45 to 1.88) 1.64* (1.45 to 1.87) 
Asian 1.17 (0.94 to 1.46) 1.21 (0.97 to 1.51) - 
Other 1.20 (0.97 to 1.49) 1.18 (0.95 to 1.46) - 
Year of delivery     
  
 
2000 to 2004 0.96 (0.83 to 1.11) 0.97 (0.84 to 1.12)  
2005 to 2009 0.90 (0.79 to 1.01) 0.92 (0.82 to 1.04) - 
2010 to 2014 1.00 (Reference)   
Deprivation Index     
  
 
1 to 3 1.00 (Reference) - - 
4 1.21* (1.06 to 1.39) 1.08 (0.94 to 1.25) - 
5 (most deprived) 1.41* (1.24 to 1.61) 1.19* (1.04 to 1.37) 1.20* (1.04 to 1.38) 
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1.39; 95% CI 1.05 to 1.86) were at significantly increased risk (Table 4.7). In this cohort, where 
15.6% of women delivered preterm, 3.2% followed spontaneous labour whilst 12.4% were 
iatrogenic. No ethnic difference was seen amongst the spontaneous preterm births, but the 
proportion of Black versus White women giving birth before 37 weeks’ gestation through 
iatrogenic delivery was 17% versus 7.9% (p<0.0001).   
 
Table 4.6 Effect of baseline characteristics on risk of preterm birth <37 weeks’ gestation 
CI= confidence interval * Results reaching statistical significance p<0.05 
 
 
Risk category Unadjusted Risk Ratio  
(95% CI) 
Adjusted Risk Ratio  
(95% CI) 




Age, years                       
  
 
<25 1.01 (0.77 to 1.33) 0.86 (0.65 to 1.14)  
25 to 29.9 0.90 (0.72 to 1.13) 0.83 (0.67 to 1.04)  
30 to 34.9 1.00 (Reference)   
35 to 39.9 1.16 (0.97 to 1.38) 1.13 (0.94 to 1.35)  
≥40 1.45* (1.18 to 1.77) 1.35* (1.09 to 1.66) 1.52* (1.13 to 2.05) 
BMI, kg/m2                     
  
 
<25 1.00 (Reference)   
25 to 29.9 1.22* (1.02 to 1.45) 1.06 (0.89 to 1.27)  
30 to 34.9 1.28* (1.05 to 1.55) 1.05 (0.86 to 1.28)  
≥35 1.27* (1.03 to 1.57) 1.06 (0.86 to 1.32)  
Nulliparity 0.94 (0.82 to 1.08) 1.19* (1.02 to 1.38) 1.17* (1.01 to 1.35) 
Multiparity 1.00 (Reference)   
Non-Smoker 1.00 (Reference) -  
Smoker 1.09 (0.84 to 1.42) 1.26 (0.97 to 1.63)  
Ethnicity        
  
 
White 1.00 (Reference) -  
Black 1.88* (1.61 to 2.20) 1.70* (1.43 to 2.02) 1.70* (1.43 to 2.01) 
Asian 1.83* (1.42 to 2.35) 1.86* (1.44 to 2.40) 1.82* (1.41 to 2.35) 
Other 1.26 (0.95 to 1.66) 1.21 (0.91 to 1.60)  
Year of delivery     
  
 
2000 to 2004 1.04 (0.86 to 1.25) 1.11 (0.92 to 1.33)  
2005 to 2009 0.98 (0.84 to 1.15) 1.04 (0.89 to 1.21)  
2010 to 2014 1.00 (Reference)   
Deprivation Index     
  
 
1 to 3 1.00 (Reference) -  
4 1.44* (1.20 to 1.72) 1.30* (1.08 to 1.56) 1.30* (1.09 to 1.56) 
5 (most deprived) 1.67* (1.41 to 1.98) 1.43* (1.19 to 1.71) 1.42* (1.18 to 1.70) 
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Table 4.7 Effect of baseline characteristics on risk of premature birth <34 weeks’ gestation 
CI= confidence interval * Results reaching statistical significance p<0.05. 
 
Neonatal unit admission was associated with Black, Asian and Other ethnicity compared to 
White (RR 1.55; 95% CI 1.25 to 1.93, RR 1.58; 95% CI 1.12 to 2.23, and RR 1.46; 95% CI 1.06 to 
2.04 respectively), and nulliparity compared to multiparity (RR 1.32; 95% CI 1.08 to 1.61) 
(Table 4.8). Year of delivery also affected the risk of neonatal unit admission with babies born 
between 2000-2004 and 2005-2009 at greater risk than those born between 2010-2014 (RR 
1.35; 95% CI 1.05 to 1.74, and RR 1.30; 95% CI 1.06 to 1.60 respectively). 
Risk category Unadjusted Risk Ratio  
(95% CI) 
Adjusted Risk Ratio 
(95% CI) 




Age, years                       
  
 
<25 1.22 (0.81 to 1.84) 1.00 (0.65 to 1.54) - 
25 to 29.9 0.94 (0.66 to 1.34) 0.84 (0.59 to 1.20) - 
30 to 34.9 1.00 (Reference)  - 
35 to 39.9 1.19 (0.89 to 1.58) 1.13 (0.84 to 1.51) - 
≥40 1.57* (1.14 to 2.19) 1.39 (0.99 to 1.94) - 
BMI, kg/m2                     
  
 
<25 1.00 (Reference)  - 
25 to 29.9 1.11 (0.84 to 1.47) 0.90 (0.68 to 1.19) - 
30 to 34.9 1.26 (0.93 to 1.47) 0.93 (0.69 to 1.26) - 
≥35 1.04 (0.74 to 1.47) 0.79 (0.56 to 1.12) - 
Nulliparity 0.92 (0.74 to 1.14) 1.18 (0.94 to 1.49) - 
Multiparity 1.00 (Reference)  - 
Non-Smoker 1.00 (Reference) - - 
Smoker 1.04 (0.67 to 1.60) 1.34 (0.87 to 2.07) - 
Ethnicity        
  
 
White 1.00 (Reference) - - 
Black 2.97* (2.28 to 3.87) 2.81* (2.10 to 3.76) 2.69* (2.03 to 3.55) 
Asian 2.58* (1.75 to 3.79) 2.67* (1.79 to 3.96) 2.48* (1.69 to 3.66) 
Other 1.77* (1.12 to 2.79) 1.68* (1.06 to 2.68) 1.69* (1.07 to 2.68) 
Year of delivery     
  
 
2000 to 2004 0.82 (0.60 to 1.13) 0.86 (0.62 to 1.18) - 
2005 to 2009 0.95 (0.75 to 1.21) 0.99 (0.78 to 1.26) - 
2010 to 2014 1.00 (Reference)  - 
Deprivation Index     
  
 
1 to 3 1.00 (Reference) - - 
4 1.54* (1.16 to 2.06) 1.24 (0.93 to 1.66) - 
5 (most deprived) 1.94* (1.48 to 2.56) 1.41* (1.06 to 1.88) 1.39* (1.05 to 1.86) 
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Table 4.8 Effect of baseline characteristics on risk of neonatal unit admission 
CI= confidence interval * Results reaching statistical significance p<0.05. 
 
A sensitivity analysis assessing the impact of centre on the significant findings of the regression 
model was conducted in two ways: including centre in the regression model and repeating the 
regression model including only the data from women who delivered their babies in the last 
five years of the study (as data from Central Manchester University Hospitals NHS Foundation 
Trust was only available for this time period). Although there were differences in the incidence 
of each adverse outcome at each centre, the maternal characteristics that significantly 
Risk category Unadjusted Risk Ratio  
(95% CI) 
Adjusted Risk Ratio 
(95% CI) 




Age, years                       
  
 
<25 1.17 (0.82 to 1.66) 0.98 (0.68 to 1.41) - 
25 to 29.9 1.04 (0.78 to 1.38) 0.97 (0.73 to 1.29) - 
30 to 34.9 1.00 (Reference)  - 
35 to 39.9 1.14 (0.89 to 1.45) 1.16 (0.91 to 1.48) - 
≥40 1.40* (1.05 to 1.86) 1.42* (1.06 to 1.90) 1.38 (0.93 to 2.04) 
BMI, kg/m2                     
  
 
<25 1.00 (Reference)  - 
25 to 29.9 1.07 (0.84 to 1.36) 1.01 (0.79 to 1.28) - 
30 to 34.9 1.20 (0.93 to 1.55) 1.13 (0.87 to 1.47) - 
≥35 1.19 (0.91 to 1.57) 1.13 (0.84 to 1.51) - 
Nulliparity 1.14 (0.95 to 1.37) 1.36* (1.11 to 1.66) 1.32* (1.08 to 1.61) 
Multiparity 1.00 (Reference)   
Non-Smoker 1.00 (Reference) - - 
Smoker 1.17 (0.83 to 1.65) 1.29 (0.92 to 1.82) - 
Ethnicity        
  
 
White 1.00 (Reference) - - 
Black 1.53* (1.24 to 1.88) 1.48* (1.18 to 1.86) 1.55* (1.25 to 1.93) 
Asian 1.48* (1.05 to 2.09) 1.58* (1.12 to 2.24) 1.58* (1.12 to 2.23) 
Other 1.45* (1.04 to 2.02) 1.44* (1.03 to 2.01) 1.46* (1.05 to 2.04) 
Year of delivery     
  
 
2000 to 2004 1.29* (1.01 to 1.66) 1.36* (1.05 to 1.76) 1.35* (1.05 to 1.74) 
2005 to 2009 1.28* (1.04 to 1.57) 1.33* (1.07 to 1.63) 1.30* (1.06 to 1.60) 
2010 to 2014 1.00 (Reference)   
Deprivation Index     
  
 
1 to 3 1.00 (Reference) - - 
4 1.29* (1.03 to 1.61) 1.20 (0.95 to 1.52) - 
5 (most deprived) 1.22* (0.97 to 1.54) 1.12 (0.88 to 1.43) - 
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increased the risk of each adverse outcome did not change when centre was included in the 
regression model.  
 
In the second sensitivity analysis, the reduction in the number of participants included due to 
restriction of the timeframe reduced power, and led to the loss of some of the significant 
results. However, the characteristics associated with the greatest increased risk of adverse 
outcome remained significant. Non-White ethnicity, living in an area of greater deprivation, 
smoking and primiparity were all associated with and increased risk of adverse outcome in this 
model. 
 
A summary of all the significant adjusted risk ratios and related confidence intervals for the 
maternal characteristics associated with adverse perinatal outcome in women with chronic 
hypertension was collated (Table 4.10). Given the strong association of ethnicity with adverse 
perinatal outcome, the prevalence, adjusted risk ratios, and related confidence intervals were 
additionally compared in Table 4.11 for all perinatal outcomes analysed and stratified by 
ethnic group.  
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Table 4.9 Adjusted risk ratios (95% confidence intervals) of significant maternal 



























(2.79 to 11.09) 
3.03 
(1.11 to 8.28) 




















(1.71 to 2.51) 
1.69 











(1.43 to 2.01) 
1.82 













(2.03 to 3.55) 
2.48 
(1.69 to 3.66) 
   
1.39 





(1.25 to 1.93) 
1.58  






*Deprivation index group 5 is associated with the greatest deprivation. 
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5.56* (2.79 to 11.1) 
1.6% 
3.03* (1.11 to 8.28) 
1.3% 






1.65* (1.45 to 1.88) 
22% 
1.21 (0.97 to 1.51) 
22% 





2.07* (1.71 to 2.51) 
12% 
1.69* (1.24 to 2.30) 
13% 





1.70* (1.43 to 2.02) 
20% 
1.86* (1.44 to 2.40) 
14% 






2.81* (2.10 to 3.76) 
9.2% 
2.67* (1.79 to 3.96) 
6.8% 






1.55* (1.25 to 1.93) 
11% 
1.58* (1.12 to 2.23) 
11% 
1.46* (1.05 to 2.04) 
* Results reaching statistical significance p<0.05.  
 
Further investigation into potential aetiology underpinning disparity in outcome within the 
cohort of pregnancies complicated by chronic hypertension  
Investigation of a surrogate for severity of maternal disease was conducted by comparing the 
proportion of mothers admitted to the high dependency unit or intensive care unit after birth. 
Black mothers versus White mothers were more likely to require high level care after birth, 
14% versus 8.2% (odds ratio 1.83; 95% CI 1.46 to 2.29).       
 
Of stillborn babies, 77% had a birthweight <10th centile and 63% had a birthweight <3rd centile. 
Most stillbirths occurred before 37 weeks’ gestation (93%). No impact of ethnicity on the 
proportion of infants with birthweight <10th centile or the gestation at delivery was found 
amongst the stillbirths. Within the entire cohort, the proportion of neonates with birthweight 
<3rd centile was higher amongst those born preterm (54% of births before 34 weeks’ gestation 
and 19% of births 34 to 37 weeks’ gestation) compared to 6.9% of births from 37 weeks’ 
gestation (Figure 4.2). Just over half the infants requiring neonatal admission had birthweights 
below the 10th centile and 40% of infants requiring neonatal unit admission had birthweight 
<3rd centile.  
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Figure 4.2 Comparison of gestation at birth and birthweight centile category   
 
Further investigation of the importance of ethnicity within birthweight centile calculation was 
assessed by comparing the Intergrowth-21st birthweight centiles, which do not include 
maternal ethnicity within its adjustment , with the GROW birthweight centiles.322,323 The 
proportion of infants classed as <3rd birthweight centile was 11% using the GROW versus 5.1% 
using Intergrowth-21st birthweight centiles; those with birthweight <10th centile were 23% 
versus 13% respectively. No infants classed as birthweight <3rd centile by Intergrowth-21st but 
not by GROW were admitted to the neonatal care unit; however, 47 infants (12%) requiring 
neonatal unit admission were classed as birthweight <3rd centile by GROW but birthweight 
>10th by Intergrowth-21st.The sensitivity and specificity for infants requiring neonatal unit 
admission were 40% and 93% for those with birthweight <3rd centile calculated using GROW, 
compared to 16% and 96% respectively for those with birthweight <3rd centile calculated using 
Intergrowth-21st.   
 
4.5 Discussion 
This large contemporary cohort study demonstrates that pregnancy complicated by chronic 
hypertension is associated with an increased risk of all adverse perinatal outcomes compared 
to recent national UK data. Maternal characteristics associated with an increased the risk of 
Student Number: 1355203 
Student Name: Louise Mary Webster 
119 
 
adverse perinatal outcome in women with chronic hypertension have been identified. Non-
White (especially Black) ethnicity, advanced maternal age, smoking status, primiparity and 
deprivation all have an impact on the perinatal complications to differing extents. Women of 
Black ethnicity with chronic hypertension are at significantly greater risk of all adverse 
perinatal outcomes than White women with chronic hypertension in pregnancy. Women of 
Asian and Other ethnicities are also at increased risk, but to a lesser extent. These findings 
underline the importance of prioritising research into optimising the management of chronic 
hypertension in pregnancy. 
 
It is striking that Black ethnicity was consistently associated with the highest increased risk for 
all adverse outcomes compared with other baseline characteristics in women with chronic 
hypertension in pregnancy, even after controlling for deprivation, maternal age, BMI and 
smoking. The explanation for this increased risk is likely to be multifactorial with biological and 
non-biological factors contributing. Women with chronic hypertension who were  of Black 
(versus White) ethnicity had a more than a five-fold increase in stillbirth risk which was similar 
among women with chronic hypertension of White ethnicity and the UK maternity population 
(0.6%).34 A disparity in incidence of stillbirth in women born in African and Caribbean countries 
(0.7%) compared to women born in the UK (0.5%) is reported by the Office for National 
Statistics,326 but these data suggest that the disparity between ethnicities among women with 
chronic hypertension is much greater. In this cohort, there was greater sensitivity (40% versus 
16%) for infants needing neonatal unit admission identified as <3rd birthweight centile using 
centiles customised for ethnicity (GROW) compared to Intergrowth-21st birthweight centile 
(without such customisation), and only a small difference in specificity (93% versus 96%). 
Though ethnicity is not a modifiable factor, these data provide a focus for future research into 
aetiology and should be considered when investigating modalities of intervention. Also, an 
awareness of these risk factors should inform antenatal care pathway stratification. 
 
To our knowledge, this is the largest cohort study of women with chronic hypertension in 
pregnancy examining the risk factors for adverse perinatal outcome in the UK. The data were 
collated from three tertiary centres, which reduces the risk of confounding found in single 
centre studies. Robust statistical methodology using regression modelling has allowed for 
identification and quantification of the impact of maternal factors on subsequent perinatal 
outcome.    
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It was not possible to assess severity of chronic hypertension within the cohort. Coding for 
superimposed pre-eclampsia was not sufficiently reliable and so the additional impact of this 
diagnosis on adverse perinatal outcome could not be assessed. Additionally, adequately 
detailed data on blood pressure control, antihypertensive treatment and other maternal co-
morbidity were not available. The surrogate outcome of high dependency unit admission was 
used to assess severity of disease and women of Black ethnicity were significantly more likely 
to require this level of care after delivery (compared to White women), suggesting a 
correlation with increased disease severity amongst this group, and supported by a 
significantly higher proportion of preterm births that were iatrogenic among mothers of Black 
ethnicity compared to White. This corresponds with the findings of another recent study that 
found an association between Black ethnicity and iatrogenic preterm delivery.315 Comparison 
of temporal changes in care between the national UK data and the cohort was not possible 
due to restrictions in the availability of NHS data for this timeframe. The only outcome that 
appeared to improve over time within the cohort was neonatal unit admission. Utilising the 
national UK data as a comparator in this study was also limited by the large amount of missing 
data. Future investigation would include collection of all maternity data from the centres 
included for this time period.    
 
The proportion of Black women in the study was much higher than the national average, 
although typical of the ethnic mix in large cities in the UK. This may have improved the power 
for comparison between Black and White women, but is a limitation for comparison with the 
national pregnancy outcome data. There were smaller numbers of women of Asian ethnic 
origin compared to other groups and further investigation of ethnic variation in outcome in 
women of Asian ethnicity is needed. It was also not possible to assess the impact of ethnic sub-
groups on risk, for example African ancestry compared to Caribbean. 
 
The risk factors for de novo postnatal hypertension that were identified by Goel and colleagues 
(2015) in a cohort of 744 women included: raised BMI, Black ethnicity and pre-existing 
diabetes.327 A previous UK study published in 1998 included only 213 pregnancies complicated 
by chronic hypertension and was not powered to compare many of the perinatal outcomes 
between ethnic groups.317 The number of adverse perinatal events in this cohort allows for 
such comparison. The incidence of chronic hypertension in Black women is known to be higher 
than in White women. There are also well described differences in pathophysiology causing 
hypertension that are related to ethnicity.27,328 Variation in socioeconomic circumstances have 
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previously been linked to these differences,329 but these cannot account entirely for the 
differences given that the model presented here included deprivation score as a baseline 
characteristic and the participants had free point-of-care access to a healthcare system for 
their antenatal care. However, it was not possible to capture adherence to treatment or 
engagement in care in this cohort, which may be a factor. Rowe and colleagues found that the 
odds of late booking after 18 weeks’ gestation for antenatal care in England were higher for 
Black women (odds ratio 5.92; 95% confidence intervals 2.97 to 11.83).330 There may be 
cultural reasons or language barriers as to why women do not access or utilise healthcare 
equally. However, the FASTER trial examined the ethnic variation in perinatal outcomes in 
women who accessed antenatal care in the first trimester and found that women of Black 
ethnicity still had an increased risk of perinatal morbidity compared to White women (odds 
ratio 3.5; 95% confidence intervals 2.5 to 4.9)331, so this cannot entirely account for the 
inequality in outcome.      
 
Comparison of customised and non-customised birthweight centiles has been highlighted by 
recent studies in the general pregnant population.332,333 The importance of accounting for 
maternal ethnicity in the calculation of birthweight centiles is unclear. Ethnicity has a strong 
association with adverse outcome within this population of women with chronic hypertension 
and birthweight centiles customised for ethnicity have greater sensitivity and comparable 
specificity in association with an important outcome indicative of adverse perinatal outcome. 
Classification of fetal and hence neonatal growth restriction has recently been examined by a 
Delphi consensus outlining criteria for diagnosis of fetal growth restriction.65 Further 
investigation into classification of neonatal growth restriction and the importance of including 
ethnicity within birthweight centile calculation is warranted.65,334 
  
Stillbirth, preterm birth, neonatal unit admission and small for gestational age infants are all 
increased in pregnancy complicated by chronic hypertension. Whilst there have been many 
advances in caring for premature babies, the long term health implications must not be 
underestimated and there is growing evidence of the increased risk to the cardiovascular and 
metabolic health of the growth restricted infant.335,336 When planning antenatal care pathways 
for women with chronic hypertension the additional risk factors of ethnicity, maternal age, 
parity, smoking, and deprivation level on outcome should be considered. Strategies to ensure 
women of Black and other ethnic minority groups engage with antenatal care and are aware of 
the increased risks associated with chronic hypertension complicating pregnancy need to be 
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developed. Additionally, consideration of the other modifiable interventions stratified by 
ethnicity including thresholds of pre-pregnancy blood pressure control warrants further 
investigation. 
 
There are marked ethnic disparities in pregnancy outcome in the UK in women with chronic 
hypertension. Further research is needed to explore the aetiology behind these differences. 
Variation in the pathophysiology underpinning primary hypertension exists.337 Outside 
pregnancy, national recommendations in the UK and the US are that first-line antihypertensive 
agents are stratified based on ethnicity with Black women receiving calcium-channel blockers 
rather than angiotensin-converting enzyme inhibitors.1,77 Consideration of the potential role of 
first-line antihypertensive agent choice in women of African and Caribbean family origin, as is 
used outside pregnancy for the treatment of chronic hypertension, is recommended, in order 
to evaluate whether this strategy might improve maternal and perinatal outcomes. 
Investigation of the impact of genetics in addition to environmental and cultural variations 
may improve our understanding of why there is ethnic variation in outcome and how this 
might be ameliorated.   
 
In conclusion, non-White ethnicity, deprivation, advanced maternal age, primiparity, and 
smoking status all increase the risk of adverse perinatal outcome in women with chronic 
hypertension. Ethnicity has the largest impact, with Black women with chronic hypertension at 
greatest risk. Further research is needed to explore the aetiology underpinning these 
disparities. An awareness of these differences should inform stratification of antenatal care 
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CHAPTER 5 LABETALOL OR NIFEDIPINE AS ANTIHYPERTENSIVE TREATMENT FOR CHRONIC 
HYPERTENSION IN PREGNANCY: THE PANDA RANDOMISED CONTROLLED FEASIBILITY TRIAL 
 
5.1 Abstract 
Data from randomised controlled trials to guide the choice of antihypertensive agent for 
pregnancy complicated by chronic hypertension are limited. This study aimed to compare 
labetalol and nifedipine for control of chronic hypertension in pregnancy, with additional 
assessment of the impact of ethnicity on efficacy of each treatment. Pregnant women with 
chronic hypertension (12+0-27+6 weeks’ gestation) were enrolled at four UK maternity centres 
between August 2014 and October 2015. Open-label first-line antihypertensive treatment was 
randomly assigned via an online minimisation protocol with two treatment groups: labetalol 
(200-1800 mg/day) or nifedipine MR (20-80 mg/day). Biomarkers and pulse wave analyses 
were measured antenatally. All other antenatal care was standard. Analysis included 112 
women (98%) who completed the study (labetalol n=55, nifedipine n=57). Mean monthly 
recruitment was 2.6 (range 1.2-3.7) women per centre. Interventions were discontinued by 
seven women (13%) assigned labetalol and five (9%) assigned nifedipine. Maximum blood 
pressure (BP) post-randomisation was 161/101 mmHg on labetalol versus 163/105 mmHg on 
nifedipine (mean difference systolic: 1.2 mmHg ((95% confidence interval) -4.9 to 7.2 mmHg), 
diastolic: 3.3 mmHg (-0.6 to 7.3 mmHg)). Mean BP was 134/84 mmHg on labetalol and 134/85 
mmHg on nifedipine (mean difference systolic: 0.3 mmHg (-2.8 to 3.4 mmHg), and diastolic: -
1.9 mmHg (-4.1 to 0.3 mmHg)). Nifedipine use was associated with a 7.4 mmHg reduction (-
14.4 to -0.4 mmHg) in central aortic pressure, measured by pulse wave analysis. No difference 
in treatment effect was observed in Black women (n=63), but a mean 4 mmHg reduction (-6.6 
to -0.8 mmHg; P=0.015) in brachial diastolic BP was observed with labetalol compared to 
nifedipine in non-Black women (n=49). Labetalol and nifedipine control mean BP to target in 
pregnant women with chronic hypertension. Good recruitment was demonstrated and 
mechanistic treatment effects observed. This study provides support for a larger definitive trial 
scrutinising the benefits and side effects of first-line antihypertensive treatment in pregnancy 
complicated by chronic hypertension.  
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With only three randomised controlled trials (total 101 women)264,265,275, data to inform 
prescribing of antihypertensive treatments for chronic hypertension in pregnancy are sparse 
and subsequently no consensus on the optimal agent(s) exists.14,16,256,338 The prevalence of 
chronic hypertension in pregnancy is estimated at 3%,7 but this figure is set to increase with 
rising maternal age and the global obesity epidemic.5,34,39 Given that chronic hypertension is 
associated with significantly increased adverse maternal and perinatal outcomes compared to 
the general pregnant population,8,29,30 defining optimal antihypertensive treatment(s) is 
warranted.16  
 
A Cochrane review examining trials (including over 4000 women) in mild to moderate 
hypertension in pregnancy (combining chronic and gestational hypertension) concluded that 
though the incidence of severe hypertension is reduced with antihypertensive treatment, no 
reduction in the incidence of adverse maternal and perinatal outcomes has been 
demonstrated.256 There have been additional concerns that antihypertensive treatment might 
increase the risk of fetal growth restriction.129 However, more recent evidence from the 
Control of Hypertension In Pregnancy Study (CHIPS) concluded that ‘tight control’ to a diastolic 
target of 85 mmHg (compared to ‘less-tight control’ to a diastolic target of 105 mmHg) did not 
increase the risk of pregnancy loss or high-level neonatal care.15 This study also demonstrated 
that the incidence of severe maternal hypertension was significantly increased with ‘less-tight’ 
control and that this was associated with an increased risk of serious maternal morbidity in 
these women (post-hoc analysis).133 The study highlights the need to determine which 
antihypertensive agent(s) provides optimal control of chronic hypertension in pregnancy to 
ameliorate these risks.  
 
Choice of antihypertensive outside pregnancy depends on ethnicity1,77 and is thought to relate 
to differences in the pathophysiology causing hypertension in those of differing ethnic 
backgrounds.81 Ethnic disparity in maternal and perinatal outcome in the general pregnant 
population is well described and likely to be multifactorial.313,314,339,340 No randomised 
controlled trials have investigated the impact of ethnicity on efficacy of antihypertensive 
treatment in pregnancy. The aims of the ‘Pregnancy And chronic hypertension: NifeDipine 
versus lAbetalol as antihypertensive treatment’ (PANDA) study were three-fold: to assess 
feasibility of such a randomised controlled trial, to evaluate mechanistic treatment effects, and 
to examine the impact of ethnicity on efficacy of each treatment. 
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This randomised controlled feasibility trial compared effectiveness of two antihypertensive 
agents commonly used as first-line treatment14,16 (labetalol and nifedipine) for the control of 
chronic hypertension in pregnancy and additionally enrolled pregnant women with chronic 
hypertension who were unwilling or unable to be randomised to antihypertensive treatment 
to a parallel observational arm.  
 
Study Design 
The main study was an open-label, phase four, feasibility randomised controlled clinical trial 
(EudraCT Number 2013-003144-23), registered with ISRCTN (DOI 10.1186/ISRCTN40973936, 
www.isrctn.com); the protocol, and other study literature were approved by the UK Research 
Ethics Committee (REC number 13/EE/0390). Women of all ethnicities were enrolled by study 
investigators using written informed consent at four consultant-led National Health Service 
(NHS) obstetric units in the United Kingdom (Guy’s and St Thomas’ NHS Foundation Trust, 
Central Manchester University NHS Foundation Trust, University of Leicester Hospitals NHS 
Trust and St George’s University Hospitals NHS Foundation Trust). The eligibility criteria 
included: women with a prenatal diagnosis of chronic hypertension or blood pressure (BP) 
readings ≥140/90 mmHg prior to 20 weeks’ gestation requiring antihypertensive treatment, as 
defined by the International Society for the Study of Hypertension in Pregnancy,21 gestation 
between 12+0 and 27+6 weeks (to allow for second trimester blood pressure nadir), singleton 
pregnancies, aged over 18 years, and the ability to provide written informed consent. Women 
were excluded if they had a contraindication or relative contraindication to either 
antihypertensive agent, such as labetalol in women with asthma. An overview of the study 
activities are outlined in Figure 5.1. 
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Figure 5.1 Overview of study activities for participants  
 
Although not mandatory for a feasibility study, a pre-trial power calculation was performed to 
guide enrolment targets and funding requests, and used the highest systolic BP as a 
continuous outcome with a standard deviation of 7 mmHg (from data analysed in the Vitamins 
In Pregnancy trial)341. The power calculation was based on testing for non-inferiority of 
nifedipine as compared to labetalol; specifically, a difference of under 4 mmHg.  If there was 
no difference between the two treatments, then complete data on 108 women was required 
to give 90% power using a one-sided test.342 A one-sided test is generally considered 
appropriate for non-inferiority studies. 114 women were recruited to allow for 5% study 
withdrawal and loss to follow-up. A non-inferiority design was chosen as the study aimed to 
demonstrate equal effectiveness of the antihypertensive agents under investigation. A Data 
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Monitoring Committee and Trial Steering Committee were convened at regular intervals 
during the study to monitor trial conduct, but without interim analysis. The Data Monitoring 
Committee was provided with reports outlining balance of intervention allocation by each 
minimisation criteria to ensure even assignment between treatment groups. Stopping 
guidelines were outlined in the study protocol. Monitoring was conducted by the King’s Health 
Partners Clinical Trials Office at regular intervals at all participating centres during the trial. 
 
Randomisation and Intervention 
Women were randomly assigned antihypertensive treatment via a MedSciNet online 
minimisation protocol with stratification for: gestation at randomisation (divided into four 
week groups: 12+0-15+6, 16+0-19+6, 20+0-23+6 and 24+0-27+6), maternity centre, systolic BP at 
randomisation (<140 mmHg, 140-149 mmHg and ≥150 mmHg), and ethnicity (Black 
(determined by self-report of whether the woman had a parent or grandparent who was 
African or Caribbean) versus non-Black (all other ethnicities)). Minimum divided daily doses of 
labetalol were 200 mg and maximum 1800 mg and for nifedipine MR 20 mg and maximum 80 
mg. Starting doses were decided by the attending clinician.  Treatment was open-label as it 
was considered clinically not feasible to mask allocation to clinicians and women in view of the 
differing recommended dosing frequency and the need to escalate treatment and add a 
second agent where needed. Allocated treatment was taken as first-line antihypertensive 
agent until delivery and replaced any antihypertensive treatment taken at study enrolment (or 
discontinuation at clinician or woman’s request) and women were followed-up until six weeks 
post-partum wherever feasible. If additional antihypertensive agents were required or women 
opted to discontinue their assigned intervention, treatment was prescribed at their clinician’s 
preference. Diastolic BP treatment target was 85 mmHg in accordance with recommendations 
from the outcomes of the Control of Hypertension In Pregnancy Study (CHIPS).15 Clinical blood 
pressures were recorded using manual and automatic machines already in use in clinical areas 
and no restrictions were placed on the positioning of the participants during blood pressure 
measurement. All other antenatal care was as standard, including concurrent treatment with 
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Primary outcome measures 
The primary process outcome was the number of women enrolled per site per month 
(calculated at the end of trial as total number of women enrolled per site divided by number of 
months of enrolment at that site)and the primary clinical outcome was the highest systolic 
blood pressure between randomisation and delivery (highest of any recorded systolic blood 
pressure measurement made between gestation at randomisation and gestation at delivery, 
excluding recordings made on the day of delivery) and in addition the mean systolic blood 
pressure during each pregnancy between randomisation and delivery will be calculated (using 
all available systolic blood pressures taken clinically and measured using the trapezium 
method analysing the area under the curve). 
 
Secondary outcome measures 
Secondary clinical outcomes, with effect size calculated, included: proportion of days with BP 
recordings of systolic BP >=160 mmHg, >=150 mmHg, or diastolic BP <80 mmHg between 
randomisation and delivery, proportion of women diagnosed with superimposed pre-
eclampsia (defined as new-onset proteinuria, a sudden increase in proteinuria if already 
present in early gestation, and an increase in hypertension)343, median gestation at delivery, 
mean birthweight, and proportion of infants admitted to the neonatal care unit in each group. 
Other secondary clinical outcomes recorded included: additional antihypertensive agent use 
(oral and parenteral), mode of delivery, estimated blood loss, other adverse maternal outcome 
(eclampsia, intracranial haemorrhage or infarct, myocardial ischaemia/ infarction, intubation, 
pulmonary oedema, hepatic dysfunction, acute renal insufficiency, placental abruption, post-
partum haemorrhage), condition of the fetus at birth (including Apgar score and umbilical cord 
gas analysis), customised birthweight centiles, and other adverse neonatal outcomes 
(respiratory distress syndrome, need for ventilator support, intraventricular haemorrhage, 
confirmed infection, necrotising enterocolitis, seizures, encephalopathy, and retinopathy of 
prematurity). Customised birthweight centiles were calculated using the GROW formula with 
adjustment for maternal height, maternal weight, maternal ethnicity, parity, infant sex, infant 
birthweight and gestation at birth (version 6.7.5.1 (2014)).322 Secondary process outcomes 
included: proportion of women withdrawing from the study, proportion of women able to 
adhere to the assigned intervention, and proportion and range of adverse events reported in 
each treatment arm. Health resource use was captured as antenatal outpatient visits 
(including scans, antenatal clinic and maternity assessment unit visits), antenatal and postnatal 
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maternal ward nights, maternal intensive care and high dependency unit nights, neonatal 
intensive care and high dependency care unit nights, neonatal special care and transitional 
care nights, and neonatal postnatal ward nights. Women were asked to complete a 
questionnaire regarding their views on trial participation at the six-week follow-up. Planned 
collection of data from home BP readings was not feasible as few women monitored their BP 
at home in this cohort. Assessment of adherence through pill count was planned, but not 
implemented to reduce the time commitment involved in study participation.  
 
Pre-specified mechanistic analyses included: collection of blood and urine samples for 
biomarker assessment (including placental growth factor (PlGF), syndecan-1, renin, 
aldosterone, angiotensinogen: creatinine ratio (AGTCR), albumin: creatinine ratio (ACR), and 
protein: creatinine ratio (PCR) quantification), and pulse wave analyses that were obtained 
using the Arteriograph® (Tensiomed, Budapest, Hungary) at randomisation, 20 weeks, 28 
weeks, 34 weeks’ gestation. All pulse wave measurements were performed with participants in 
the sitting position. The Arteriograph® cuff was then applied to the left arm over the brachial 
artery for estimation of central aortic pressure (mmHg), pulse wave velocity (m/s) and 
augmentation index (%) as previously described by Khalil and colleagues (2012).231 All 
recordings were made by researchers who had received appropriate training on the use of the 
Arteriograph®. The results of the pulse wave analyses were not given to the women or their 
doctors and did not influence the subsequent management of the pregnancies.  
 
Statistical analysis 
For the primary analysis, the intention to treat principle was applied; women were analysed in 
the groups into which they were randomly allocated regardless of allocation received. The 
statistical software Stata/SE version 14 for Windows was used for all analyses. The number and 
percentage were calculated for binary and categorical variables. The mean and standard 
deviation (SD) or the median and interquartile range (IQR) were calculated for continuous 
variables. Linear regression with robust standard errors (SE) were used for the primary and 
other continuous outcomes. Adjustment was made for baseline covariates (ethnicity, 
gestational age at randomisation and centre). For continuous measures, an adjustment was 
also made for corresponding baseline measurement (systolic BP at randomisation for the 
primary clinical outcome).  For binary outcomes, binary regression with a log link was used to 
calculate risk ratios (RR). Analysis of the primary clinical outcomes was repeated excluding 
Student Number: 1355203 
Student Name: Louise Mary Webster 
130 
 
women delivering their baby before 24 completed weeks of pregnancy, as women who deliver 
before viability did not complete the intended course of treatment.  
 
Subgroup analyses assessing the impact of ethnicity on treatment efficacy were performed 
using linear regression adjusting for baseline co-variates.  Results are reported for both groups 
and an interaction test carried out for any moderation of the treatment effect by the 
subgroup. A sensitivity analysis was also performed to evaluate the impact of date recruited on 
the primary outcome, using linear regression with a treatment × time interaction. Explanatory 
analysis of longitudinal biomarkers (excluding women with Chronic Kidney Disease) and pulse 
wave measures was conducted using interval regression models on log-transformed data 
allowing for gestation effects and the baseline measures. This approach made optimal use of 
all measurements and increased power by combining four techniques: transforming to a 
Normal distribution, the use of interval regression to include concentrations too small to be 
measured as censored at the lower limit of detection (rather than discarding them), combining 
all measurements in a single regression model, and the use of the pre-randomisation 
measurement as a covariate (a technique also known as ANCOVA).  Group means and 
treatment effects were calculated as geometric means and ratios of geometric means given 
that log transformations were used. Serious adverse events and adverse events were collated 
and listed by allocation and grouped by symptom. Treatment effects were calculated as 
estimated differences in the mean or risk ratios with 95% confidence intervals.  
 
5.4 Results 
Between August 2014 and October 2015, 265 women were screened to enter the trial (flow of 
trial participants is shown in Figure 5.1), of whom 65% met all eligibility criteria. The most 
common reason for ineligibility was inaccurate information regarding the diagnosis of chronic 
hypertension captured on booking referral letters or at booking appointments (e.g. previous 
gestational hypertension). Nine women (3%) were ineligible as they had a concurrent diagnosis 
of asthma and labetalol was therefore contraindicated. There were no women with a 
contraindication to nifedipine MR. Of eligible women, 66% agreed to participate. The most 
common reason given for declining participation was reluctance to change from their current 
antihypertensive therapy. Recruitment stopped when the enrolment target was reached as per 
the pre-specified primary process outcome. 114 women with singleton pregnancies and a 
diagnosis of chronic hypertension were randomised to first-line antihypertensive therapy with 
either labetalol (n=56) or nifedipine (n=58). The participants not included in the analysis 
included one woman lost to follow-up as she emigrated during her pregnancy, and one who 
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withdrew due to time constraints of waiting for dispensing from the clinical trials pharmacy 
and no further information was available. An additional 23 pregnant women with chronic 
hypertension, but who were unwilling or unable to be randomised to antihypertensive 
treatment took part in the observational arm of the study and are included in the analyses of 
Chapter 6 and 7 (Figure 5.2). 
 
Figure 5.2 Flow diagram of trial and sub-study participants  
Blue boxes indicate the flow of trial participants as analysed in Chapter 5, the purple box 
represents the cohort of women participating in the biomarker sub-study in Chapter 6, the 
green box represents the cohort of women participating in the vascular function sub-study in 
Chapter 7, and the red boxes indicate those who were ineligible, declined participation, or lost 
to follow-up.  
 
Most baseline maternal characteristics at enrolment in each treatment group were similar 
between treatment groups (Table 5.2), except that time from diagnosis of chronic 
hypertension to study entry was longer in the labetalol group (54 versus 20 months), and the 
number of women with renal disease (labetalol n=5 versus nifedipine n=9) and diabetes 
(labetalol n=5 versus nifedipine n=8) at study entry was higher in the nifedipine group. The 
results were adjusted allowing for these differences, but this had no significant impact on the 
outcomes observed (P=0.29).  
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Table 5.1 Baseline maternal characteristics at enrolment 
Characteristic 
Randomised to labetalol 
n=56 
Randomised to nifedipine 
n=58 
Age at enrolment, years 
median (IQR) 
36.0 (32.0-39.1) 35.0 (30.3-38.5) 
Gestational age at randomization, weeks 
median (IQR) 
16.6 (13.7-21.3) 16.9 (14.6-21.1) 
Ethnicity number (%)   
Black  30 (54%) 32 (55%) 
White 17 (30%) 18 (31%) 
Asian 6 (11%) 3 (5%) 
Other 3 (5%) 5 (9%) 
Deprivation quintile*  
number (%) 
  
1st 2 (4%) 2 (4%) 
2nd 2 (4%) 6 (11%) 
3rd  3 (6%) 5 (9%) 
4th  14 (27%) 16 (30%) 





stopped prior to pregnancy 
55 (98%) 56 (97%) 
Smoking during pregnancy 1 (2%) 1 (2%) 
Smoking history unknown 0 (0%) 1 (2%) 
Body mass index, kg/m2 
mean (SD) 
number (%) 
31.2 (7.1) 30.5 (4.9) 
19-25 17 (30%) 9 (16%) 
26-30 13 (23%) 24 (41%) 
31-35 9 (16%) 17 (29%) 
≥36 17 (30%) 8 (14%) 




0 14 (25%) 13 (22%) 
1 15 (27%) 21 (36%) 
2 16 (29%) 14 (24%) 
3  11 (20%) 10 (17%) 
History of pre-eclampsia 
number (%)  
15 (27%) 16 (28%) 
Time since diagnosis of chronic 
hypertension, months  
median (IQR)  
53.5 (8.3-109.5) 20.4 (1.1-75.1) 
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Type of Chronic Hypertension 
Number (%) 
  
Primary 51 (91%) 48 (83%) 
Secondary 5 (9%) 10 (17%) 
Other medical history 
number (%) 
  
Venous thromboembolism 2 (4%) 1 (2%) 
Diabetes mellitus (type I or type II) 5 (9%) 8 (14%) 
Renal disease 5 (9%) 9 (16%) 
Cardiac disease 2 (4%) 0 
Systemic lupus erythematous/ 
Anti-phospholipid syndrome 
1 (2%) 1 (2%) 
Uterine artery Dopplers 
number (%) 
46 (84%) 45 (79%) 
Pulsitility Index  
Mean (SD) 
1.0 (0.4) 1.2 (0.4) 
Pulsitility Index >1.4 
Number (%) 
5 (11%) 11 (24%) 
BP at booking, mmHg 
mean (SD) 
  
Systolic 136 (125-144) 138 (128-144) 
Diastolic 88 (81-92) 86 (80-90) 
BP at study entry, mmHg 
median (IQR)  
  
Systolic 143 (133-150) 141 (132-151) 
Diastolic 92 (85-98) 91 (86-96) 
Oral antihypertensive medication taken 
at study entry 
number (%) 
41 (73%) 38 (66%) 
* n=52 in the labetalol group and n=54 in the nifedipine group as unable to link postcodes to 
lower super output areas and therefore unable to assign deprivation index. SD= standard 
deviation, IQR= interquartile range  
 
Feasibility Outcomes 
The feasibility of conducting this trial in women with chronic hypertension in pregnancy was 
confirmed (Table 5.2), with the enrolment target reached over 14 months. Sites with a 
dedicated antenatal clinic where the women with chronic hypertension were seen found this 
facilitated identification of eligible women and enrolment to the trial. Recruitment rate was 
2.6 women per month (range of 1.2-3.7 per month). Women self-identifying as of Black 
ethnicity accounted for 56% of those enrolled, confirming feasibility of recruiting women of 
differing ethnic backgrounds. Geographical variation in the proportion of Black women 
enrolled was seen reflecting the demographics of the local population of each hospital. The 
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assigned intervention was discontinued by 12 women due to side effects of the medication; 
seven (13%) in the labetalol arm and five (9%) in the nifedipine arm. 
 
Table 5.2 Summary of feasibility outcomes 
Feasibility outcome 
Total number enrolled 
n=114 
Women enrolled per centre  
number (%) 
 
Guy’s and St Thomas’ NHS Foundation Trust 56 (49%) 
Central Manchester University Hospitals NHS Foundation Trust 33 (29%) 
University Hospitals of Leicester NHS Trust  12 (11%) 
St George’s University Hospitals NHS Foundation Trust 13 (11%) 
Enrolment rate per centre  
(women enrolled per month site recruiting) 
 
Guy’s and St Thomas’ NHS Foundation Trust 3.7 
Central Manchester University Hospitals NHS Foundation Trust 2.8 
University Hospitals of Leicester NHS Trust 1.2 
St George’s University Hospitals NHS Foundation Trust 1.9 
Mean of all centres 2.6 
Proportion of those enrolled of Black ethnicity  
Guy’s and St Thomas’ NHS Foundation Trust 70% 
Central Manchester University Hospitals NHS Foundation Trust 46% 
University Hospitals of Leicester NHS Trust 17% 
St George’s University Hospitals NHS Foundation Trust 77% 
 
Clinical Outcomes 
Labetalol and nifedipine demonstrated effectiveness at controlling BP to therapeutic target in 
women with chronic hypertension in pregnancy (mean BP post-randomisation: labetalol 
134/84 mmHg versus nifedipine 134/85 mmHg). No difference was observed in highest 
brachial BP following randomisation to either treatment arm (Table 5.3). A sensitivity analysis 
excluding those who delivered before 24 weeks’ gestation and evaluating the impact of date 
recruited had no effect on the results. Further analysis of the number of days with brachial BP 
readings out of target ≥160 mmHg systolic, ≥150 mmHg systolic, and <80 mmHg diastolic 
demonstrated no difference between treatment groups.  
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Maximum BP, mmHg 
mean (SD) 
   
Systolic 161 (14.7) 163 (19.2) 1.2 (-4.9 to 7.2) 
Diastolic 101 (10.2) 105 (11.7) 3.3 (-0.6 to 7.3) 
Mean BP, mmHg 
mean (SD) 
   
Systolic 134 (8.5) 134 (9.2) 0.3 (-2.8 to 3.4) 
Diastolic 84 (6.6) 85 (5.5) -1.9 (-4.1 to 0.3) 
Results adjusted for systolic BP at randomisation ethnicity, gestational age at randomisation 
and centre. SD= standard deviation 
 
Secondary maternal and perinatal outcomes (Table 5.4) showed more women on nifedipine 
developed superimposed pre-eclampsia than those allocated labetalol, but these differences 
were not significant (RR 1.78; 0.84-3.77). The same number of women in each group were 
diagnosed with early onset superimposed pre-eclampsia prior to 34 weeks’ gestation (n=6 
(11%) in each treatment group). The number of women requiring additional oral 
antihypertensive agents was comparable between groups. There was a greater proportion of 
women treated with intravenous antihypertensive agents in the nifedipine group (14% versus 
4%). The proportions of women requiring induction of labour and caesarean section were 
comparable. The median gestation at delivery was similar between groups. Adverse maternal 
outcomes were reported for 6 (11%) women in the labetalol arm compared to 8 (14%) in the 
nifedipine arm (Table 5.5).  
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RR (95% CI) 
Time between randomisation 
and delivery, days 
mean (SD) 
134 (39) 127 (44)  
Superimposed pre-eclampsia 
number (%) 




6 (11%) 6 (11%)  
Additional oral antihypertensive 
agents 
number (%) 
   
0 37 (67%) 36 (63%)  
1 15 (27%) 20 (35%)  




2 (4%) 8 (14%)  
Adverse maternal outcome* 
number (%) 
6 (11%) 8 (14%)  
Mode of delivery 
number (%)  
   
Spontaneous vaginal delivery 22 (40%) 21 (37%)  
Assisted vaginal delivery 2 (4%) 4 (7%)  
Elective prelabour LSCS 9 (16%) 13 (23%)  
Emergency prelabour LSCS 14 (26%) 11 (19%)  
Emergency LSCS in labour 8 (15%) 8 (14%)  
Estimated blood loss at delivery, 
ml 
mean (SD) 
600 (500) 610 (550)  
Gestation at delivery, weeks  
median (IQR) 
38.6 (37.7-39.4) 38.0 (36.4-39.1) -0.6 (-1.3 to 0.1) 
Preterm birth <37 weeks  
number (%) 
12 (22%) 20 (35%)  
Preterm Birth <34 weeks 
number (%) 
10 (18%) 11 (19%)  
Condition of fetus at delivery 
number (%) 
   
Livebirth 51 (93%) 52 (91%)  
Miscarriage 1 (2%) 3 (5%)  
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Termination of pregnancy 1 (2%) 1 (2%)  
Stillbirth 2 (4%) 1 (2%)  
Neonatal outcomes n=51 n=52  
Apgar Score 
number (%) 
   
<7 at 1 min 7 (14%) 9 (17%)  
<7 at 5 min 1 (2%) 1 (2%)  
Paired Cord Gases    
Obtained 
number (%) 
24 (47%) 26 (50%)  
Arterial cord pH 
median (IQR) 
7.23 (7.19-7.29) 7.24 (7.18-7.26)  
Birthweight, g  
mean (SD) 
2957 (790) 2732 (883) -240 (-589 to 109) 
Customised birthweight centile 
mean (SD) 
33.4 (31.2) 27.7 (26.3)  
Birthweight <10th customised 
centile 
number (%) 
16 (31%) 17 (33%)  
Birthweight <3rd customised 
centile 
number (%) 
6 (12%) 10 (19%)  
Admitted to neonatal unit  
number (%) 
11 (22%) 15 (29%) 1.3 (0.7-2.5) 
Adverse perinatal outcome* 
number (%) 
11 (22%) 17 (33%)  
*Details of adverse maternal and perinatal outcomes provided in Table 5.5 and Table 5.6.  
Results adjusted for ethnicity, gestational age at randomisation and centre. Risk ratios only 
calculated for pre-specified secondary outcomes.  
SD= standard deviation, IQR= interquartile range 
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Table 5.5 Details of adverse maternal outcomes 






Any maternal complication 6 (11%) 8 (14%) 
Maternal death 0 0 
Central Nervous System   
Eclampsia 0 0 
Glasgow coma score <13 0 0 
Intracranial haemorrhage or infarct 0 0 
Transient ischaemic attack 0 0 
Cortical blindness or retinal detachment 0 0 
Posterior reversible encephalopathy 0 0 
Cardiorespiratory   
Positive inotropic support required 0 0 
Myocardial ischaemia or infarction 0 0 
Oxygen saturations <90% >2 hours (pre-eclampsia) 0 0 
≥50% Oxygen therapy required for >1 h 0 0 
Intubation (other than for caesarean section) 0 0 
Pulmonary oedema 0 0 
Haematological   
Transfusion of any blood product 2 (4%) 5 (9%) 
Platelet count <50×10⁹ per L, with no transfusion 1 (2%) 0 
Hepatic   
Dysfunction 0 0 
Haematoma or rupture 0 0 
Renal   
Acute renal insufficiency (creatinine >150 µmol/L;  
no pre-existing renal disease 
1 (2%) 0 
Acute renal failure (creatinine >200 µmol/L; 
pre-existing renal disease 
1 (2%) 2 (4%) 
Dialysis 0 0 
Obstetric   
Placental abruption 0 1 (2%) 
HELLP syndrome 1 (2%) 0 
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Six women delivered their baby before 24 weeks and three women had a stillbirth after 24 
weeks’ gestation. Four had late miscarriages (one in the labetalol group and three in the 
nifedipine group). Two women (one in each treatment group) underwent second trimester 
termination of pregnancy after enrolling in the study (one for abnormal amniocentesis result 
post-randomisation and one for severe early onset growth restriction). There were two 
stillbirths in the labetalol group (both with severe early onset growth restriction) and one in 
the nifedipine group (trisomy 13 diagnosed on amniocentesis after study enrolment). There 
was no significant difference in mean birthweight: 2960 g in the labetalol arm versus 2730 g in 
the nifedipine arm (adjusted mean difference -240 g; -590, 110 g). There was a high proportion 
of babies born below the 10th and 3rd birthweight centile in each treatment group. Neonatal 
unit admission was slightly lower in the labetalol group compared to the nifedipine group (22% 
versus 29%). Adverse neonatal outcomes were reported for 11 (22%) infants in the labetalol 
arm and 17 (33%) infants in the nifedipine arm (Table 5.6).  
Table 5.6 Details of adverse neonatal outcomes 






Any neonatal complication 11 (22%) 17 (33%) 
Neonatal Death 0 0 
Infant death >28 days post delivery  0 1 (2%) 
Central nervous system   
Interventricular Haemorrhage 0 0 
Seizures 0 0 
Encephalopathy 0 0 
Retinopathy of prematurity 0 0 
Respiratory   
Respiratory Distress Syndrome 7 (14%) 11 (21%) 
Need for additional respiratory support 6 (12%) 12 (23%) 
Gastrointestinal   
Necrotising enterocolitis 3 (6%) 2 (4%) 
Hypoglycaemia 6 (12%) 8 (15%) 
Sepsis 1 (2%) 5 (10%) 
Congenital anomalies* 1 (2%) 4 (8%) 
Chromosomal abnormalities* 0 1 (2%) 
Neonatal outcome data is only presented for the livebirths. 
*Congenital anomalies by treatment group included; labetalol: one infant with hypospadias; 
nifedipine: one infant with jejunal atresia and a deletion on the short arm of chromosome 16, 
one infant with trachea-oesophageal fistula, and one infant with tetralogy of fallot. All of these 
women were randomised after 16 weeks’ gestation. 
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Maternal and neonatal health resource use was similar between treatment groups (Table 5.7).  
 
Table 5.7 Health resource use category by randomised treatment group (mean and standard 
deviation) 






Number of antenatal clinics, antenatal day unit visits and 
ultrasound visits in pregnancy  
19 (8) 20 (8) 
Number of maternal antenatal and postnatal ward 
nights  
4 (3) 7 (7) 
Number of maternal intensive care unit and/or high 
dependency unit nights 
0.4 (1.1) 0.9 (1.9) 
Number of neonatal intensive care unit and/or high 
dependency care nights 
2 (10) 6 (23) 
Number of neonatal special care and/or transitional care 
nights 
2 (6) 3 (12) 
Number of neonatal postnatal ward nights 2 (2) 2 (2) 
 
A pre-specified exploratory subgroup analysis of the impact of ethnicity on efficacy of each 
treatment did not show any significant difference in mean systolic or diastolic brachial BP in 
Black women (systolic 0.5 mmHg; -4 to 5 mmHg; diastolic 0.1 mmHg; -3 to 3 mmHg). No 
difference in mean systolic BP was seen between treatment groups in the non-Black women (-
0.4 mmHg; -4 to 3 mmHg), but a 4 mmHg (-6.6 to -0.8 mmHg; P=0.015) reduction in mean 
diastolic BP was seen in the labetalol arm in non-Black women. 
 
Mechanistic Outcomes 
Pulse wave analysis was performed in a subgroup of 83 women at three centres (nifedipine 
n=43, labetalol n=40). There was a mean 7.4 mmHg decrease (-0.4 to -14.4 mmHg) in central 
aortic pressure between randomisation and delivery in those assigned nifedipine compared to 
labetalol. Augmentation index was 8.2% lower (-3.0 to -13.3%) in those assigned nifedipine 
compared to labetalol, though a sensitivity analysis examining the impact of centre on this 
finding demonstrated significant variation in this parameter by centre. There was no significant 
difference in pulse wave velocity between treatment groups (Table 5.8). 
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Table 5.8 Effect of treatment on pulse wave analysis measures across gestation post-
randomisation 













Central aortic pressure,  
mmHg 
132 (20.2) 126 (12.9) -7 (-0.4 to -14.4) 0.04 
Augmentation index,  
% 
21 (14.9) 13 (11.7) -8.2 (-3.0 to -13.3) 0.002 
Pulse wave velocity,  
m/s 
8.8 (1.7) 8.7 (1.5) -0.1 (-0.4 to 0.7) 0.62 
Pulse wave analyses were only assessed at three sites, which accounts for the reduction in the 
number of participants presented for this analysis. Results adjusted for baseline measures, 
gestation and repeat readings from the same women. 
SD=standard deviation 
 
Analysis of gestational change in urinary PCR by treatment group included samples from 73 
women (collected at three centres) without chronic kidney disease (nifedipine n=35, labetalol 
n=38). The PCR increased by 44% (21 to 71%) across gestation post-randomisation in women 
assigned nifedipine compared to women prescribed labetalol (Figure 5.3). The mean PCR post-
randomisation was 11.5 mg/mmol (SD 1.9) in the nifedipine group compared to 7.5 mg/mmol 
(SD 1.8) in the labetalol group.  The analysis was repeated excluding the women who 
developed superimposed pre-eclampsia (labetalol n=35 versus nifedipine n=27) with minimal 
effect on the results; PCR increased by 43% (18 to 74%) and the mean PCR post-randomisation 
was 11.5 mg/mmol (SD 1.9) in the nifedipine group compared to 7.4 mg/mmol (SD 1.9) in the 
labetalol group. Urinary ACR analysis demonstrated a similar increase in those randomised to 
nifedipine compared to labetalol, but no other treatment effects were observed on the 
biomarkers tested (PlGF, syndecan-1, renin, aldosterone and AGTCR).   
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Figure 5.3 Treatment effects on urinary protein: creatinine ratio across gestation post-
randomisation 
Number of participants sampled at each time point is detailed in the table below the graph and 
the standard error bars are included at each time point. 
 
Adverse Events and Acceptability 
There were four Serious Adverse Events reported, all for unplanned hospital admissions not 
related to the pregnancy: one was in the labetalol arm (admission for epistaxis) and three in 
the nifedipine arm (one case of gastroenteritis, one case of deep vein thrombosis and one case 
of influenza). None were deemed to be related to the assigned intervention. The adverse 
events reported are presented in Table 5.9. In the labetalol group, 21 (38%) women reported 
an adverse event compared to 15 (26%) in the nifedipine group. The postnatal questionnaire 
was answered by 34% of the women who completed the study. When asked if they would take 
the same treatment again in another pregnancy, 72% of the women taking labetalol said they 
‘definitely would’ compared to 90% of those assigned nifedipine, and 11% of those assigned 
labetalol said they ‘probably would not’ take the treatment again compared to 5% of those 
assigned nifedipine.    
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Table 5.9 Summary of adverse events reported in each treatment arm 






Total 21 (38%) 15 (26%) 
Headache 10 (18%) 11 (19%) 
Dizziness 5 (9%) 2 (4%) 
Lethargy 2 (4%) 0 
Epistaxis 1 (2%) 1 (2%) 
Scalp tingling 2 (4%) 0 
Shortness of breath 5 (9%) 1 (2%) 
Abdominal pain/nausea 2 (4%) 2 (4%) 
Peripheral oedema 2 (4%) 1 (2%) 
Chest pain 1 (2%) 0 
Hot flushes 1 (2%) 1 (2%) 
Eye spasm 1 (2%) 0 
Nasal congestion 1 (2%) 0 
Nipple pain 1 (2%) 0 
 
5.5 Discussion 
To our knowledge this is the first randomised controlled feasibility trial comparing labetalol 
and nifedipine for control of chronic hypertension in pregnancy. These are two of the most 
commonly used agents in many countries for treatment of hypertensive disorders of 
pregnancy. This study confirms the high prevalence of adverse maternal and perinatal 
outcomes in women with chronic hypertension in pregnancy; 21% developed superimposed 
pre-eclampsia, 8% experienced fetal loss, 32% of infants were small for gestational age 
(birthweight <10th centile), 16% had a birthweight <3rd centile, and 25% required neonatal unit 
admission, similar to that reported in a recent systematic review.8 Recruitment to randomised 
controlled trials of medication in pregnancy is challenging in view of the real and perceived risk 
of fetal harm. We confirmed the feasibility of conducting a randomised controlled trial 
investigating effectiveness of first-line antihypertensive agents for the treatment of chronic 
hypertension in pregnancy Additionally, this feasibility study has produced data allowing 
exploration of the important characteristics contributing to adequate BP control in such 
pregnancies. Demonstrating feasibility is important given the costly nature of large multicentre 
studies and need for suitable pragmatic designs to ensure definitive studies will fully answer 
the research questions posed.344 Of the women meeting all eligibility criteria to enter the 
study, two-thirds consented to participation and 98% completed the study. Ethnic diversity in 
recruitment was also demonstrated, enabling investigation of variation in treatment efficacy.  
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This study demonstrates that labetalol and nifedipine can be used to achieve a mean systolic 
and diastolic BP within treatment target over gestation in pregnant women with chronic 
hypertension. The maximum and mean BP post-randomisation were comparable between 
treatment groups; this is clinically important because of the paucity of data available to guide 
antihypertensive treatment prescribing for chronic hypertension in pregnancy.14,16,256 Given the 
potential contraindications (such as labetalol in women with asthma) and the possible side 
effect profiles of these drugs, evidence that they have similar ability to control hypertension to 
treatment target is of benefit. The study was not powered to assess variation in the secondary 
maternal and perinatal outcomes, but further larger trials should evaluate differences in 
incidence of superimposed pre-eclampsia, preterm delivery and small for gestational age 
infants. Variation in treatment effect by ethnicity was also noted, with labetalol having a 
greater effect on reducing diastolic BP in non-Black women, as previously demonstrated with 
beta-blocker use outside pregnancy.80 The clinical significance of this difference needs to be 
established. 
 
Nifedipine use was associated with reduced central aortic pressure and augmentation index. 
No treatment effect was observed on pulse wave velocity analyses; this is consistent with the 
findings of the ACCT trial (2005) that augmentation index is a more sensitive marker of arterial 
stiffening and cardiovascular risk in younger individuals, with pulse wave velocity 
demonstrating greater association with increased cardiovascular risk in older individuals.345 
Calcium channel blockers (versus beta-blockers) have been demonstrated to lower central 
aortic pressure in the CAFÉ study (non-pregnant hypertensive population).244 The exact 
mechanism behind these haemodynamic differences is not clear, but this finding in 
combination with the ASCOT trial results (of which ‘CAFÉ’ was a subgroup analysis) suggested a 
greater decrease in long term cardiovascular risk with calcium channel blockers as first-line 
antihypertensive agent compared to beta-blockers, perhaps mediated through this reduction 
in central aortic pressure.245 National guidance no longer recommends beta-blockers as first-
line antihypertensive treatment outside pregnancy; calcium channel blockers are 
recommended as first-line antihypertensive treatment in Black women and angiotensin 
converting enzyme inhibitors (avoided in pregnancy due to fetal risks) are recommended for 
women under 55 years of age of other ethnic backgrounds.1,77 African and Caribbean women 
are at increased risk of chronic hypertension and its associated cardiovascular morbidity, from 
a younger age than women of other ethnic origins.328 There is evidence that maternal and 
perinatal outcomes vary by ethnic background.313,314,339,340 The implications of the first-line 
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treatment recommendations outside pregnancy on the selection of antihypertensive agents in 
pregnancy needs to be investigated further. 
 
Increased proteinuria across gestation with nifedipine use (compared to labetalol) was 
demonstrated even when those who developed superimposed pre-eclampsia and with pre-
existing renal disease were excluded from the analysis. Proteinuria is known to increase during 
gestation in normotensive pregnancy due to increased glomerular filtration.223 In this cohort 
the mean PCR increased post study enrolment by 2.4 mg/mmol. It is not clear if the difference 
in proteinuria between treatment groups is a beneficial effect of labetalol or a side effect of 
nifedipine on renal function, and the clinical significance is unclear given the concentrations 
fall within the normal range. It seems probable that this is a side effect of nifedipine given 
similar findings in a Cochrane systematic review of an increase in proteinuria/pre-eclampsia in 
women with mild to moderate hypertension in pregnancy randomised to calcium channel 
blockers versus none (four studies, 725 women; RR 1.40 (1.06-1.86).256 Studies in non-pregnant 
individuals with hypertension and chronic kidney disease suggest that dihydropyridine calcium 
channel blockers (including nifedipine) are less effective at reducing proteinuria and therefore 
offer less renal protection than other antihypertensive agents.346 Investigation into the 
potential pathophysiology behind these differences has suggested that glomerular 
hypertension may be caused by dihydropyridine calcium channel blockers that dilate the 
afferent but not the efferent renal arterioles.347 The variation in mechanism of action of 
antihypertensive agents in pregnancy needs to be explored further given that crossing a 
threshold of proteinuria is utilised in the diagnosis of pre-eclampsia;348 however the benefits of 
hypertensive control may outweigh a small increase in proteinuria.  
 
The main strengths of this study include enrolment at four centres located around the UK 
reducing the risk of clinical practice bias. The study was designed and conducted as a 
randomised controlled feasibility trial in line with CONSORT guidance.349 A computer-
generated minimisation protocol was used to ensure balance within groups of maternal 
baseline characteristics. This reduced the risk of imbalance of baseline characteristics within 
treatment arms affecting the outcomes of the study. The study enrolled women with primary 
and secondary hypertension, which increases generalisability of the results; however, this 
introduced potential bias as reflected in the imbalance of women with chronic kidney disease 
and diabetes between treatment groups. 
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Whilst this study has confirmed feasibility a larger definitive study is required to assess further 
the effectiveness of labetalol and nifedipine for control of BP in pregnancy complicated by 
chronic hypertension. The power calculation utilised an estimated standard deviation in the 
primary outcome of 7 mmHg, but the standard deviation of the highest systolic blood pressure 
demonstrated in this study was much greater at 14.7 to 19.2 mmHg. This information can be 
utilised in the power calculation for the definitive study. The study was not powered to answer 
the additional question of ethnic variation in effectiveness of first-line antihypertensive agents 
in pregnancy, but demonstrated the feasibility of recruiting women of all ethnic groups. This 
was a non-inferiority study, which increased the number of participants required to answer the 
primary outcome. Consideration should be given to a superiority design for the definitive 
study, but the findings of this feasibility study suggest that labetalol and nifedipine are 
comparable for treatment of chronic hypertension in all pregnant women. However, a 
superiority design should be chosen in a study examining the efficacy of calcium-channel 
blockers compared to labetalol in women of Black ethnicity with chronic hypertension in 
pregnancy, given that calcium-channel blockers are recommended as first-line 
antihypertensive treatment in those of African/Caribbean family origin outside pregnancy.1    
 
The study was open-label subjecting the results to potential performance bias.259 It was 
considered clinically not feasible to mask allocation to clinicians and women in view of the 
differing recommended dosing frequency and need to escalate treatment and add a second 
agent where needed. It was not possible to fully assess clinician adherence to the target blood 
pressure and treatment regime in this multicentre pragmatic trial and future studies assessing 
efficacy of individual agents might elucidate further information regarding variation in 
adherence to such protocols. In this study methyldopa was not included; however recent 
evidence (though not from a randomised head-to-head comparison) suggested that this agent 
may be associated with benefit in maternal and perinatal outcome compared to labetalol, and 
it should be considered for comparison in a definitive trial.350 
  
Evidence from the CHIPS trial15 demonstrates maternal benefit of ‘tight control’ of BP utilising 
antihypertensive agents in reducing the incidence of severe hypertension without an increase 
in adverse perinatal outcomes.133 This is the largest head-to-head trial in pregnant women with 
chronic hypertension assessing effectiveness of antihypertensive agents in controlling BP. 
There are three previous head-to-head studies including 101 women in total that have 
compared the incidence of severe hypertension between randomised treatment groups (RR 
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1.1; 0.71-1.81).264,265,275 Randomised controlled trials comparing antihypertensive treatment of 
chronic hypertension in pregnancy are limited and most were conducted at least 20 years 
ago.302 The antihypertensive treatments compared in this trial are first-line agents maximising 
the utility of the results in every day practice.16 
 
Women with chronic hypertension are at increased risk of cardiovascular morbidity and 
mortality compared to normotensive women and those with the transient condition of 
gestational hypertension.306 A recent trial comparing management strategies for chronic 
hypertension outside pregnancy (the SPRINT study) stopped recruitment early due to the 
significant 25% reduction seen in a composite cardiovascular outcome (stroke, myocardial 
infarction and cardiac failure) with tighter control of systolic hypertension to a target of 120 
mmHg rather than the standard treatment target of 140 mmHg; however this was coupled 
with a significant increase in hypotension, syncope and acute kidney injury.305 In pregnancy, 
reducing the incidence of severe hypertension and maintaining tighter BP control might  have 
short and long term maternal health benefits and prevent adverse pregnancy outcomes 
associated with unnecessary obstetric intervention and acceleration of cardiovascular risk. 
 
Future research should further explore the mechanistic actions of each drug to establish the 
effectiveness of antihypertensive agents in the chronic hypertensive pregnant population and 
assess the utilisation of differences in treatment effect on individuals. A definitive trial will 
need to address potential treatment effects on other maternal and perinatal outcomes such as 
superimposed pre-eclampsia and fetal growth restriction. The impact of antenatal 
management strategies in women with chronic hypertension on long term health of the 
mother and her child should also be considered. 
 
In conclusion, labetalol and nifedipine control mean systolic and diastolic BP to treatment 
target in pregnant women with chronic hypertension. Good recruitment was demonstrated 
and mechanistic treatment effects observed. This study provides support for a larger definitive 
trial scrutinising the benefits and side effects of first-line antihypertensive treatment in 
pregnancy complicated by chronic hypertension. 
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CHAPTER 6 CHRONIC HYPERTENSION IN PREGNANCY: THE IMPACT OF ETHNICITY 




Black ethnicity is associated with worse pregnancy outcomes in women with chronic 
hypertension.  Pre-existing endothelial and renal dysfunction, and poor placentation may 
contribute but pathophysiological mechanisms underpinning increased risk are poorly 
understood. This cohort study aimed to investigate the relationship between ethnicity and 
longitudinal changes in markers of endothelial, renal and placental dysfunction in women with 
chronic hypertension. In women with chronic hypertension and singleton pregnancies, plasma 
concentrations of placental growth factor (PlGF), syndecan-1, renin, aldosterone, and urinary 
angiotensinogen: creatinine ratio (AGTCR), protein: creatinine ratio (PCR) and albumin: 
creatinine ratio (ACR) were quantified during pregnancy and postpartum. Comparisons of 
longitudinal biomarker concentrations were made using log-transformation and random 
effects logistic regression allowing for gestation. Logged estimates with 95% confidence 
intervals of the geometric means and their ratios to the reference group in each analysis were 
calculated. Of 117 women, superimposed pre-eclampsia was diagnosed in 21% (n=25); 54% 
(n=63) of the cohort self-identified as of Black ethnicity. Black women had 43% lower plasma 
renin (95% confidence interval -58% to -23%) and 41% lower plasma aldosterone (95%CI -45% 
to -15%) concentrations over gestation. PlGF concentrations were 67% lower (95% CI -79% to -
48%), and AGTCR, PCR and ACR were higher over gestation, in women with subsequent 
superimposed pre-eclampsia (compared to those without superimposed pre-eclampsia). 
Changes in placental (PlGF) and renal (AGTCR/PCR/ACR) biomarkers predated the 
development of superimposed pre-eclampsia.  Ethnic variation in the renin-angiotensin-
aldosterone system exists in women with chronic hypertension in pregnancy and may indicate 
how treatment can be optimised to improve pregnancy outcomes.  
 
6.2 Introduction  
Chronic hypertension is estimated to affect 3% of pregnancies7,30 and is associated with 
adverse maternal and perinatal outcome.8,29 A recent systematic review by Bramham and 
colleagues (2014) reported a relative risk of superimposed pre-eclampsia of 7.7 (95% 
confidence interval 5.7 to 10.1) compared to the risk of pre-eclampsia in the general pregnant 
population.8 Adverse perinatal outcomes such as stillbirth, fetal growth restriction and 
prematurity are also more common in women with chronic hypertension and occur 
independently from a diagnosis of superimposed pre-eclampsia.43,45,54 Women of Black 
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ethnicity, compared to women of White ethnicity with chronic hypertension, have an 
increased risk of superimposed pre-eclampsia,45 which may be contributory, but greater 
understanding of the interplay of known biomarkers and ethnicity in women with chronic 
hypertension may provide insight into pathophysiological mechanisms.     
 
Pre-eclampsia is characterized by placental and maternal vascular dysfunction.351 Placental 
growth factor (PlGF) and syndecan-1 are placental and endothelial biomarkers that have 
previously been shown to decrease in concentration in the maternal circulation prior to the 
onset of the clinical signs of pre-eclampsia.199,201,207 A recent study by Chappell and colleagues 
(2013) has demonstrated that low PlGF, in women presenting before 35 weeks’ gestation with 
suspected preeclampsia, has high sensitivity and negative predictive value for preeclampsia 
within 14 days.203 Diagnosing superimposed pre-eclampsia in women with chronic 
hypertension is challenging because gestational progression of hypertension may occur in 
response to the physiological changes in pregnancy, without the sequelae of pre-eclampsia. 
Variation in these biomarkers over gestation in women with chronic hypertension requires 
further exploration. 
  
The kidney is of critical importance in blood pressure regulation primarily via salt and water 
homeostasis. A key mechanism underpinning this homeostatic function is the role of the 
kidney in the systemic renin-angiotensin-aldosterone system (RAAS). Increased glomerular 
filtration and upregulation of the circulating RAAS are amongst the physiological changes that 
characterise normotensive pregnancy.352,353 Changes in the RAAS and other renal biomarkers 
(protein: creatinine ratio (PCR) and albumin: creatinine ratio (ACR)) have been demonstrated 
in pre-eclampsia;225,354 however there are limited data from longitudinal cohorts examining 
these biomarkers in pregnant women with chronic hypertension.109 The impact of ethnicity on 
these biomarkers in pregnancy also requires exploration. Black women are more likely to have 
low renin hypertension337 and ethnic differences in RAAS function in pregnancy may partly 
explain disparity observed in clinical outcome.314,315  
 
This study aimed to investigate the longitudinal variation in endothelial and renal biomarkers 
in women with chronic hypertension in pregnancy, and the impact of subsequent 
superimposed pre-eclampsia and ethnicity on these biomarkers.  
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This was a nested cohort study of women with chronic hypertension who participated in the 
‘Pregnancy And chronic hypertension: NifeDipine versus lAbetalol as antihypertensive 
treatment’ trial between 2014 and 2016. The study was registered with ISRCTN (DOI 
10.1186/ISRCTN40973936, www.isrctn.com) and approved by the UK Research Ethics 
Committee (REC number 13/EE/0390). The study was reported in line with STROBE guidance 
for observational studies.325  
 
Study Design 
Women were enrolled at three consultant-led National Health Service (NHS) obstetric units in 
the United Kingdom (Guy’s and St Thomas’ NHS Foundation Trust, Central Manchester 
University NHS Foundation Trust, and University of Leicester Hospitals NHS Trust). The 
eligibility criteria included: women with a prenatal diagnosis of chronic hypertension or blood 
pressure readings ≥140/90 mmHg prior to 20 weeks’ gestation requiring antihypertensive 
treatment, (as defined by the International Society for the Study of Hypertension in Pregnancy 
classification of hypertensive disorders of pregnancy,21) between 12 and 27.9 weeks’ gestation, 
singleton pregnancies, aged over 18 years, and the ability to provide informed consent. No 
formal power calculation was performed, but all women participating in the main trial at the 
sites afore mentioned, were asked to participate in the sub-study. Participants were asked to 
provide longitudinal samples of blood and urine at study entry and at follow-up antenatal visits 
across gestation and at six weeks postpartum. Baseline demographic and antenatal booking 
data were collected at enrolment. Ethnicity (Black versus non-Black) was determined by self-
report of a parent or grandparent who was African/Caribbean (Black ethnicity) or not (non-
Black ethnicity). Blood pressure readings taken at all subsequent antenatal visits and daily 
during hospital admissions (highest of that day) were recorded in addition to other maternal 
and perinatal outcome data (superimposed pre-eclampsia, mode of delivery, gestation at 
delivery, pregnancy loss, birthweight, birthweight centile and neonatal unit admission). 
Superimposed pre-eclampsia was defined as new-onset proteinuria, a sudden increase in 
proteinuria if already present in early gestation, and an increase in hypertension, as defined by 
the American College of Obstetrics and Gynaecology.343 Customised birthweight centiles were 
calculated using the GROW formula with adjustment for maternal height, maternal weight, 
maternal ethnicity, parity, infant sex, infant birthweight and gestation at birth (version 6.7.5.1 
(2014)).322 Birthweight below the 3rd centile represents fetal growth restriction.65 Women with 
PCR >30 mg/mmol at study entry (likely indicative of chronic kidney disease) were excluded 
from the analysis of urinary biomarkers. 
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Analysis of Samples 
Venous blood and midstream urine samples were placed on ice immediately after collection, 
spun at 1400xg for 10 minutes and stored at -80 ֯C within four hours. The following tests were 
conducted without knowledge of clinical outcomes. 
Placental and endothelial biomarkers: Plasma PlGF and plasma syndecan-1 concentrations 
were measured on all antenatal samples. PlGF was quantified using the Triage PlGF Test (Alere, 
San Diego, USA) according to the manufacturer’s instructions. Syndecan-1 concentrations were 
measured using a solid phase sandwich ELISA kit for quantification of human syndecan-1 
(Abnova, Taipei City, Taiwan), in accordance with manufacturer’s instructions. 
Renal biomarkers: Plasma renin and aldosterone concentration, and urinary AGTCR, PCR, and 
ACR were quantified for all samples (antenatal and postnatal). Plasma renin and aldosterone 
were measured using Diasorin Liaison direct renin and aldosterone reagents respectively 
(Diasorin, Wokingham, UK), run on the Liaison chemiluminescence analyser.  
Urinary angiotensinogen concentrations were determined using a solid phase sandwich ELISA 
kit (Immuno-Biological Laboratories, Gunma, Japan) according to manufacturer’s 
instructions.355 The urinary angiotensinogen concentrations were then normalised to urinary 
creatinine to provide AGTCR. Urinary creatinine, protein and albumin reagents were supplied 
by Siemens Healthcare Diagnostics Ltd (Camberley, UK). Urinary creatinine reacted with picric 
acid under alkaline conditions to form a red Janovsky complex (the Jaffé reaction). The initial 
rate of absorbance change was measured at a wavelength of 505 nm and compared to that of 
a known calibrant. This was directly proportional to the concentration of creatinine in the 
sample. A blank reaction rate was performed using reagent 1 (sodium hydroxide, before 
picrate addition) to minimise interference from bilirubin. Urinary protein forms a blue 
coloured complex with pyrogallol red, under acid conditions and in the presence of molybdate 
ions. The absorbance of this complex was measured at 596 nm, and related to that of a 
previous calibration assay. Urine albumin was measured using a polyethylglycol enhanced 
immunoturbidimetric method. The sample was diluted and then reacted with antiserum to 
form a precipitate that was measured turbidimetrically at 340nm. Urine albumin was 
measured on the Siemens Advia 2400 analyser.  
 
Statistical Analysis 
The statistical software Stata version 14 (StataCorp, College Station, Texas) and GraphPad 
Prism 7 (Graph Pad Software, San Diego, California) were used for all analyses. The 
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investigation was divided into two parts. Analysis A compared baseline characteristics, clinical 
outcomes and endothelial and renal biomarkers between women with chronic hypertension 
who developed superimposed pre-eclampsia and women with chronic hypertension who did 
not develop superimposed pre-eclampsia. Analysis B compared baseline characteristics, clinical 
outcomes and endothelial and renal biomarkers between women with chronic hypertension 
self-identifying as of Black ethnicity with women with chronic hypertension self-identifying as 
of non-Black ethnicity. An additional analysis examined the relationship between PlGF and 
birthweight centile. Baseline characteristics and clinical outcomes were compared between 
subgroups in analyses A and B using t-tests or Mann-Whitney test for continuous variables 
depending on the distributions and Fisher’s exact test for categorical variables. Mean post-
enrolment systolic and diastolic blood pressure were calculated using the trapezium method of 
analysing the area under the curve for each woman. Variation in longitudinal endothelial and 
renal biomarkers for analyses A and B was assessed using random effects GLS regression with 
robust standard errors356  on log-transformed data allowing for gestation effects. Logged 
estimates with 95% confidence intervals of the geometric means and of their ratios to the 
reference group in each analysis were calculated. Standard mathematic methods converted 
these to percentage differences between groups: percent difference = (exp[parameter]– 1) x 
100%. An interaction test examining the correlation between ethnicity, diagnosis of 
superimposed pre-eclampsia and gestation was performed using a random-effects regression 




The cohort recruited to the study included 121 women with singleton pregnancies and chronic 
hypertension (Figure 6.1). Longitudinal samples (332 in total) were obtained in 117 (97%) 
women; outcome data were unavailable for four (3.3%) women (two women lost to follow-up 
and two withdrew from the study). For analysis A, the cohort was divided into women 
diagnosed with superimposed pre-eclampsia and compared with women who were not 
diagnosed with superimposed pre-eclampsia (n=25 versus n=92) and for analysis B, the cohort 
was divided into women self-identifying as of Black ethnicity versus women self-identifying as 
of non-Black ethnicity (n=63 versus n=54).     
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Figure 6.1 Overview flow of study participants including grouping for analyses A and B 
CHT= chronic hypertension, SPE=superimposed pre-eclampsia  
 
The baseline demographics of the women who provided samples for the analyses are detailed 
in Table 6.1. The women who developed superimposed pre-eclampsia, compared to those who 
did not, were younger (33 years versus 36 years; p 0.04), and a higher proportion of the 
women who developed superimposed pre-eclampsia, compared to those who did not, had 
pre-existing diabetes mellitus (24% versus 6.5%; p 0.02). Fewer black women were nulliparous, 
compared to non-Black women (6.3% versus 33%; p 0.0003), and the diastolic blood pressure 
was higher in Black women than non-Black women at antenatal booking (88 mmHg versus 85 
mmHg; p 0.03). Otherwise the groups were comparable at baseline. 
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Table 6.1 Baseline demographics for the cohort 













Age at study entry, years 
mean (SD) 
35 (5) 33* (6) 36 (5) 36 (5) 35 (6) 
Body mass index, Kg/m2 
mean (SD) 
31 (6.2) 31 (5.8) 31 (6.3) 32 (5.5) 30 (6.9) 
Nulliparity 
number (%) 
22 (19%) 7 (28%) 15 (16%) 4* (6.3%) 18 (33%) 
Smoker 
number (%) 
1 (0.9%) 0 1 (1.1%) 0 1 (1.9%) 
Booking blood pressure, 
mmHg 
median (IQR) 
     
Systolic 
135 
(126 to 142) 
134 
(127 to 140) 
136 
(126 to 142) 
139 
(126 to 147) 
134 
(126 to 140) 
Diastolic 
88 
(81 to 92) 
85 
(82 to 90) 
88 
(81 to 92) 
88* 
(84 to 96) 
85 
(80 to 90) 
Renal disease 
number (%) 
10 (8.5%) 3 (12%) 7 (7.6%) 4 (6.3%) 6 (11%) 
Diabetes mellitus 
number (%) 
12 (10%) 6* (24%) 6 (6.5%) 7 (11%) 5 (9.3%) 
Centre 
number (%) 
     
Guy’s and St Thomas’ NHS 
Foundation Trust 
73 (62%) 10 (40%) 64 (70%) 48 (76%) 25 (46%) 
Central Manchester 
University Hospitals NHS 
Foundation Trust 
29 (25%) 8 (32%) 21 (23%) 13 (21%) 16 (30%) 
University Hospitals of 
Leicester NHS Trust 
15 (13%) 7 (28%) 8 (8.7%) 2 (3.2%) 13 (24%) 
Randomised treatment 
number (%) 
94 (80%) 19 (76%) 75 (82%) 52 (83%) 42 (78%) 
Labetalol 47 (40%) 6 (24%) 41 (45%) 25 (40%) 22 (41%) 
Nifedipine 47 (40%) 13 (52%) 34 (37%) 27 (43%) 20 (37%) 
CHT= chronic hypertension, SPE=superimposed pre-eclampsia, SD= standard deviation, IQR= 
interquartile range 
*denotes characteristics that are significantly different between the compared subgroups 
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Maternal and perinatal outcomes for the cohort as a whole, in addition to the subgroups 
within analysis A (superimposed pre-eclampsia versus chronic hypertensive controls) and B 
(Black women versus non-Black women), are shown in Table 6.2 and 6.3. There were no 
differences in outcome between labetalol and nifedipine arms of the trial. Superimposed pre-
eclampsia was diagnosed in 21% (n=25) of the whole cohort of women with chronic 
hypertension, with 31% (n=36) of infants being born before 37 weeks’ gestation and 91% 
(n=106) livebirths. Of the 106 livebirths, 29% (n=31) had a birthweight below the 10th centile, 
15% (n=16) had a birthweight below the 3rd centile, and 23% (n=25) required admission to the 
neonatal unit.  
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Table 6.2 Maternal outcomes 













Highest blood pressure 
per woman, mmHg 
median (IQR) 
     
Systolic 
163  
(153 to 172) 
173* 
(167 to 183) 
160  
(151 to 169) 
167 
(153 to 176) 
159 
(154 to 170) 
Diastolic 
98  
(92 to 107) 
106*  
(99 to 112) 
97  
(90 to 103) 
99  
(93 to 107) 
98 
(90 to 104) 
Mean blood pressure 
per woman†, mmHg 
median (IQR) 
     
Systolic 
133 
(127 to 137) 
137* 
(131 to 142) 
132 
(127 to 136) 
134 
(127 to 140) 
132 
(128 to 134) 
Diastolic 
84 
(81 to 89) 
87* 
(84 to 93) 
84 
(81 to 88) 
86* 
(82 to 90) 
83 
(81 to 86) 
Incidence of severe 
hypertension‡, days  
number (%)  
     
0 44 (38%) 7 (28%) 37 (40%) 20 (32%) 24 (44%) 
1 30 (26%) 4 (16%) 26 (28%) 14 (22%) 16 (30%) 
2 15 (12%) 1 (4%) 14 (15%) 10 (16%) 5 (9.3%) 




25 (21%) 25 (100%) 92 (0%) 9 (14%) 16 (30%) 
Mode of delivery 
number (%) 
     
Spontaneous vaginal 
delivery 
39 (34%) 4 (16%) 35 (39%) 20 (32%) 19 (35%) 
Assisted vaginal delivery 6 (5.2%) 3 (12%) 3 (3.3%) 4 (6.5%) 2 (3.7%) 
Elective Caesarean 
section 
16 (14%) 2 (8%) 14 (16%) 6 (9.7%) 10 (19%) 
Emergency Caesarean 
section 
54 (47%) 16* (64%) 38 (42%) 32 (52%) 22 (41%) 
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(35.9 to 39) 
34.7* 
(30.3 to 37.9) 
38.3  
(37 to 39.3) 
37.9 




Preterm birth <37 
weeks 
number (%) 
36 (31%) 14* (56%) 22 (24%) 19 (30%) 17 (31%) 
Perinatal outcome 
number (%) 
     
Livebirth 106 (91%) 23 (92%) 83 (91%) 56 (89%) 50 (93%) 
Miscarriage 4 (3.4%) 0 4 (4.3%) 3 (4.8%) 1 (1.9%) 
Termination of 
pregnancy 
3 (2.6%) 1 (4%) 2 (2.2%) 2 (3.2%) 1 (1.9%) 
Stillbirth 4 (3.4%) 1 (4%) 3 (3.2%) 2 (3.2%) 2 (3.7%) 
CHT= chronic hypertension, SPE=superimposed pre-eclampsia  
*denotes outcomes that are significantly different between the compared groups 
†Mean blood pressure of all antenatal blood pressures during study participation 
‡Severe hypertension= systolic blood pressure ≥160 mmHg and/or diastolic blood pressure 
≥110 mmHg 
 
Within the subgroups, the greatest differences in maternal and perinatal outcome were seen 
in the women with chronic hypertension who developed superimposed pre-eclampsia 
compared to chronic hypertensive controls. The highest systolic (173 mmHg versus 160 mmHg; 
p 0.0001), highest diastolic (106 mmHg versus 97 mmHg; p 0.0002), mean systolic (137 mmHg 
versus 132 mmHg; p 0.005) and mean diastolic (87 mmHg versus 84 mmHg; p 0.002) blood 
pressures were higher in the women with superimposed pre-eclampsia compared to those 
with no superimposed pre-eclampsia. Women diagnosed with superimposed pre-eclampsia 
were more likely to have an emergency Caesarean birth, compared to those without 
superimposed pre-eclampsia (64% versus 42%; p 0.03). Additionally, preterm birth before 37 
weeks’ gestation occurred more frequently in women with superimposed pre-eclampsia than 
without (56% versus 24%; p 0.003). The infants born to mothers who were diagnosed with 
superimposed pre-eclampsia, compared to those who were not, had lower birthweights 
(2270g versus 3020g; p <0.0001) and were more likely to be admitted to the neonatal unit 
(52% versus 14%; p 0.0007). The only significant difference in maternal and perinatal outcome 
found between the women of Black ethnicity and those of non-Black ethnicity, was higher 
mean post-enrolment diastolic blood pressure (Black women: 86 mmHg versus non-Black 
women: 83 mmHg; p 0.03). 
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Table 6.3 Perinatal outcomes 















(2360 to 3250) 
2270*  
(1320 to 2840) 
3020  
(2690 to 3440) 
2980  
(2520 to 3180) 
2930  












25 (23%) 12* (52%) 13 (14%) 12 (21%) 13 (26%) 
CHT= chronic hypertension, SPE=superimposed pre-eclampsia  




 The longitudinal changes in PlGF and syndecan-1 are displayed in Figures 6.2, 6.3 and 6.4. 
Analysis A (superimposed pre-eclampsia versus no superimposed pre-eclampsia) 
demonstrated that PlGF concentration increased across gestation in both groups (Figure 6.2); 
however, the PlGF concentrations were 67% lower (95% confidence interval -79% to -48%; 
p=<0.001) in women who developed superimposed pre-eclampsia compared to those who did 
not. In analysis B, PlGF concentration increased across gestation in women of Black ethnicity 
and women of non-Black ethnicity (Figure 6.2). There was no overall difference in 
concentrations between groups (-2%; 95% confidence interval -43% to 68%; p=0.94). 
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Figure 6.2 Placental growth factor concentrations across gestation in pregnant women with 
chronic hypertension.  
Comparison A: superimposed pre-eclampsia (SPE) versus no SPE. Comparison B: women of 
Black ethnicity versus non-Black ethnicity 
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Given the high proportion of infants born below the 3rd and 10th centile in this cohort of 
women with chronic hypertension, an additional analysis assessed the gestational changes in 
PlGF by birthweight centile category (<3rd, 3rd to 10th and >10th) (Figure 6.3). PlGF <100 pg/mL 
at 20 to 23.9 weeks’ gestation to predict subsequent birthweight <3rd centile demonstrated 
88% sensitivity (95% confidence interval 47% to 100%), 83% specificity (95% confidence 
interval 70% to 92%), and the negative predictive value was 98% (95% confidence interval 88% 
to 100%).   
 
Figure 6.3 Placental growth factor concentration and infant birthweight centile  
A: Placental growth factor across gestation in pregnant women with chronic hypertension 
divided by birthweight centile categories  
B: Box plot of placental growth factor concentration at 20 to 23.9 weeks and 24 to 29.9 weeks’ 
gestation divided by infant birthweight centile category 
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Syndecan-1 concentrations increased significantly across gestation in all subgroups (p <0.0001) 
(Figure 6.4). Postnatal syndecan-1 concentrations were 83% lower (95% confidence interval -
87% to -78%; p=<0.001) than antenatal syndecan-1 concentrations. No significant differences 
were found in syndecan-1 concentrations either in women with chronic hypertension who did 
and did not develop superimposed pre-eclampsia (-5%; 95% confidence interval -24% to 18%; 
p=0.62), or in women with chronic hypertension of Black or non-Black ethnicity (-5%; 95% 
confidence interval -22% to 15%; p=0.59).  
 
Figure 6.4 Syndecan-1 concentrations across gestation in pregnant women with chronic 
hypertension.  
Comparison A: superimposed pre-eclampsia (SPE) versus no SPE. Comparison B: women of 
Black ethnicity versus non-Black ethnicity. 
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Plasma renin concentrations did not vary significantly over the gestation studied (12 to 35.9 
weeks) (Figure 6.5); however antepartum renin concentrations were significantly higher than 
in samples taken six weeks postnatally (p <0.0001). In the women who developed 
superimposed pre-eclampsia, the mean renin concentrations at each gestational time point 
tended to be higher than in women who did not develop superimposed pre-eclampsia until 32 
to 35.9 weeks’ gestation. However, these differences were not statistically significant when 
longitudinal measures were compared (34%; 95% confidence interval -2% to 82%; p=0.06). In 
Black women with chronic hypertension with or without superimposed pre-eclampsia, the 
mean renin concentrations were significantly lower across gestation compared to women of 
non-Black ethnicity (-43%; 95% confidence interval -58% to -23%; p=<0.001). Further analysis 
explored the differences between gestational renin concentrations and six-week postnatal 
renin concentrations. In women of Black ethnicity, postnatal renin concentrations were 81% 
lower (95% confidence interval -91% to -58%; p=<0.001) compared with antenatal 
concentrations and in non-Black women the postnatal renin concentrations were 54% lower 
(95% confidence interval -73% to -22%; p=0.004) than antenatal values in this group. An 
interaction test examined the potential relationship between ethnicity, gestation and diagnosis 
of superimposed pre-eclampsia and did not demonstrate a significant correlation.  
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Figure 6.5 Renin concentrations across gestation in pregnant women with chronic 
hypertension.  
Comparison A: superimposed pre-eclampsia (SPE) versus no SPE. Comparison B: women of 
Black ethnicity versus non-Black ethnicity. 
 
Aldosterone concentrations were 57% higher (95% confidence interval 43% to 68%; p=<0.001) 
in pregnancy than at six weeks postpartum. No significant difference was found in aldosterone 
concentrations between the women who did and did not develop superimposed pre-eclampsia 
(5%; 95% confidence interval -20% to 39%; p=0.73) (Figure 6.6). In the women of Black 
ethnicity compared to those of non-Black ethnicity who did or did not develop superimposed 
pre-eclampsia, aldosterone concentrations in pregnancy were 31% lower (95% confidence 
interval -45% to -15%; p=0.001). There was no difference in aldosterone concentrations 
between ethnic groups at the six-week postnatal timepoint (13%; 95% confidence interval -
46% to 131%; p=0.72). Across gestation, aldosterone concentrations increased by 70% in the 
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women of non-Black ethnicity (95% confidence interval 39% to 209%; p=<0.001); however, in 
the Black women no significant increase in aldosterone concentrations was demonstrated 
across gestation (13%; 95% confidence interval -7% to 37%; p=0.23). An interaction test 
explored the potential association of ethnicity, gestation and diagnosis of superimposed pre-
eclampsia and did not demonstrate a significant correlation. 
 
Figure 6.6 Aldosterone concentrations across gestation in pregnant women with chronic 
hypertension.  
Comparison A: superimposed pre-eclampsia (SPE) versus no SPE. Comparison B: women of 
Black ethnicity versus non-Black ethnicity. 
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Urinary AGTCR increased across gestation and was significantly lower at six weeks postpartum 
(-79%; 95% confidence interval -86% to -69%; p=<0.001). In the women with superimposed 
pre-eclampsia, compared to chronic hypertensive controls, the AGTCR was 63% higher across 
gestation (95% confidence interval 10% to 142%; p=0.02) (Figure 6.7). There was no difference 
between the AGTCR in women of Black or non-Black ethnicity (12%; 95% confidence interval -
22% to 61%; p=0.53). No correlation between the systemic RAAS (plasma renin and 
aldosterone) or the intra-renal RAS (AGTCR) was found. 
 
 
Figure 6.7 Urinary angiotensinogen: creatinine concentrations across gestation in pregnant 
women with chronic hypertension.  
Comparison A: superimposed pre-eclampsia (SPE) versus no SPE. Comparison B: women of 
Black ethnicity versus non-Black ethnicity. 
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PCR increased across gestation in all subgroups (51%; 95% confidence interval 24% to 84%; 
p=<0.001) and returned to levels comparable to the 12 to 16.9 week mean ratio by six weeks 
postpartum. PCR was overall significantly higher across gestation in the women who 
subsequently developed superimposed pre-eclampsia compared to those who did not (29%; 
95% confidence interval 5% to 57%; p=0.01) (Figure 6.8). There was no significant difference in 




Figure 6.8 Urinary protein: creatinine ratio concentrations across gestation in pregnant 
women with chronic hypertension.  
Comparison A: superimposed pre-eclampsia (SPE) versus no SPE. Comparison B: women of 
Black ethnicity versus non-Black ethnicity. 
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ACR did not vary significantly across gestation in the cohort as a whole (20%; 95% confidence 
interval -10% to 59%; p=0.22). However, in the women who were subsequently diagnosed with 
superimposed pre-eclampsia compared to chronic hypertensive controls, ACR was higher 
(123%; 95% confidence interval 67% to 197%; p=<0.001) (Figure 6.9). There was no difference 
in ACR when women of Black and non-Black ethnicity were compared (10%; 95% confidence 
interval -19% to 50%; p=0.55). 
 
Figure 6.9 Urinary albumin: creatinine ratio concentrations across gestation in pregnant 
women with chronic hypertension.  
Comparison A: superimposed pre-eclampsia (SPE) versus no SPE. Comparison B: women of 
Black ethnicity versus non-Black ethnicity. 
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This study has confirmed that low PlGF across gestation in women with chronic hypertension 
in pregnancy predates the clinical presentation of superimposed pre-eclampsia and fetal 
growth restriction. To our knowledge, this is the first study in women with chronic 
hypertension to demonstrate the potential utility of PlGF as a predictive tool for fetal growth 
restriction; with further validation, PlGF concentrations <100 pg/mL at 20 to 23.9 weeks’ 
gestation may aid risk stratification and timing of ultrasound surveillance in this group. The 
high incidence of adverse maternal and perinatal outcomes in women with chronic 
hypertension in pregnancy is highlighted by this study with 21% of women developing 
superimposed pre-eclampsia, comparable with the findings of other studies ranging from 17 to 
25%.7,30,46,53 Women with chronic hypertension who did not develop superimposed pre-
eclampsia were also at increased risk of adverse perinatal outcome compared to background 
incidence, but a significantly greater proportion of adverse perinatal outcomes were seen in 
the women who developed superimposed pre-eclampsia.  
 
Syndecan-1 is a transmembrane heparin sulphate proteoglycan expressed on the extracellular, 
luminal surface of epithelial cells and syncytiotrophoblasts, forming part of the glycocalyx of 
these cells. Syndecan-1 is involved in the regulation of cell adhesion, proliferation, motility, 
intra-cellular signalling and angiogenesis.205 Our findings confirm circulating syndecan-1 
concentrations increase across gestation as previously demonstrated;207 however in this study 
syndecan-1 concentrations did not differ significantly in women with chronic hypertension 
who developed subsequent superimposed pre-eclampsia compared with chronic hypertensive 
controls. This finding is in contrast to results reported by Gandley and colleagues (2016) who 
reported that plasma syndecan-1 concentrations at 20 weeks’ gestation were significantly 
lower in women who developed subsequent pre-eclampsia (174 ng/mL versus 272 ng/mL; p 
<0.05).207 Further exploration of the role of syndecan-1 in the pathophysiology of placental 
disease in different populations is required to determine the clinical utility of this biomarker. 
 
The role of the systemic RAAS in the pathophysiology of placental disease in women with 
chronic hypertension in pregnancy is unclear. No significant variation in plasma renin or 
aldosterone concentrations were found across gestation in the women who did and did not 
develop superimposed pre-eclampsia. Previous studies have demonstrated that the RAAS is 
upregulated in normotensive pregnancy and our study confirms that this upregulation occurs 
in both the Black and non-Black women with chronic hypertension, though it is unclear if this is 
in response to, or the cause of other physiological changes that occur in pregnancy such as 
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increased plasma volume and vasodilation.103 Brown and colleagues (1997) performed a cross-
sectional study and found that women diagnosed with pre-eclampsia had lower plasma 
concentrations of renin and aldosterone compared to normotensive pregnant women.354 
Another longitudinal study by August and colleagues (1990) in 25 pregnant women with 
chronic hypertension, demonstrated reduced plasma renin activity and lower urinary 
aldosterone concentrations in those who developed subsequent superimposed pre-eclampsia 
compared to those who did not.109 Importantly our study confirms that systemic renin and 
aldosterone concentrations in Black women with chronic hypertension are lower across 
gestation compared to non-Black women in keeping with the non-pregnant state, and any 
future investigation of the role of the systemic RAAS in pregnancy should account for this 
ethnic variation. 
 
It is interesting that although there is variation in the systemic RAAS between ethnic groups, 
no variation in the intrarenal RAS was observed, nor was any relationship between systemic 
and intrarenal identified. This is in keeping with the findings of other studies outside 
pregnancy that suggest that in individuals with low-renin hypertension, in whom intrarenal 
RAS is active, independently of systemic RAAS and may play a role in the pathogenesis of 
hypertensive nephropathy.218 Increased urinary AGTCR were found across gestation in women 
who developed superimposed pre-eclampsia compared to those who did not. Pathological 
upregulation of the intrarenal RAS in pre-eclampsia would be consistent with findings outside 
pregnancy; an activated intrarenal RAS has been reported in the progression of renal injury in 
diabetic and membranous nephropathy.219 However, our findings do not agree with a cross-
sectional study reported by Yilmaz and colleagues (2009), who compared time-of-disease 
AGTCR in 30 women with pre-eclampsia with 30 normotensive pregnant women. They found 
that urinary AGTCR were lower in women with pre-eclampsia.357 This study did, however, 
report a positive correlation between urinary AGTCR, high blood pressure and proteinuria, and 
concluded that ‘local RAS activation in the kidneys may be one of the contributing factors in 
the development of pre-eclampsia’.357 In this respect our findings concur, but further 
investigation is required to establish the importance of the intrarenal RAS in the 
pathophysiology of superimposed pre-eclampsia.    
 
PCR and ACR were higher across gestation in women with chronic hypertension who 
developed subsequent superimposed pre-eclampsia compared to those who did not. This may 
represent underlying nephropathy in this group of women with chronic hypertension, as 
Student Number: 1355203 
Student Name: Louise Mary Webster 
170 
 
described by Crews and colleagues (2010).224 However, another study by Poon and colleagues 
(2008) found higher first trimester ACR was associated with subsequent development of pre-
eclampsia,358 so it may be that the association of higher PCR/ACR from the first trimester is 
indicative of endothelial dysfunction with subsequent development of superimposed pre-
eclampsia. The clinical utility of these findings are unclear, as proteinuria is known to increase 
in normotensive pregnancy and identifying when protein excretion is abnormal is 
problematic.221,226 It is also notable that the mean PCR and ACR values across gestation in the 
women in our cohort who developed subsequent superimposed pre-eclampsia were below 30 
mg/mmol and 8 mg/mmol respectively (prior to diagnosis), which are currently utilised for 
clinical diagnosis.21  
 
In this study, the proportion of the Black women developing superimposed pre-eclampsia was 
lower than the proportion of non-Black women (14% versus 30%; p=0.07), though this was not 
significant and may relate in part to the higher proportion of multiparous women in the Black 
group. The significant difference in booking and mean post-enrolment diastolic blood 
pressures in women of Black ethnicity, compared to non-Black, suggests potential ethnic 
variation in disease severity, which has been demonstrated in the non-pregnant population.359-
361 Variation in the systemic RAAS may play a role in ethnic disparity in disease severity. Our 
study has highlighted differences in the RAAS, in particular a third trimester increase in 
aldosterone concentrations that is present in the non-Black women, but not in the Black 
women and these findings warrant further exploration. 
 
The strengths of this study include multicentre recruitment of a wide ethnic mixture of women 
with chronic hypertension in pregnancy. Longitudinal sampling has allowed assessment of 
variation of biomarkers across gestation prior to development of adverse outcome. In 
contrast, a limitation of the study was the absence of time-of-disease sampling, preventing 
comparison of each biomarker at the time of clinical diagnosis of superimposed pre-eclampsia, 
and the findings of this study would require validation in a much larger cohort. Future research 
should aim to examine longitudinal and time of disease biomarker concentrations, with 
simultaneous quantification of other biomarkers that are involved in pathophysiological 
pathways such as the RAAS. This would provide further explanation of the mechanisms 
underpinning increased adverse maternal and perinatal outcome in pregnant women with 
chronic hypertension.  
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Changes in placental and renal biomarkers predate development of superimposed pre-
eclampsia. Low plasma PlGF has a strong association with subsequent fetal growth restriction 
in women with chronic hypertension and ethnic variation in RAAS biomarkers may relate to 
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CHAPTER 7 LONGITUDINAL CHANGES IN VASCULAR FUNCTION PARAMETERS IN 
PREGNANT WOMEN WITH CHRONIC HYPERTENSION AND ASSOCIATION WITH 
ADVERSE OUTCOME: A COHORT STUDY  
 
7.1 Abstract 
Increased vascular function measures such as central aortic pressure (CAP), pulse wave 
velocity (PWV) and augmentation index (AIX) are associated with cardiovascular morbidity in 
the non-pregnant population. These haemodynamic parameters may also change in pregnancy 
prior to development of adverse maternal and perinatal outcomes. The aim of this study was 
to evaluate the association between longitudinal vascular function parameters and adverse 
outcomes in pregnant women with chronic hypertension. Pregnant women recruited to the 
PANDA (Pregnancy And chronic hypertension: NifeDipine versus lAbetalol as antihypertensive 
treatment) study in three UK maternity units had serial pulse wave analyses performed using 
the Arteriograph® (Tensiomed, Budapest, Hungary) while in a sitting position. Brachial systolic 
(SBP) and diastolic blood pressure (DBP), CAP, AIX, and PWV were measured across gestation 
from 12 weeks onwards. AIX was additionally adjusted for a heart rate of 75 beats per minute 
(AIX-75). Statistical analysis used random-effects logistic regression models and compared 
those who developed superimposed pre-eclampsia (SPE) to those who did not, women who 
delivered a small for gestational age infant (<10th birthweight centile) (SGA10) to those who 
delivered an infant with birthweight >10th centile, and women of Black ethnicity with women 
of non-Black ethnicity. The cohort included 97 women (57% (n=55) of Black ethnicity) with 
chronic hypertension and singleton pregnancies. SPE was diagnosed in 18% (n=17) and 30% 
(n=29) of infants were SGA10. In women who developed subsequent SPE compared to those 
who did not, brachial SBP (148 versus 139 mmHg; p=0.002), DBP (87 versus 82 mmHg; p=0.01), 
CAP (139 versus 128 mmHg; p=0.001) and AIX-75 (29 versus 22%; p=0.01) were all higher 
across gestation. Brachial SBP (146 versus 138 mmHg; p=0.001), DBP (86 versus 82 mmHg; 
p=0.01), CAP (137 versus 127 mmHg; p=<0.0001), and PWV (9.1 versus 8.5 m/s; p=0.02) were 
higher across gestation in women who delivered an SGA10 infant compared to women who 
delivered an infant with birthweight >10th centile. No longitudinal differences were found in 
the vascular function parameters in women of Black ethnicity compared to non-Black ethnicity. 
Variation in vascular function parameters and brachial blood pressure exist longitudinally in 
pregnant women with chronic hypertension who develop adverse maternal and perinatal 
outcome. Further investigation of the potential clinical utility of these findings is warranted.  
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Pulse wave analysis is a non-invasive technique that utilises the peripheral pressure 
waveforms, and generation of the corresponding central waveform, to derive vascular function 
measures, such as central aortic pressure (CAP), augmentation index of the aorta (AIX), and 
pulse wave velocity of the aorta (PWV). These parameters are considered markers of arterial 
stiffness and, in the non-pregnant population, are associated with an increased risk of 
cardiovascular disease.240,241,362 There is also evidence that these measures may change in 
pregnancy prior to development of adverse outcomes such as pre-eclampsia.252,253 Increased 
brachial blood pressure is associated with subsequent adverse perinatal outcome. A recent 
post-hoc analysis of the Control of Hypertension In Pregnancy Study (CHIPS) (2016) 
demonstrated that severe hypertension was associated with an increased risk of superimposed 
pre-eclampsia (SPE) (odd ratio 6.09; 95% confidence interval 4.37 to 8.49) and small for 
gestational age infants (<10th birthweight centile- SGA10) (odds ratio 2.06; 95% confidence 
interval 1.44 to 2.96).133 
 
Chronic hypertension complicates 3% of pregnancies.7,30 The risk of adverse maternal and 
perinatal outcomes in women with chronic hypertension, such as SPE8,29,45 and fetal growth 
restriction8,54, are increased compared to the general pregnant population. The increased 
maternal vascular resistance and decreased maternal vascular compliance that is associated 
with chronic hypertension may cause maladaptation of the maternal circulation to the 
physiological demands of pregnancy.110,308 However the mechanisms underpinning these 
differences in outcome in women with chronic hypertension in pregnancy are likely to be 
multifactorial and are currently poorly understood. Previous studies have demonstrated an 
association between the diagnosis of pre-eclampsia and subsequent increased risk of 
cardiovascular morbidity and mortality.140,363 Investigation of arterial stiffness parameters in 
women with chronic hypertension in pregnancy may offer some insight into the mechanism 
behind this increased risk.  
 
Previous studies have demonstrated an association between Black ethnicity and adverse 
pregnancy outcome.313-315,329 Prevalence of chronic hypertension is higher at a younger age 
among Black women, compared to White women,25,27 and Black ethnicity, compared to White, 
is associated with an increased lifetime risk of cardiovascular morbidity and mortality.364,365 A 
sub-analysis of the women with chronic hypertension who participated in the Vitamin In 
Pregnancy trial demonstrated an association between Black ethnicity (compared to White) and 
development of SPE (adjusted odds ratio 2.31; 95% confidence interval 1.47 to 3.63).45 Ethnic 
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variation in vascular function parameters has been demonstrated in the non-pregnant 
population; Black individuals aged 20 to 70 years had increased AIX compared with those who 
were White (21 versus 18%; p=0.001) and PWV (7.4 versus 7.1 m/s; p=0.001).366 Exploration of 
the impact of ethnicity on pulse wave analyses in pregnancy complicated by chronic 
hypertension may provide insight into pathophysiological mechanisms underpinning ethnic 
differences in pregnancy outcome.    
  
This study aimed to investigate longitudinal variation in vascular function parameters, using 
pulse wave analysis, in women with chronic hypertension in pregnancy, to establish the impact 
of ethnicity, SPE and SGA10 on these measures. 
 
7.3 Methods 
This was a nested cohort study of women with chronic hypertension who participated in the 
PANDA (Pregnancy And chronic hypertension: NifeDipine versus lAbetalol as antihypertensive 
treatment) study between 2014 and 2016. The PANDA study was primarily a randomised 
controlled feasibility study comparing labetalol and nifedipine for control of chronic 
hypertension in pregnancy (demonstrating comparable effectiveness of both agents at 
controlling blood pressure to treatment target across gestation), but women who were 
ineligible for randomisation (due to medication contraindication) or declined randomisation 
were recruited to an observational arm of the study. The study was registered with ISRCTN 
(DOI 10.1186/ISRCTN40973936, www.isrctn.com) and approved by the UK Research Ethics 
Committee (REC number 13/EE/0390). The study has been reported in line with STROBE 
guidance for reporting of cohort studies.325  
 
Study Design 
Women were enrolled at three consultant-led National Health Service (NHS) obstetric units in 
the United Kingdom (Guy’s and St Thomas’ NHS Foundation Trust, Central Manchester 
University NHS Foundation Trust, and St George’s University Hospitals NHS Foundation Trust). 
The eligibility criteria included women with a prenatal diagnosis of chronic hypertension or 
blood pressure readings ≥140/90 mmHg prior to 20 weeks’ gestation requiring 
antihypertensive treatment, as defined by the International Society for the Study of 
Hypertension in Pregnancy classification of hypertensive disorders of pregnancy,21 between 12 
and 27.9 weeks’ gestation, singleton pregnancies, aged over 18 years, and with ability to 
provide informed consent. Longitudinal vascular function of the study participants was 
measured using pulse wave analysis. Baseline demographic and antenatal booking data were 
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collected at enrolment. Ethnicity (Black versus non-Black) was determined by whether the 
woman had a parent or grandparent who was African or Caribbean by self-report. Clinical 
blood pressure readings taken at all subsequent antenatal visits (using automated and manual 
blood pressure devices) and daily during hospital admissions (highest of that day) were 
recorded in addition to other maternal and perinatal outcome data (SPE, mode of delivery, 
gestation at delivery, pregnancy loss, birthweight, birthweight centile and neonatal unit 
admission). SPE was defined as new-onset proteinuria, a sudden increase in proteinuria if 
already present in early gestation, and an increase in hypertension, as recommended by the 
American College of Obstetrics and Gynaecology practice bulletin.343 Customised birthweight 
centiles were calculated using the GROW formula with adjustment for maternal height, 
maternal weight, maternal ethnicity, parity, infant sex, infant birthweight and gestation at 
birth (version 6.7.5.1 (2014)).322 Infant birthweight below the 10th centile was considered 
diagnostic of small for gestational age (SGA10).  
  
Pulse Wave Analysis 
Pulse wave analyses were obtained using the Arteriograph® (Tensiomed, Budapest, Hungary), 
an oscillometric single-cuff device. Readings were obtained at study enrolment, 20 weeks, 28 
weeks, and 34 weeks’ gestation (+/- two weeks). All pulse wave measurements were 
performed with participants in the sitting position. The Arteriograph® cuff was applied to the 
left arm over the brachial artery for estimation of CAP (mmHg), PWV (m/s) and AIX (%).The AIX 
was also converted to an additional vascular function parameter AIX-75, adjusting for a heart 
rate of 75 beats per minute as previously described by Khalil and colleagues (2012).231 The 
device additionally recorded brachial SBP and DBP (mmHg). All recordings were made by 
researchers who had received appropriate training on the use of the Arteriograph®. The results 
of the pulse wave analyses were not given to the women or their doctors and did not influence 
the subsequent management of the pregnancies.   
 
Statistical Analysis 
The statistical software Stata version 14 (StataCorp, College Station, Texas) and GraphPad 
Prism 7 (Graph Pad Software, San Diego, California) were used for all analyses. The 
investigation was divided into three parts. Baseline characteristics, clinical brachial blood 
pressure measurements, clinical outcomes and longitudinal vascular function parameters were 
compared between women with chronic hypertension who developed SPE and women with 
chronic hypertension who did not develop SPE (analysis A), women with chronic hypertension 
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who gave birth to an SGA10 infant with women with chronic hypertension who gave birth to 
an infant with a birthweight >10th centile (analysis B) and Black women with chronic 
hypertension with non-Black women with chronic hypertension (analysis C).  
 
Baseline characteristics and clinical outcomes were compared between subgroups using t-tests 
or Mann-Whitney test for continuous variables depending on the distributions and Fisher’s 
exact test or Chi-squared test for categorical variables. The mean and standard deviation (SD) 
of each vascular function parameter within each comparison was calculated. Variation in 
longitudinal vascular function measurements was assessed in each comparative analysis (A, B 
and C) using random effects regression models allowing for gestation effects, which provided 
adjusted mean differences with 95% confidence intervals for each analysis. Further 
investigation of the data included the comparison of clinical brachial systolic and diastolic 
blood pressures in analysis A, B and C.   
 
7.4 Results 
The total number of women enrolled into this cohort study was 106 (Figure 7.1 details flow of 
study participants). Of these, four (3.8%) withdrew or were lost to follow-up, and five (4.7%) 
were excluded from the analysis as they had a second trimester pregnancy loss. Longitudinal 
vascular function assessments (290 in total) were obtained in 97 women (92%). Of the 290 
readings obtained, 16 (5.5%) did not provide an AIX or PWV value and eight (2.9%) of the 
readings with AIX and PWV could not be included in the analyses of these parameters, as the 
standard deviation of the pulse wave was greater than the pre-specified 1.5 cut-off. For 
analysis A the cohort was divided into women diagnosed with SPE (n=17) and compared with 
women who were not diagnosed with SPE (n=80), for analysis B women with infants born 
below the 10th birthweight centile (n=29) were compared with women with infants born above 
the 10th birthweight centile (n=68), and for analysis C the cohort was divided into women of 
Black ethnicity (n=55) versus women self-identifying as of non-Black ethnicity (n=42). The 
results are presented with summary tables for comparisons of the vascular function variables 
within each of the three analyses (Tables 7.4, 7.5 and 7.6), but the figures are collated by 
vascular function variable across the three analyses (A, B and C) to allow visual comparison of 
the longitudinal variation and inter-relationship between analyses (Figures 7.2 to 7.7).       
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Figure 7.1 Overview flow of study participants including grouping for analyses A, B and C 
CHT= chronic hypertension, SPE=superimposed pre-eclampsia, SGA10=neonates with 
birthweight below the 10th centile 
Participants of vascular function sub-study only presented in this schematic.  
 
The baseline demographics of the cohort are detailed in Table 7.1. Body mass index was higher 
in the Black women compared to the non-Black women (32 kg/m2 versus 29 kg/m2; p=0.02). 
There was a lower proportion of nulliparous women in the group of Black ethnicity compared 
to non-Black ethnicity (3.6% versus 31%; p=<0.0001), and the median antenatal booking SBP 
was higher in the women of Black ethnicity compared to the women of non-Black ethnicity 
(140 mmHg versus 134 mmHg; p=0.02). Otherwise baseline characteristics were comparable 
between subgroups. 
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Table 7.1 Baseline demographics for the cohort 












Age at study entry, years 
mean (SD) 
35 (6) 34 (6) 35 (5) 35 (5) 35 (6) 
Body mass index, Kg/m2 
mean (SD) 
31 (5.7) 31 (4.6) 30 (6.0) 32* (5.6) 29 (6.5) 
Nulliparity 
number (%) 
15 (15%) 4 (24%) 11 (14%) 2* (3.6%) 13 (31%) 
Smoker 
number (%) 
1 (1.0%) 0 1 (1.3%) 0 (0%) 1 (2.4%) 
Booking blood pressure, 
mmHg 
median (IQR) 
     
Systolic 
136 
(126 to 142) 
138 
(130 to 142) 
136 
(125 to 143) 
140* 
(128 to 148) 
134 
(125 to 140) 
Diastolic 
88 
(80 to 92) 
84 
(80 to 89) 
88 
(80 to 92) 
88 
(80 to 92) 
84 
(80 to 90) 
Centre 
number (%) 
     
Guy’s and St Thomas’ 
NHS Foundation Trust 
54 (56%) 6 (35%) 48 (60%) 35 (64%) 19 (45%) 
Central Manchester 
University Hospitals NHS 
Foundation Trust 
32 (33%) 9 (53%) 23 (29%) 14 (25%) 18 (43%) 
St George’s University 
Hospitals NHS 
Foundation Trust 





87 (90%) 16 (94%) 71 (89%) 50 (91%) 37 (88%) 
Labetalol 45 (47%) 6 (35%) 39 (49%) 26 (47%) 19 (45%) 
Nifedipine 42 (43%) 10 (59%) 32 (40%) 24 (44%) 18 (43%) 
CHT= chronic hypertension, SPE=superimposed pre-eclampsia, SD= standard deviation, IQR= 
interquartile range 
*denotes characteristics that are significantly different between the compared subgroups 
(p=<0.05) 
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Adverse maternal and perinatal outcomes were common in the cohort as a whole (Tables 7.2 
and 3), with 18% (n=17) of women developing SPE in their pregnancy, 63% (n=61) of women 
requiring a Caesarean birth, 24% (n=23) of births occurring before 37 weeks’ gestation, and 
3.1% (n=3) stillbirths. Other adverse neonatal outcomes included 30% (n=29) SGA10, 14% 
(n=14) of infants with birthweight <3rd centile, and 22% (n=21) required admission to the 
neonatal unit. There were no significant differences in maternal and perinatal outcomes 
between the women of Black ethnicity and non-Black ethnicity (Table 7.2 and 7.3).  
Table 7.2 Maternal outcomes of the cohort 












Highest blood pressure per 
woman, mmHg 
median (IQR) 
     
Systolic 
162 
(151 to 174) 
180* 
(166 to 189) 
160  
(150 to 169) 
167 
(153 to 175) 
158 
(150 to 171) 
Diastolic 
98  
(91 to 106) 
107* 
(98 to 116) 
97  
(90 to 103) 
100  
(92 to 107) 
96 
(90 to 104) 
Superimposed pre-eclampsia 
number (%) 
17 (18%) 17 (100%) 0 (0%) 7 (13%) 10 (24%) 
Mode of delivery 
number (%) 
     
Spontaneous vaginal delivery 31 (32%) 2 (12%) 29 (36%) 16 (29%) 15 (36%) 
Assisted vaginal delivery 5 (5.2%) 2 (12%) 3 (3.8%) 4 (7.3%) 1 (2.4%) 
Elective Caesarean section 17 (18%) 0 (0%) 17 (21%) 9 (16%) 8 (19%) 
Emergency Caesarean section 44 (45%) 13* (76%) 31 (39%) 26 (47%) 18 (43%) 
Gestation at delivery, weeks 
median (IQR) 
38 
(37 to 39.3) 
33* 
(30.3 to 36.4) 
39 
(37.8 to 39.3) 
38 
(37.2 to 39.3) 
38 
(36.4 to 39.2) 
Preterm birth <37 weeks 
number (%) 
23 (24%) 13* (76%) 10 (13%) 11 (20%) 12 (29%) 
Perinatal outcome 
number (%) 
     
Livebirth 94 (97%) 17 (100%) 77 (96%) 54 (98%) 40 (95%) 
Stillbirth 3 (3.1%) 0 (0%) 3 (3.8%) 1 (1.8%) 2 (4.8%) 
CHT= chronic hypertension, SPE=superimposed pre-eclampsia *denotes outcomes that are 
significantly different between the compared groups **Severe hypertension= systolic blood 
pressure ≥160 mmHg and/or diastolic blood pressure ≥110 mmHg 
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The women who developed SPE had higher peak SBP and DBP (180 mmHg versus 160 mmHg; 
p=0.0003 and 107 versus 97 mmHg; p=0.004 respectively) and were more likely to require an 
emergency Caesarean section for delivery (76% versus 39%; p=0.006). Women with SPE were 
delivered earlier (median 33 weeks’ gestation) compared to those without (median 39 weeks’ 
gestation; p=<0.0001). with lower birthweight babies (1560g versus 3030g;) p=<0.0001) and a 
greater proportion of infants who required admission to the neonatal unit (76% versus 10%; 
p=<0.0001).  
 
Table 7.3 Neonatal outcomes for the live births within the cohort 














(2580 to 3260) 
1560* 
(1040 to 2510) 
3030  
(2790 to 3460) 
2980  
(2520 to 3190) 
2930  













21 (22%) 13* (76%) 8 (10%) 10 (19%) 11 (28%) 
CHT= chronic hypertension, SPE=superimposed pre-eclampsia, SGA10= birthweight <10th centile  
*denotes outcomes that are significantly different between the compared groups 
 
Analysis A: Comparison of vascular function parameters between women with chronic 
hypertension who did and did not develop superimposed pre-eclampsia 
 A summary of the comparison of vascular function parameters in women who did and did not 
develop SPE is in Table 7.4. Across gestation the SBP and DBP measurements taken by the 
Arteriograph® were higher in the women whose pregnancies were complicated by SPE (148 
mmHg versus 139 mmHg; p=0.002 and 87 mmHg versus 82 mmHg; p=0.01), as were the 
central aortic pressure and the AIX adjusted for a heart rate of 75 beats per minute (139 
mmHg versus 128 mmHg; p=0.001 and 29% versus 22%; p=0.01 respectively).  
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Table 7.4 Variation in vascular function parameters across gestation in women who did and 















148 (17) 139 (15) 10 (4 to 16) 0.002      
Brachial DBP 
(mmHg) 
87 (10) 82 (10) 5 (1 to 9) 0.01  
CAP (mmHg) 139 (22) 128 (16) 12 (5 to 20) 0.001 
PWV (m/s) 9.0 (1.7) 8.6 (1.4) 0.6 (-0.2 to 1.3) 0.12      
AIX (%) 21 (16) 17 (13) 4 (-1 to 9) 0.11     
AIX-75 (%) 29 (13) 22 (12) 6 (1 to 11) 0.01      
Mean difference adjusted for gestation. SD= standard deviation, SPE= superimposed pre-
eclampsia, CHT= chronic hypertensive, SBP= systolic blood pressure, DBP= diastolic blood 
pressure, CAP= central aortic pressure, PWV= pulse wave velocity, AIX= augmentation index, 
AIX-75= augmentation index adjusted for a heart rate of 75 beats per minute 
 
Analysis B: Comparison of vascular function parameters between women with chronic 
hypertension who delivered a small for gestational age infant (birthweight <10th centile) and 
those who delivered an infant with a birthweight ≥10th centile. 
A summary of the comparison of vascular function parameters in women who gave birth to an 
SGA10 infant with those who gave birth to an infant with a birthweight above the 10th centile 
is presented in Table 7.5. Brachial SBP and DBP were significantly higher across gestation in the 
women who delivered an SGA10 infant (146 mmHg versus 138 mmHg; p=0.001 and 86 mmHg 
versus 82 mmHg; p=0.01 respectively). Mean central aortic pressure across gestation was 137 
mmHg in women who gave birth to an SGA10 infant compared to 127 mmHg in women whose 
infant’s birthweight was ≥10th centile (p=<0.0001). In addition, the mean PWV across gestation 
was 9.1 m/s in women who delivered an SGA10 infant compared to 8.5 m/s in those who did 
not (p=0.02).      
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Table 7.5 Variation in vascular function parameters across gestation in women who gave 















146 (18) 138 (13) 9 (4 to 14) 0.001      
Brachial DBP 
(mmHg) 
86 (13) 82 (9) 4 (1 to 8) 0.01     
CAP (mmHg) 137 (22) 127 (15) 11 (5 to 18) <0.0001 
PWV (m/s) 9.1 (1.7) 8.5 (1.3) 0.7 (0.1 to 1.4) 0.02      
AIX (%) 19 (15) 17 (13) 3 (-2 to 7) 0.25     
AIX-75 (%) 26 (13) 22 (12) 4 (0 to 8) 0.05     
Mean difference adjusted for gestation. SD= standard deviation, SGA10= birthweight <10th 
centile, CHT= chronic hypertensive, SBP= systolic blood pressure, DBP= diastolic blood pressure, 
CAP= central aortic pressure, PWV= pulse wave velocity, AIX= augmentation index, AIX-75= 
augmentation index adjusted for a heart rate of 75 beats per minute 
 
Analysis C: Comparison of vascular function parameters between women with chronic 
hypertension of Black ethnicity and non-Black ethnicity 
Table 7.6 summarises the vascular function comparisons made between women of Black and 
non-Black ethnicity with chronic hypertension in pregnancy. No significant differences in 
vascular function across gestation were found by ethnic group. 
 
















142 (17) 139 (13) 4 (-1 to 8) 0.17    
Brachial DBP 
(mmHg) 
84 (11) 82 (9) 2 (-1 to 5) 0.18    
CAP (mmHg) 132 (19) 128 (17) 5 (-1 to 11) 0.12 
PWV (m/s) 8.7 (1.5) 8.6 (1.5) 0.3 (-0.3 to 0.9) 0.34 
AIX (%) 18 (13) 17 (15) 2 (-2 to 6) 0.45    
AIX-75 (%) 23 (12) 23 (14) 1 (-3 to 5) 0.52  
Mean difference adjusted for gestation. SD= standard deviation, CHT= chronic hypertensive, 
SBP= systolic blood pressure, DBP= diastolic blood pressure, CAP= central aortic pressure, PWV= 
pulse wave velocity, AIX= augmentation index, AIX-75= augmentation index adjusted for a 
heart rate of 75 beats per minute 
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Longitudinal variation in vascular function parameters across gestation  
The graphs in Figures 7.2 to 7.7 demonstrate the gestational variation in each vascular function 
parameter for each comparison (A, B and C). 
 
Figure 7.2 Brachial systolic blood pressure across gestation in pregnant women with chronic 
hypertension.  
Comparison A: SPE versus no SPE. Comparison B: SGA10 versus no SGA10. Comparison C: 
women of Black ethnicity versus women of non-Black ethnicity. The limits of the axes represent 
the maximum and minimum value within the dataset for each parameter. 
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Figure 7.3 Brachial diastolic blood pressure across gestation in pregnant women with chronic 
hypertension.  
Comparison A: SPE versus no SPE. Comparison B: SGA10 versus no SGA10. Comparison C: 
women of Black ethnicity versus women of non-Black ethnicity. The limits of the axes represent 
the maximum and minimum value within the dataset for each parameter. 
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Figure 7.4 Central aortic blood pressure across gestation in pregnant women with chronic 
hypertension 
Comparison A: SPE versus no SPE. Comparison B: SGA10 versus no SGA10. Comparison C: 
women of Black ethnicity versus women of non-Black ethnicity. The limits of the axes represent 
the maximum and minimum value within the dataset for each parameter. 
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Figure 7.5 Pulse wave velocity across gestation in pregnant women with chronic 
hypertension 
Comparison A: SPE versus no SPE. Comparison B: SGA10 versus no SGA10. Comparison C: 
women of Black ethnicity versus women of non-Black ethnicity. The limits of the axes represent 
the maximum and minimum value within the dataset for each parameter. 
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Figure 7.6 Augmentation index across gestation in pregnant women with chronic 
hypertension 
Comparison A: SPE versus no SPE. Comparison B: SGA10 versus no SGA10. Comparison C: 
women of Black ethnicity versus women of non-Black ethnicity. The limits of the axes represent 
the maximum and minimum value within the dataset for each parameter. 
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Figure 7.7 Augmentation index adjusted to a heart rate of 75 beats per minute across 
gestation in pregnant women with chronic hypertension 
Comparison A: SPE versus no SPE. Comparison B: SGA10 versus no SGA10. Comparison C: 
women of Black ethnicity versus women of non-Black ethnicity. The limits of the axes represent 
the maximum and minimum value within the dataset for each parameter. 
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Comparison of clinical systolic and diastolic blood pressure readings for each comparison 
Given the relationship observed between brachial SBP and DBP and outcomes as measured 
using the Arteriograph®, further comparison was made repeating analysis A, B and C utilising 
the clinically recorded blood pressure measurements taken within the study. This analysis 
confirmed that there was a significant relationship between brachial blood pressure and 
subsequent SPE with systolic blood pressure 11 mmHg higher across gestation (95% 
confidence interval 7 to 15 mmHg; p <0.0001) and diastolic blood pressure 5 mmHg higher 
across gestation (95% confidence interval 2 to 8 mmHg; p 0.003) in women who developed SPE 
compared to those who did not. Raised brachial blood pressure was also associated with 
subsequent SGA10 in women with chronic hypertension, with systolic blood pressure 9 mmHg 
higher (95% confidence interval 5 to 12 mmHg; p <0.0001) and diastolic blood pressure 4 
mmHg higher (95% confidence interval 1 to 6 mmHg; p 0.002) in women who gave birth to 
SGA10 infants compared to women who gave birth to infants who had a birthweight ≥10th 
centile. No relationship was demonstrated between clinical blood pressure and ethnicity. 
Figures 7.8 and 7.9 present the comparisons made of clinical systolic and diastolic blood 
pressure measurements across gestation respectively. 
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Figure 7.8 Clinical systolic blood pressure across gestation in pregnant women with chronic 
hypertension.  
Comparison A: superimposed pre-eclampsia (SPE) versus no SPE. Comparison B: Women giving 
birth to infants <10
th
 birthweight centile. Comparison C: women of Black ethnicity versus non-
Black ethnicity. 
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Figure 7.9 Clinical diastolic blood pressure across gestation in pregnant women with chronic 
hypertension.  
Comparison A: superimposed pre-eclampsia (SPE) versus no SPE. Comparison B: Women giving 
birth to infants <10
th
birthweight centile. Comparison C: women of Black ethnicity versus non-
Black ethnicity. 
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This cohort study demonstrates that longitudinally elevated brachial systolic and diastolic 
blood pressure predate the development of adverse pregnancy outcome in women with 
chronic hypertension. These findings are in keeping with data from other studies 
demonstrating an association between elevated blood pressure and adverse outcome.133 An 
increase in other vascular function parameters across gestation also pre-dates the 
development of SPE and SGA10 in this cohort. Women with chronic hypertension are at high 
risk of adverse pregnancy outcome, as highlighted by this study. SPE was diagnosed in 18%, 
which is in keeping with the incidence reported in other studies of 17 to 25%.7 Caesarean 
section was required for 63% of this cohort, which compares with 26% caesarean section rate 
in the general UK pregnant population (data obtained for NHS England maternity statistics 
2013 to 2014).324 Adverse perinatal outcomes were also increased with 24% of infants born 
before 37 weeks’ gestation, 30% SGA10 and 22% of infants requiring neonatal unit admission. 
 
To our knowledge this is the first study to report longitudinal changes in pulse wave analyses 
using the Arteriograph® device exclusively in women with chronic hypertension in pregnancy. 
An association between increased central aortic pressure and subsequent diagnosis of pre-
eclampsia has previously been demonstrated by Khalil and colleagues (2014) using this device 
in women who were normotensive at study enrolment.252 Additionally, raised AIX and AIX-75 
have been demonstrated in women with pre-eclampsia, both prior to and at the time of 
diagnosis.232,250-252 Our study did not demonstrate an association between unadjusted AIX and 
pregnancy outcome, but AIX-75 was increased across gestation in women who developed SPE, 
compared to those who did not. A cross-sectional cohort study of 41 pregnant women with 
chronic hypertension, conducted by Tomimatsu and colleagues (2014), also demonstrated an 
association between increased AIX-75 and SPE.253 This study also demonstrated increased 
brachial SBP and CAP pre-dated the development of SPE with SGA10 at 26 to 32 weeks’ 
gestation compared with women with chronic hypertension who had SPE alone, SGA10 alone, 
or no SPE/SGA10. The approach of subdividing their cohort did reduce the number of women 
within each group used for the comparative analysis and this reduction in power may have 
affected the results. 
 
The relationship between blood pressure and placental insufficiency is complex. There are 
many studies that demonstrate an increased incidence of fetal growth restriction associated 
with chronic hypertension in pregnancy, both in association with and independently of a 
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diagnosis of SPE.8,29,45,54 Previously fetal growth restriction has been linked to antihypertensive 
treatment in women with hypertensive disorders of pregnancy, with a hypothesis that the 
reduction in blood pressure caused by the antihypertensive agents also reduced placental 
blood flow, leading to fetal growth restriction.129 However, the Control of Hypertension In 
Pregnancy Study (CHIPS, reported 2015) demonstrated that there was no adverse effect of 
tight blood pressure control (target DBP 80-85 mmHg), compared to less tight control (target 
DBP 100-105 mmHg), on the risk of SGA10 between intervention groups (16% versus 20%; 
odds ratio 0.78, 95% confidence interval 0.56 to 1.08).15 The impact of antihypertensive 
treatment on the incidence of fetal growth restriction if a diastolic blood pressure target below 
85 mmHg is utilised needs to be established, as the CHIPS protocol recommended cessation of 
antihypertensive treatment if diastolic was <80 mmHg. However, our study demonstrates an 
association between increased brachial SBP and DBP across gestation and subsequent delivery 
of an SGA10 infant in women with chronic hypertension in pregnancy. Though superimposed 
pre-eclampsia may explain some of this increased risk, the relationship between increased 
blood pressure and subsequent delivery of an SGA10 infant requires further investigation, as it 
seems probable that increased blood pressure increases the risk of placental insufficiency. The 
increase in PWV, a marker of arterial stiffness, associated with the subsequent birth of an 
SGA10 infant demonstrated by this study, would support this hypothesis.  
 
There is evidence that pre-eclampsia is associated with subsequent increased cardiovascular 
risk. A systematic review reported by Bellamy and colleagues (2007), demonstrated that a 
diagnosis of pre-eclampsia in pregnancy was associated with a relative risk of 2.16 (95% 
confidence interval 1.86 to 2.52) for developing ischaemic heart disease after 11.7 years, and a 
relative risk for stroke of 1.81 (95% confidence interval 1.45 to 2.27) after 10.4 years compared 
to women whose pregnancies were not complicated by pre-eclampsia.363 This study offers 
potential insight into the mechanisms of this increased risk, as arterial stiffness markers are 
increased in women who develop superimposed pre-eclampsia, compared to those who do 
not, and arterial stiffness parameters are increased in those with an increased cardiovascular 
risk in the non-pregnant population.240,362 
 
No ethnic variation in vascular function parameters was demonstrated in this study. Khalil and 
colleagues (2009) also found no ethnic variation in vascular function parameters, but in 
normotensive pregnancy.230 However, a study by Brewster and colleagues (2010) 
demonstrated increased resistance artery contractility in Black normotensive pregnant 
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women, compared with White.367 In order to confirm if ethnic variation in vascular function 
parameters exist and have a role in the pathophysiology underpinning the ethnic disparity in 
pregnancy outcome observed in previous cohort studies, a much larger study is needed. 
 
The strengths of this study include focusing on recruitment in women with chronic 
hypertension to allow investigation of vascular function differences in this group alone. The 
study was conducted at three centres, making the results more generalizable and including a 
wider-UK cohort. Performing longitudinal pulse wave analyses allowed assessment of changes 
in vascular function parameters that occurred prior to clinical diagnosis of any adverse 
outcome. The limitations include the relatively small number of participants, though our study 
was larger than previous studies that examined vascular function in chronic hypertension 
alone.253 The potential clinical utility of these parameters in diagnosis of SPE could not be 
ascertained as no ‘time of disease’ readings were obtained, and 8.4% of readings did not 
record the AIX or PWV, suggesting further optimisation of this technique is required prior to 
establishing the use of this device in clinical practice. 
 
Future research needs to establish whether the measurement of vascular function parameters 
in pregnancy complicated by chronic hypertension offers benefit above the standard brachial 
blood pressure measurements used in current clinical practice. This is particularly pertinent 
given the association demonstrated within this study between increased clinical systolic and 
diastolic blood pressure and subsequent SPE and/or SGA10. Differing antihypertensive agent 
effects on vascular function parameters have been observed, in the absence of brachial blood 
pressure variation.244 If such treatment differences were observed in a pregnant population, 
the assessment of vascular function may prove a useful adjunct to current clinical 
management of chronic hypertension in pregnancy. It would also be beneficial to establish if 
vascular function parameters measured in the first or second trimester could be used to 
predict SPE or SGA10 and hence aid risk stratification and antenatal care pathways. 
 
In conclusion, variation in vascular function parameters and brachial blood pressure exist 
longitudinally in pregnant women with chronic hypertension who develop adverse maternal 
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CHAPTER 8 CONCLUSIONS AND FUTURE RESEARCH 
 
8.1 Summary of key findings 
In this thesis I have demonstrated through a systematic review and meta-analysis that 
antihypertensive treatment substantially reduces the risk of severe hypertension in women 
with chronic hypertension in pregnancy compared to non-active treatment; no significant 
differences in other maternal or perinatal outcomes were observed with antihypertensive use. 
This systematic review highlights the paucity of data available to guide the treatment of 
chronic hypertension in pregnancy. Given the recent evidence that tight control of 
hypertension, compared with less tight control, in pregnancy reduces the risk of severe 
hypertension with no significant adverse perinatal outcome, the optimal antihypertensive 
agent(s) to achieve and maintain tight blood pressure control needs to be identified. 
 
My cohort study of 4481 women with chronic hypertension in pregnancy confirmed, in a 
contemporary UK population, the increased risk of adverse maternal and perinatal outcomes 
compared with the general pregnant population. I demonstrated that Black ethnicity, 
compared to White, was the maternal characteristic most strongly associated with an 
increased risk of all adverse perinatal outcomes. This study included adjustment for 
deprivation and was conducted in a free healthcare setting suggesting that the impact of 
variation in outcome by ethnicity is likely to be mediated through multifactorial pathways, with 
potential pathophysiological differences that require further exploration.      
 
As part of a wider team, I conducted the first randomised controlled feasibility trial comparing 
labetalol and nifedipine for treatment of chronic hypertension in pregnancy. The feasibility of 
conducting this study in pregnancy was confirmed, with 114 women randomised at four UK 
sites and 112 women completing the study. Labetalol and nifedipine demonstrate comparable 
effectiveness within the limits of this feasibility study, but much larger head-to-head 
randomised controlled trials are needed to establish which agent(s) provides optimal blood 
pressure reduction, potentially improving maternal outcome without causing perinatal harm. 
Mechanistic differences in treatment effect were demonstrated with a reduction in central 
aortic pressure, and not brachial blood pressure, across gestation in women randomised to 
nifedipine compared to labetalol. An increase in protein: creatinine ratio in women 
randomised to nifedipine, compared to labetalol, was also noted, but mean concentrations did 
not reach a threshold deemed clinically significant, so the importance of this finding is 
uncertain. This study also explored possible ethnic variation in drug response and 
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demonstrated a modest reduction in mean diastolic blood pressure across gestation in women 
of non-Black ethnicity (all ethnicities other from African and Caribbean). Outside pregnancy 
there is evidence that individuals of African and Caribbean family origin respond optimally to 
calcium-channel blockers rather than beta-blockers and the impact of ethnicity on choice of 
antihypertensive agent within pregnancy should be investigated further in a much larger study. 
 
Further exploration of placental, endothelial and renal biomarkers in women with chronic 
hypertension in pregnancy demonstrated a strong association between low placental growth 
factor concentrations across gestation and subsequent development of superimposed pre-
eclampsia and/or delivery of infants <3rd birthweight centile. The predictive performance of 
placental growth factor <100 pg/ml when measured at 20 to 23+6 weeks’ gestation for fetal 
growth restriction (birthweight <3rd centile) was good and the potential clinical utility of this 
test to guide antenatal ultrasound surveillance in this high-risk group should be examined 
further. In addition, ethnic differences in the maternal systemic renin-angiotensin-aldosterone 
system were demonstrated with Black women with chronic hypertension having lower 
circulating renin and aldosterone concentrations across gestation compared with non-Black 
women. Interestingly renin and aldosterone concentrations decreased significantly in all ethnic 
groups postpartum suggesting the systemic renin-angiotensin-aldosterone system is 
upregulated during pregnancy in all women. No ethnic differences in the intrarenal renin-
angiotensin system were demonstrated and given the complexity and number of components 
of the systemic renin-angiotensin-aldosterone system, the importance of ethnic variation in 
circulating maternal renin and aldosterone concentrations requires further investigation. 
 
Vascular function assessment through pulse wave analysis and estimation of arterial stiffness 
indices shows promise for clinical utility in the general non-pregnant population. My study, 
examining variation in vascular function parameters across gestation in women with chronic 
hypertension in pregnancy, demonstrated increased arterial stiffness indices in women who 
had subsequent adverse outcome (superimposed pre-eclampsia and infant birthweight <10th 
centile), but also demonstrated a strong association between raised brachial systolic and 
diastolic blood pressure and subsequent adverse pregnancy outcome, making the additional 
clinical benefit of pulse wave analyses unclear in women with chronic hypertension in 
pregnancy.    
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8.2 Strengths and limitations 
The strengths of the systematic review in Chapter 3 include that it is the largest examining the 
optimal antihypertensive treatment for chronic hypertension in pregnancy. The review also 
focused on chronic hypertension rather than a mixed group including women with gestational 
hypertension, which is important given the differing pathophysiology of these conditions. The 
systematic review is limited by the number of studies and the number of participants, but this 
highlights the paucity of data in this area and the need for further large randomised controlled 
trials addressing the optimal treatment of chronic hypertension in pregnancy. 
 
To my knowledge, the cohort study is the largest UK dataset of women with chronic 
hypertension in pregnancy. Data was collated from three centres, which adds an additional 
strength and allows robust regression modelling to highlight maternal characteristics that are 
associated with an increased risk of adverse perinatal outcome in women with chronic 
hypertension. The study is limited by the absence of information about severity of 
hypertension during each pregnancy. Additionally, comparison of the cohort of women with 
chronic hypertension with the other women who had pregnancies during the study timeframe 
at each centre would have made a more robust comparison of the increased risk of each 
adverse outcome. 
 
The randomised controlled feasibility study is, to my knowledge, the first to compare labetalol 
and nifedipine for control of chronic hypertension in pregnancy. Invaluable feasibility 
information was obtained to inform the design of the definitive trial. In addition, mechanistic 
differences in each antihypertensive treatment were found that warrant further exploration. 
Given this is a feasibility study, the clinical findings require validation in a much larger study. 
 
The mechanistic sub-studies highlighted variation in biomarker and vascular function 
parameters that may provide insight into pathophysiological pathways increasing the risk of 
adverse maternal and perinatal outcome in women with chronic hypertension in pregnancy. 
They were small in size and require further investigation in larger cohorts and expansion of the 
parameters examined to further enhance our understanding.   
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8.3 Future research and perspectives 
Chronic hypertension contributes significantly to global morbidity and mortality. The 
significant increase in adverse maternal and perinatal outcomes such as superimposed pre-
eclampsia and fetal growth restriction in pregnancy complicated by chronic hypertension has 
again been highlighted in this body of work. Further research into the pathophysiology 
underpinning these increased risks in women with chronic hypertension in pregnancy warrants 
further investigation. In particular, the impact of ethnicity on pathophysiological mechanisms 
needs to be explored further, given the disparity in pregnancy outcomes.  
 
This study has demonstrated that increased brachial blood pressure is associated with 
placental dysfunction in women with chronic hypertension and future research should assess if 
a more assertive approach to reducing blood pressure in the first and second trimester confers 
any improvement in pregnancy outcome. It is imperative that further randomised controlled 
trials in women with chronic hypertension in pregnancy examine the optimal antihypertensive 
agent(s) to achieve and maintain this reduction in blood pressure. In order to inform the 
design of the definitive trial, I undertook a national clinician survey assessing which 
antihypertensive agents are most commonly used as first-line treatment for chronic 
hypertension in pregnancy. This confirmed that labetalol is most commonly prescribed (84%, 
n=51), with nifedipine (30%, n=18) and methyldopa (24%, n=14) as other first-line agents 
(further details of findings in Appendix). I have also established a local Hypertension in 
Pregnancy Participant and Public Involvement group to ensure that the research questions 
considered in the definitive study are important to the women we care for and that outcomes 
included are patient centred. 
 
The challenges of antihypertensive medication adherence in pregnancy need to be explored, 
as pregnant women are often faced with balancing home and work-life whilst managing their 
chronic condition, and the first-line antihypertensive agents in current use are taken at a 
minimum twice per day and often three times per day. Our group is examining the utility of 
urinary drug metabolites testing in samples taken from the women who participated in our 
randomised controlled feasibility trial to explore objective adherence and how this could be 
incorporated into the definitive trial. Other more subjective methods for monitoring 
adherence include the use of the Morisky scale. Consideration of the benefit of alternative 
antihypertensive agents such as amlodipine in pregnancy should also be made. Additional 
qualitative work should examine women’s experience of taking antihypertensive treatment 
during pregnancy and factors that could improve adherence.     
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Optimisation of the management of hypertension in pregnancy should be explored further 
with investigation of the use of home blood-pressure monitoring, offering women 
empowerment in the management of their chronic condition, that may benefit their future 
health. Other interventions and aspects of pre-pregnancy, antenatal and postpartum 
management need to be considered, such as dedicated antenatal clinics. The CHIPS trial has 
demonstrated that targeting a diastolic blood pressure of 85 mmHg in pregnancy reduces the 
risk of severe hypertension in women with hypertension, but it is unclear if further maternal 
benefit or perinatal harm would be associated with even tighter control. The SPRINT trial had 
to end recruitment early when a significant reduction in cardiovascular morbidity and 
mortality was demonstrated with a systolic blood pressure target of 120 mmHg compared to 
140 mmHg (albeit with increased serious adverse events), and the potential impact of 
suboptimal control of hypertension in pregnancy on a woman’s long-term health needs to be 
considered further, but carefully balanced with fetal and infant wellbeing. 
 
Pregnancy offers a unique opportunity to educate and empower women about their chronic 
conditions and the potential impact on their future health. Chronic hypertension is the most 
common pre-existing medical condition associated with adverse maternal and perinatal 
outcomes and is additionally associated with long-term maternal morbidity and mortality. 
Given the increasing incidence of chronic hypertension with rising maternal age and the 
growing prevalence of obesity, further research is required to optimise the short and long-
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Appendix 1 Prospero registration of systematic review 
PROSPERO International prospective register of systematic reviews 
Systematic review of antihypertensive treatment in pregnancy complicated by chronic 
hypertension  
Louise Webster, Frances Conti-Ramsden, Paul Seed, Catherine Nelson-Piercy, Lucy Chappell  
Citation  
Louise Webster, Frances Conti-Ramsden, Paul Seed, Catherine Nelson-Piercy, Lucy Chappell. 
Systematic review of antihypertensive treatment in pregnancy complicated by chronic 




In women with chronic hypertension in pregnancy: 
• Which anti-hypertensive treatment is associated with fewest episodes of severe 
hypertension in pregnancy? 
• Does frequency of adverse maternal outcomes (e.g. pre-eclampsia, stroke, death) and mode 
of delivery vary by antihypertensive agent? 
• Does frequency of fetal and neonatal adverse outcomes (e.g. growth restriction, preterm 
delivery, neonatal unit admission) vary by antihypertensive agent? 
Searches 
The following databases will be searched:  
- MEDLINE (via OVID) 
- EMBASE (via OVID) 
- Cochrane Central Register of Controlled Trials (CENTRAL) 
Databases will be searched from their earliest entries until 30th April 2015. No language 
restriction will be used in searches. Searches will be adapted to each database and details of 
each planned strategy are listed in the appendix.  
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In addition, any currently registered relevant clinical trials will be searched for via:  
- Clinicaltrials.gov 
- ISRCTN.com 
Other grey literature will be sought by reviewing thesis titles from WorldCat Dissertations and 
Theses database. 
Types of study to be included 
Randomised Controlled Trials only 
Condition or domain being studied  
Chronic hypertension in pregnancy and antihypertensive treatment 
Participants/ population 
The population is pregnant women diagnosed with chronic hypertension prior to pregnancy or 
diagnosed up to 20 weeks’ gestation. The definitions of chronic hypertension used by each 
study will be tabulated. Where chronic hypertension is not described the study will be 
excluded. Both primary and secondary chronic hypertension will be included. Studies with 
intention to treat chronic hypertension, regardless of level of hypertension at study entry, will 
also be included. Studies in which participants had gestational hypertension (GH) or chronic 
hypertension will only be included if the data for the chronic hypertension population are 
reported separately 
Intervention(s), exposure(s) 
Types of Intervention 
• Any antihypertensive drug compared with alternative intervention (e.g. bed rest) or placebo 
• One antihypertensive versus another antihypertensive drug 
Eligibility criteria (Published and unpublished RCTs in any language will be assessed for 
eligibility) 
• Pregnant women with chronic hypertension randomised to antihypertensive treatment arm 
and compared prospectively with at least one other treatment arm 
• Definition of chronic hypertension reported 
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• Any trial designs other than RCT.  
• Studies not separating outcome data of participants with gestational or chronic hypertension 
Comparator(s)/ control 
Types of Intervention 
• Any antihypertensive drug compared with alternative intervention (e.g. bed rest) or placebo 
• One antihypertensive versus another antihypertensive drug 
Eligibility criteria (Published and unpublished RCTs in any language will be assessed for 
eligibility) 
• Pregnant women with chronic hypertension randomised to antihypertensive treatment arm 
and compared prospectively with at least one other treatment arm 
• Definition of chronic hypertension reported 
Exclusion criteria 
• Any trial designs other than RCT.  
• Studies not separating outcome data of participants with gestational or chronic hypertension 
Context 
Chronic hypertension (CHT) is estimated to affect up to 2-3% of UK pregnancies. This figure is 
set to increase with an ageing maternal population and the rise in obesity. Pregnancies 
complicated by CHT are associated with an increased risk of adverse outcomes for mother and 




- Severe hypertension (defined as SBP>160mmHg and/or DBP>110mmHg or as given in paper, 
with tabulated definitions) 
• Fetal/Neonatal 
- Birthweight 
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- Superimposed pre-eclampsia (with tabulated definitions)  
- Need for additional antihypertensive agent during pregnancy (enteral or parenteral) 
- Caesarean section delivery 
- Estimated blood loss at delivery 
- Eclampsia 
- HELLP syndrome (with tabulated definitions) 
- Placental abruption 
- Other severe maternal morbidity: Disseminated Intravascular Coagulation, Acute Kidney 
Injury, Acute Liver Injury, Stroke etc. 
- Intensive Therapy Unit/High Dependency Unit admission nights 
- Maternal death 
- Adverse events and drug side effects, including numbers withdrawn from each trial and 
reasons why (if available) 
• Fetal/Neonatal:  
- Fetal loss: Miscarriage if <24 weeks’ gestation, Stillbirth >24 weeks’ gestation (or as defined) 
- Neonatal Death (death within the first 28 days of life) 
- Preterm birth (<37 weeks and subdivided into <34 weeks wherever possible) 
- Small for gestational age (SGA) babies (subdivided into birth centiles <10th centile, <3rd 
centile where possible) 
- APGAR score at 5 minutes 
- Arterial cord pH  
- Neonatal unit admission 
- Any neonatal morbidity thought to be related to maternal antihypertensive treatment such 
as hypo/hypertension, hypoglycaemia, etc. 
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Data extraction, (selection and coding) 
The titles and abstracts generated from the database searches will be independently screened 
by two authors. If either author considers the study to meet inclusion criteria it will be 
included for full text assessment. Any disagreements will be resolved by involving a third 
independent reviewer. Any foreign language trials will be translated. Data from eligible trials 
will be manually extracted and entered into a standard extraction table independently by the 
two primary reviewers. Data from all studies will then be collectively tabulated. Where there is 
lack of clarity in data or study design, every effort will be made to contact the authors of the 
RCT for further information.  
Data will be collected and tabulated on:  
- Definition of chronic hypertension 
- Clinical outcomes of interest as defined 
- Criteria specified by Risk of Bias Tool 
- Funding source 
Risk of bias (quality) assessment 
Each individual RCT will be quality assessed by one author using the Cochrane Collaboration 
Risk of Bias tool and then checked by a second author. Where there are any disagreements, 
they will be resolved by discussion with a third author. The following areas of each study will 
be considered for bias: 
• Sequence generation 
• Allocation concealment 
• Blinding of participants, personnel and outcome assessors 
• Incomplete outcome data 
• Selective outcome reporting 
• Any other sources of bias (including funding source) 
Sub-group analysis will be performed based on this quality assessment. 
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Strategy for data synthesis 
The review will be performed in line with PRISMA guidelines. For all outcomes the analysis will 
be conducted on an intention to treat basis. If a study contains only per-protocol data for a 
particular endpoint, it will be excluded from the main analysis. Meta-analysis will be 
undertaken where there is more than one study with analysable data. When there is only one 
study, the estimates from that study will be presented. Treatment effects will be presented as 
estimated differences in the mean or odds ratios with 95% confidence intervals. In the event of 
important significant treatment effects, the Number Needed to Treat (NNT) or Number 
Needed to Harm (NNH) will also be given. Conventional significance will be at the usual 5% 
level (2-sided). 
Heterogeneity of results between studies will be tested using a Chi2 test. Significant 
heterogeneity will be assessed using Tau2 and by visual inspection of the forest plot.  
Where there are sufficient studies of different populations, entry criteria or treatments, meta-
regression and subgroup analysis will be used to investigate the differences between study 
results. Meta-regression will be performed with reported variables that are suspected to 
influence efficacy of treatment. Publication bias will be investigated using Egger’s test and 
funnel plots. 
Where data collected are insufficient for quantitative synthesis, they will be tabulated for 
presentation and explored in the discussion. If outcomes of interest are not able to be 
quantitatively synthesised, recommendations for the definitive trial to obtain these data will 
be made in the study conclusions 
Analysis of subgroups or subsets 
Subgroup analysis will be performed by:  
- Ethnicity  
- Age  
- BMI  
- Quality 
Dissemination plans: 
It is intended that the results of this review will be reported and disseminated at international 
conferences and in peer-reviewed scientific journals. 
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Contact details for further information: 
Dr Webster, Division of Women's Health, King's College London, Women's Health Academic 
Centre, 10th floor North Wing, St Thomas' Hospital, SE1 7EH 
louise.m.webster@kcl.ac.uk 
Organisational affiliation of the review  King's College London (www.kcl.ac.uk) 
Review team 
Dr Louise Webster, King's College London 
Dr Frances Conti-Ramsden, King's College London 
Mr Paul Seed, King's College London 
Professor Catherine Nelson-Piercy, King's College London 
Dr Lucy Chappell, King's College London 
Anticipated or actual start date  01 May 2015 
Anticipated completion date  02 May 2016 
Funding sources/sponsors  King's College London 
Conflicts of interest   None known 
Language    English 
Country    England 
Subject index terms status 
Subject indexing assigned by CRD 
Subject index terms: Antihypertensive Agents; Female; Humans; Hypertension; Pregnancy; 
Pregnancy Complications, Cardiovascular 
Stage of review    Ongoing 
Date of registration in PROSPERO 21 May 2015 
Date of publication of this revision 21 May 2015 
DOI 10.15124/CRD42015020733  
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Appendix 2 ISRCTN registration of randomised controlled feasibility study 
http://www.isrctn.com/ISRCTN40973936?q=ISRCTN40973936&filters=&sort=&offset=1&total
Results=1&page=1&pageSize=10&searchType=basic-search 
ISRCTN40973936 DOI 10.1186/ISRCTN40973936  
Pregnancy And chronic hypertension; NifeDipine or labetalol as Anti-hypertensive treatment. 
Condition category  Circulatory System  
Date applied   08/07/2014  
Date assigned   10/09/2014  
Last edited   30/03/2016  
Prospective/Retrospective Retrospectively registered  
Overall trial status  Completed  
Recruitment status  No longer recruiting  
Plain English Summary: 
Background and study aims  
Chronic hypertension is high blood pressure that usually needs to be treated with medication. 
It is important that high blood pressure is diagnosed and treated; without treatment it can 
cause damage to the heart, brain and kidneys, and complications such as a stroke. Around 3% 
of pregnant women have been diagnosed with high blood pressure before they become 
pregnant. A pre-existing high blood pressure puts pregnant women at an increased risk of 
complications in pregnancy such as pre-eclampsia and the baby not growing properly. We 
want to find out which one of two different drugs work best at lowering the blood pressure in 
pregnant women without any harmful effects for the mother or the baby. Both drugs are 
commonly used in pregnancy. Labetalol has a license for pregnancy which means that it has 
undergone clinical trials that have found it to be safe and effective for its use. Nifedipine is not 
licensed in pregnancy but can be used ‘off-label’ (outside its license) if it is felt that the 
benefits of treatment are likely to outweigh the risks of harm to the mother or baby. These 
medications have been used by doctors in the UK for many years to treat pregnant women 
with high blood pressure and the medicines safety watchdog has reviewed this study and given 
its approval. As the choice of drug for high blood pressure outside of pregnancy depends partly 
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on ethnic background, our study is also looking at which treatment works best in pregnant 
women from different ethnic backgrounds. 
Who can participate?  
Women aged 18 and over, with chronic hypertension, between 12 and 28 weeks pregnant with 
one baby, and who need treatment for their blood pressure.  
What does the study involve?  
We are comparing two of the main drug treatments for chronic hypertension in pregnancy: 
labetalol and nifedipine. Participants are randomly allocated into 1 of 2 groups. Those in group 
1 are given labetalol. Those in group 2 are given nifedipine. Both participants and their doctors 
know which treatment they are getting to make sure they are taking the right dose. All 
participants are seen regularly by healthcare professionals and are asked to give extra blood 
and urine samples on five occasions during their pregnancy, usually at the same time that their 
routine blood tests are performed. These samples are used to measure substances in the 
blood and urine at the end of the study to see if we can find out how each drug works. 
Participants are also asked for extra measurements of their blood pressure and to have a 
simple ultrasound (at the base of the neck) to check how the different drugs are working.  
What are the possible benefits and risks of participating?  
We know that both treatments will lower a woman’s blood pressure, which helps avoid 
complications of high blood pressure in pregnancy. Each participant is seen regularly by the 
hospital doctors and midwives (as usual) and by the research team. The PANDA trial will 
provide information to help improve the treatment of women with high blood pressure in 
pregnancy in the future. We do not anticipate any serious side-effects from either drug. Both 
of them are taken by lots of pregnant women worldwide and serious side-effects are rare. A 
woman cannot take labetalol if she suffers from asthma or some heart conditions. Possible 
side-effects do, however, include, feeling faint on standing, headache, rashes, scalp tingling, 
difficulty in passing urine, tummy pain, nausea, vomiting and liver damage. A woman cannot 
take nifedipine if she has certain heart conditions. Possible side-effects include nausea, 
vomiting or diarrhoea, swelling of the legs, palpitations, headache and dizziness. 
Where is the study run from? 
The lead centre for the trial is Guy’s and St Thomas’ Hospital, London. The maternity units in 
Manchester and Leicester are also taking part.  
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When is the study starting and how long is it expected to run for? 
August 2014 to September 2015 
Who is funding the study? 
The study is being funded by Tommy’s Charity and by the King’s Health Partners Challenge 
Fund.  
Who is the main contact? 
Dr Lucy Chappell  
Contact details 
Women’s Health Academic Centre, St Thomas’ Hospital, London, SE1 7EH, United Kingdom 
+44 (0)20 7188 3639 
lucy.chappell@kcl.ac.uk  
Additional identifiers 
EudraCT number 2013-003144-23  
Study information 
Scientific title 




Nifedipine is as effective as labetalol at controlling blood pressure in women with chronic 
hypertension in pregnancy, with greater efficacy in women of African/ Caribbean family origin  
Ethics approval 
1. East of England- Cambridge East Research Ethics Committee (REC), 03/02/2014, REC Ref 
13/EE/0390 
2. Medicines and Healthcare products Regulatory Agency (MHRA), 31/01/2014, Ref: 
14523/0251/001-0002  
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Study design   Randomised controlled trial (feasibility study)  
Primary study design  Interventional  
Secondary study design Randomised controlled trial  
Trial setting   Hospitals  
Trial type   Treatment  
Patient information sheet 
Not available in web format, please use the contact details below to request a patient 
information sheet  
Condition   Chronic hypertension in pregnancy  
Intervention 
Women with be randomised to one of two treatments: labetalol or nifedipine, with the dose 
adjusted for blood pressure control  
Primary outcome measures 
As of 24/02/2016: 
1. Primary clinical outcome measure: Highest systolic blood pressure (BP) between 
randomisation and delivery (highest of any recorded systolic BP measurement made between 
gestation at randomisation and gestation at delivery, excluding recordings made on the day of 
delivery and in addition average systolic BP during each pregnancy between randomisation 
and delivery will be calculated (using all available systolic BPs taken clinically using area under 
the curve by trapezium method) 
2. Primary process outcome measure: Number of women enrolled per site per month 
(calculated at end of trial as total number of women enrolled per site divided by number of 
months of enrolment at that site) 
Previous 
1. Primary clinical outcome measure: Highest systolic blood pressure between randomisation 
and delivery (highest of any recorded systolic blood pressure measurement made between 
gestation at randomisation and gestation at delivery, excluding recordings made in labour) 
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2. Primary process outcome measure: Number of women enrolled per site per month 
(calculated at end of trial as total number of women enrolled per site divided by number of 
months of enrolment at that site)  
Secondary outcome measures 
Clinical: 
1. Maternal outcomes including:  
1.1. Maternal morbidity or mortality (pre-eclampsia, eclampsia, intracranial haemorrhage or 
infarct, myocardial ischaemia/ infarction, intubation, pulmonary oedema, hepatic dysfunction, 
acute renal insufficiency, placental abruption, post-partum haemorrhage) (assessed on 
maternal discharge after delivery) 
1.2. Gestation at delivery (assessed at delivery) 
1.3. Mode of delivery (assessed at delivery) 
1.4. Indication for delivery (assessed at delivery) 
1.5. Number of episodes of systolic BP >=160mmHg, >=150mmHg (including home monitoring) 
(assessed between randomisation and delivery, excluding recordings made in labour)  
1.6. Diastolic BP <80mmHg (assessed between randomisation and delivery, excluding 
recordings made in labour) 
1.7. Need for additional oral or parenteral antihypertensive medication (assessed between 
randomisation and delivery) 
2. Perinatal outcomes including:  
2.1. Neonatal morbidity (admission to neonatal unit (length and place of stay), respiratory 
distress syndrome, need for ventilator support, intraventricular haemorrhage, confirmed 
infection, necrotising enterocolitis, seizures, encephalopathy, retinopathy of prematurity, 
other indications and main diagnoses related to neonatal unit admission) (assessed on 
discharge of infant)  
2.2. Stillbirth (assessed at time of death) 
2.3. Neonatal death (assessed at time of death) 
2.4. Birth weight (assessed at delivery) 
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2.5. Birth weight centile (assessed at delivery) 
2.6. Umbilical artery pH at birth (assessed at delivery) 
3. Health resource use outcomes including: 
3.1. Number of antenatal attendances (clinic and day unit) (assessed on maternal discharge) 
3.2. Maternal admission nights (ward, delivery suite, intensive care) (assessed on maternal 
discharge) 
3.3. Neonatal admission nights (including level of care) (assessed on discharge of infant) 
4. Process: 
4.1. Medication adherence (through self-report and pill count) (assessed as average of self-
report and average of pill count checked at each visit between randomisation and delivery) 
4.2. Side-effects of medication (assessed through direct questioning at each antenatal visit 
between randomisation and delivery) 
4.3. Satisfaction with medication (assessed through postnatal questionnaire)  
Overall trial start date   14/08/2014  
Overall trial end date   31/05/2016  
Eligibility 
Participant inclusion criteria 
1. Chronic hypertension (defined as diastolic BP >=90mmHg present at booking or before 20 
weeks' gestation, or requiring treatment outside pregnancy and/or at time of referral)  
2. Gestation 12-28 weeks at recruitment  
3. Singleton pregnancy  
4. Able to provide informed consent  
5. Age >=18 years  
Participant type   Patient  
Age group    Adult  
Gender     Female  
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Target number of participants  114  
Participant exclusion criteria 
1. Contraindication to labetalol (including asthma, uncontrolled heart failure, Prinzmetal's 
angina, marked bradycardia, hypotension, sick sinus syndrome, second- or third- degree AV 
block, cardiogenic shock, metabolic acidosis, severe peripheral arterial disease; 
phaeochromocytoma) or nifedipine (including cardiogenic shock; advanced aortic stenosis; 
within 1 month of myocardial infarction; unstable or acute attacks of angina)  
2. Insufficient understanding of the trial  
Recruitment start date   14/08/2014  
Recruitment end date   30/09/2015  
Trial participating centre 
Women’s Health Academic Centre, St Thomas’ Hospital, London, SE1 7EH, United Kingdom 
Sponsor information 
Organisation   
Kings College London, Guys and St Thomas's NHS Foundation Trust (UK)  
Sponsor details 
KHP-CTO, 16th Floor Tower Wing, Great Maze Pond, London, SE1 9RT, United Kingdom 
+44 (0)20 7188 5732 
jackie.pullen@kcl.ac.uk  
Sponsor type    Hospital/treatment centre  
Funders 
Funder type    Charity  
Funder name    Tommy’s Charity and KHP Challenge Fund (UK)  
Editorial Notes 
30/03/2016: Ethics approval information added. 25/02/2016: changed overall trial end date 
from 30/09/2015 to 31/05/2016 
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Appendix 3 Clinician survey results 
 
